WO2001070741A1 - 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors - Google Patents

5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors Download PDF

Info

Publication number
WO2001070741A1
WO2001070741A1 PCT/US2001/002657 US0102657W WO0170741A1 WO 2001070741 A1 WO2001070741 A1 WO 2001070741A1 US 0102657 W US0102657 W US 0102657W WO 0170741 A1 WO0170741 A1 WO 0170741A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
methyl
pyrimidin
pyrido
cyclopentyl
Prior art date
Application number
PCT/US2001/002657
Other languages
French (fr)
Inventor
Richard John Booth
Ellen Myra Dobrusin
Peter Laurence Toogood
Scott Norman Vanderwel
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to APAP/P/2002/002643A priority Critical patent/AP2002002643A0/en
Priority to AU2001233028A priority patent/AU2001233028A1/en
Priority to NZ520962A priority patent/NZ520962A/en
Priority to IL15148001A priority patent/IL151480A0/en
Priority to EEP200200506A priority patent/EE200200506A/en
Priority to BR0109056-9A priority patent/BR0109056A/en
Priority to KR1020027011627A priority patent/KR20020075805A/en
Priority to JP2001568942A priority patent/JP2003528101A/en
Priority to EA200200802A priority patent/EA200200802A1/en
Priority to PL01358271A priority patent/PL358271A1/en
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Priority to SK1247-2002A priority patent/SK12472002A3/en
Priority to DZ013308A priority patent/DZ3308A1/en
Priority to CA002401368A priority patent/CA2401368A1/en
Priority to MXPA02008535A priority patent/MXPA02008535A/en
Priority to EP01905114A priority patent/EP1268476A1/en
Priority to HU0300136A priority patent/HUP0300136A2/en
Publication of WO2001070741A1 publication Critical patent/WO2001070741A1/en
Priority to IS6524A priority patent/IS6524A/en
Priority to NO20024235A priority patent/NO20024235L/en
Priority to BG107161A priority patent/BG107161A/en
Priority to HR20020798A priority patent/HRP20020798A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates to 5-alkylpyridopyrimidines as inhibitors of cyclin- dependent kinases, particularly cyclin-dependent kinase 4.
  • the compounds of the invention are useful for the treatment of inflammation, cell proliferative diseases such as cancer and restenosis, and neurodegenerative diseases such as Alzheimer's disease.
  • Cyclin-dependent kinases and related serine/threonine protein kinases are cellular enzymes that perform essential functions in regulating cell division and proliferation.
  • the cyclin-dependent kinase catalytic units of which nine have been identified, are activated by regulatory units known as cy dines.
  • the cyclin- dependent kinases include (Cdk) Cdkl, Cdk2, Cdk4, Cdk5, Cdk6, and Wee- 1 kinase. Increased activity or temporally abnormal activation of these kinases results in development of human tumors and other proliferative disorders such as restenosis.
  • Compounds that inhibit Cdks either by blocking the interaction between a cyclin and its kinase partner, or by binding to and inactivating the kinase, cause inhibition of cell proliferation and thus are useful for treating tumors and other abnormally proliferating cells.
  • flavopiridol is a flavonoid that is a potent inhibitor of Cdk2 and Cdk4, and has been shown to inhibit several types of breast and lung cancer cells (Kaur et al, J Natl. Cancer Inst., 1992;84:1736-1740; Kaur et al., Int. J. Oncol, 1996;9:1143-1168).
  • Olomoucine is a flavonoid that is a potent inhibitor of Cdk2 and Cdk4
  • [2-(hydroxyethylamine)-6-benzylamine-9-methylpurme] is a potent inhibitor of Cdk2 and Cdk5 (Vesely et al, Eur. J. Biochem., 1994;224:771-786), and has been shown to inhibit proliferation of approximately 60 different human tumor cell lines used by the National Cancer Institute (NCI) to screen for new cancer therapies (Abraham et al., Biol. Cell, 1995;83:105-120).
  • Cdk inhibitors have been shown to treat cardiovascular disorders such as restenosis and atherosclerosis.
  • Other diseases in which Cdk inhibitors are useful include those caused by a variety of infectious agents, including DNA and RNA viruses, and inflammatory disorders such as rheumatoid arthritis.
  • An object of this invention is to provide a group of small molecular weight organic compounds that are potent Cdk inhibitors, and as such are useful for preventing and treating diseases caused by abnormally proliferating cells.
  • This invention provides 5 -alkyl pyridopyrimidines that are useful for treating inflammation, cell proliferative diseases such as cancer and restenosis, and neurodegenerative diseases such as Alzheimer's disease.
  • the compounds of the invention display unexpected improvements in pharmacokinetic properties over prior art compounds, including unanticipated metabolic stability and low clearance rates.
  • the compounds of the invention are unexpectedly selective inhibitors of Cdk4.
  • the compounds of the invention are readily synthesized, and can be administered to patients by a variety of methods.
  • the compounds of the invention are those having the structure of Formula I:
  • R2 is (a) hydrogen; (b) lower alkyl optionally substituted with one, two, or three groups independently selected from halogen, hydroxy, lower alkoxy, amino, mono- or dialkylamino, carboxy, alkoxycarbonyl, thio alkyl, nitrile, aryl, heteroaryl, or a carbocyclic group containing from 3 to 7 members, up to two of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen; or
  • R3 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro, -COR 4 , -CO 2 R 4 , -CONR 4 R 5 ,
  • Y is N or CR 7 ;
  • R9 is lower alkyl, haloalkyl, or aryl
  • X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NR 4 R 5 , -N(0)R 4 R 5 ,
  • T is O, S, NR 4 , N(0)R 4 NR 4 R 5 W, or CR 4 R 5 ;
  • Q is O, S, NR 4 , N(O)R 4 NR 4 R 5 W, C0 2 , or a carbocyclic group containing from
  • 3 to 7 members up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono or dialkylamino;
  • R6 is lower alkyl, haloalkyl, or aryl
  • R 7 is NR 4 R 5 , N(0)R 4 R 5 , NR 4 R 5 R9 ⁇ , OH, OR 4 , SR 4 , halo, COR 4 , (CH 2 ) n R 4 ,
  • W is an anion
  • R 4 and R 5 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (CH 2 ) n Ar, arylalkyl, aryl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or heteroaryl, or R 4 and R 5 together with the nitrogen to which they are attached form a carbocyclic ring containing 3 to 8 members, up to four of which members are optionally carbonyl groups or heteroatoms independently selected from oxygen, sulfur, S(O), S(0) 2 , and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, three, or four groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, aminoalkylcarbonyl, trifluoromethyl, trifluoromethylalkyl, trifluoromethyl
  • R 4 additionally can be lower alkyl unsubstituted or substituted with one, two, or three groups independently selected from halogen, 5-oxo-4,5-dihydro- lH-l,2,4-triazol-3-yl-sulfanyl, 5-oxo-4,5-dihydro-lH-l,2,4-triazol-3-yl- sulf ⁇ nyl, 5-oxo-4,5-dihydro-lH-l,2,4-triazol-3-yl-sulfony
  • R 7 and Z are as defined above, or can be taken together with the carbons to which they are attached to form
  • G and J are independently C ⁇ 2 , NH, or O;
  • B is NH, S, CH 2 , or O;
  • D is C or N, provided that Rl 0 is nothing when D is N; and RlO and Rl 1 are independently hydrogen, halogen, lower alkyl, lower alkoxy, or alkylcarbonyl.
  • Preferred compounds have Formula I wherein Y is CR 7 .
  • preferred compounds are those wherein R 7 is NR R 5 , and R 4 and R 5 are taken together with the N to which they are attached to form a ring such as piperazine, piperidine, pyrrolidine, morpholine, each of which can be optionally substituted.
  • the present invention also provides pharmaceutical compositions that comprise a compound of Formula I together with a pharmaceutically acceptable diluent, carrier, or excipient.
  • the present invention also provides methods for inhibiting cyclin-dependent kinase and growth factor-mediated kinase enzymes.
  • the present invention also provides a method of treating subjects suffering from diseases caused by cellular proliferation.
  • the method entails inhibiting proliferation of tumorigenic cells of epithelial origin and vascular smooth muscle proliferation, and/or cellular migration by administering a therapeutically effective amount of a compound of Formula I to a subject in need of treatment.
  • the invention also provides compounds useful in the diagnosis and treatment of cancer, psoriasis, vascular smooth muscle cell proliferation associated with atherosclerosis and postsurgical vascular stenosis and restenosis in mammals.
  • the present invention also provides a method of treating subjects suffering from diseases caused by DNA tumor viruses such as herpes viruses.
  • novel compounds encompassed by the instant invention are those described by the general Formula I set forth above, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
  • X, Y, Z, and R ⁇ are as defined above for Formula I.
  • Preferred compounds of Formula II are those in which X and Z are independently hydrogen, Cl, or F; Y is CR 7 ; and R ⁇ is hydrogen, Cl, F, Br, or CN.
  • Especially preferred compounds of Formula III are those in which X and Z are independently hydrogen, Cl, or F; Y is CR 7 ; and R ⁇ is hydrogen, Cl, F, Br, or CN.
  • Preferred compounds of Formula IV are those in which X and Z are independently hydrogen, Cl, or F; Y is CR 7 ; and R ⁇ is hydrogen, Cl, F, Br, or CN.
  • the most preferred invention compounds have the Formula V
  • R2 is alkyl or cycloalkyl
  • R3 is hydrogen or halo
  • R9 is alkyl
  • X and Z independently are hydrogen or halo
  • R 7 is NR 4 R 5 ;
  • R 4 and R 5 are taken together with the nitrogen to which they are attached to form a 5- or 6-membered carbocyclic ring, optionally containing an oxygen, nitrogen, or sulfur heteroatom, and optionally substituted with alkyl or substituted alkyl groups.
  • Especially preferred compounds of Formula V are those wherein R 7 is
  • alkyl By “alkyl,” “lower alkyl,” and “ ⁇ -CI Q alkyl” in the present invention is meant a straight or branched hydrocarbon radical having from 1 to 10 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, iso-pentyl, n-hexyl, and the like.
  • halogen in the present invention is meant fluorine, bromine, chlorine, and iodine.
  • Alkenyl means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and one double bond and includes ethenyl, 3-buten-l-yl, 2-ethenylbutyl, 3-hexen-l-yl, and the like.
  • Alkynyl means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and one triple bond and includes ethynyl, 3-butyn-l-yl, propynyl, 2-butyn-l-yl, 3-pentyn-l-yl, and the like.
  • Cycloalkyl means a monocyclic or polycyclic hydrocarbyl group such as cyclopropyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclobutyl, adamantyl, norpinanyl, decalinyl, norbornyl, cyclohexyl, and cyclopentyl.
  • groups can be substituted with groups such as hydroxy, keto, amino, alkyl, and dialkylamino, and the like. Also included are rings in which 1 to 3 heteroatoms replace carbons.
  • heterocyclyl means a cycloalkyl group also bearing at least one heteroatom selected from O, S, or N, examples being oxiranyl, pyrrolidinyl, piperidyl, tetrahydropyran, and morpholine.
  • alkoxy straight or branched chain alkoxy groups having 1-10 carbon atoms, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and
  • alkoxy refers to polyethers such as -0-(CH ) 2 -0- CH3, and the like.
  • Alkanoyl groups are alkyl groups linked through a carbonyl, i.e., C1 -C5-C(0)-. Such groups include formyl, acetyl, propionyl, butyryl, and isobutyryl.
  • acyl means an alkyl or aryl (Ar) group bonded through a carbonyl group, i.e., R-C(O)-.
  • acyl includes a C1 -C alkanoyl, including substituted alkanoyl, wherein the alkyl portion can be substituted by NR 4 R 5 or a carboxylic or heterocyclic group.
  • Typical acyl groups include acetyl, benzoyl, and the like.
  • Amide is an amino carbonyl group such as -CONR 4 R 5 .
  • the alkyl, alkenyl, alkoxy, and alkynyl groups described above are optionally substituted, preferably by 1 to 3 groups selected from NR 4 R 5 , phenyl, substituted phenyl, thio Cj-Cg alkyl, C ⁇ -C ⁇ alkoxy, hydroxy, carboxy,
  • Substituted nitrogen means nitrogen bearing C ⁇ -Cg alkyl or (CH ) n Ph where n is 1, 2, or 3. Perhalo and polyhalo substitution is also included.
  • substituted alkyl groups include 2-aminoethyl, 2-hydroxyethyl, pentachloroethyl, trifluoromethyl, 2-diethylaminoethyl,
  • 2-ethylsulfanylefhynyl 4-( 1 -piperazinyl)-3 -(butynyl), 3 -phenyl-5-hexynyl, 3-diethylamino-3-butynyl, 4-chloro-3 -butynyl, 4-cyclobutyl-4-hexenyl, and the like.
  • Typical substituted alkoxy groups include aminomethoxy, trifluoromethoxy, 2-diethylaminoethoxy, 2-ethoxycarbonylethoxy,
  • substituted alkyl, alkenyl, and alkynyl groups include dimethylaminomethyl, carboxymethyl, 4-dimethylamino-3-buten-l-yl, 5-ethylmethylamino-3-pentyn-l-yl, 4-morpholinobutyl, 4-tetrahydropyrinidylbutyl, 3-imidazolidin-l-ylpropyl, 4-tetrahydrothiazol-3-yl- butyl, phenylmethyl, 3-chlorophenylmethyl, and the like.
  • anion means a negatively charged counterion such as chloride, bromide, trifluoroacetate, and triethylammonium.
  • heteroaryl is meant one or more aromatic ring systems of 5-, 6-, or 7-membered rings containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur.
  • heteroaryl groups include, for example, thienyl, furanyl, thiazolyl, triazolyl, imidazolyl, (is)oxazolyl, oxadiazolyl, tetrazolyl, pyridyl, thiadiazolyl, oxadiazolyl, oxathiadiazolyl, thiatriazolyl, pyrimidinyl, (iso)quinolinyl, napthyridinyl, phthalimidyl, benzimidazolyl, and benzoxazolyl.
  • a preferred heteroaryl is pyridine.
  • aryl is meant an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, or phenanthryl), which can be mono-, di-, or trisubstituted with, e.g., halogen, lower alkyl, lower alkoxy, lower alkylthio, trifluoromethyl, lower acyloxy, aryl, heteroaryl, and hydroxy.
  • a preferred aryl is phenyl.
  • cancer includes, but is not limited to, the following cancers: breast, ovary, cervix, prostate, testis, esophagus, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, adenocarcinoma, bone, colon, adenocarcinoma, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, and leukemia.
  • salts refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
  • salts refers to the relatively nontoxic, inorganic and organic acid addition salts of compounds of the present invention.
  • salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed.
  • Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate and laurylsulphonate salts, and the like.
  • alkali and alkaline earth metals such as sodium, lithium, potassium, calcium, magnesium and the like
  • non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.
  • esters of the compounds of this invention include C ⁇ -Cg alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C5-C7 cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. C1 -C4 alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.
  • Examples of pharmaceutically acceptable, non-toxic amides of the compounds of this invention include amides derived from ammonia, primary C ⁇ -C5 alkyl amines and secondary C ⁇ -Cg dialkyl amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C1 -C3 alkyl primary amines and
  • Ci-C 2 dialkyl secondary amines are preferred.
  • Amides of the compounds of the invention may be prepared according to conventional methods.
  • prodrug refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood.
  • a thorough discussion is provided in T. Higuclii and V. Stella, "Pro-drugs as Novel Delivery Systems,” Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference.
  • the compounds of the present invention are useful for treating cancer (for example, leukemia and cancer of the lung, breast, prostate, and skin such as melanoma) and other proliferative diseases including but not limited to psoriasis,
  • a further embodiment of this invention is a method of treating subjects suffering from diseases caused by vascular smooth muscle cell proliferation.
  • Compounds within the scope of the present invention effectively inhibit vascular smooth muscle cell proliferation and migration. The method entails inhibiting vascular smooth muscle proliferation, and/or migration by administering an effective amount of a compound of Formula I to a subj ect in need of treatment. .
  • the compounds of the present invention can be formulated and administered in a wide variety of oral and parenteral dosage forms, including transdermal and rectal administration. It will be recognized to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt, ester, amide, prodrug, or solvate of a compound of Formula I.
  • a further embodiment of this invention is a pharmaceutical composition
  • a pharmaceutically acceptable carrier can be either a solid or liquid.
  • Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispensable granules.
  • a solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material.
  • the carrier is a finely divided solid such as talc or starch which is in a mixture with the finely divided active component.
  • the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • compositions of this invention preferably contain from about 5% to about 70% or more of the active compound.
  • Suitable carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like.
  • a preferred form for oral use are capsules, which include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it.
  • cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
  • a low melting wax such as a mixture of fatty acid glycerides or cocoa butter
  • the active component is dispersed homogeneously therein, as by stirring.
  • the molten homogenous mixture is then poured into convenient size molds, allowed to cool, and thereby to solidify.
  • Liquid form preparations include solutions, suspensions, and emulsions such as water or water/propylene glycol solutions.
  • liquid preparations can be formulated in solution in aqueous polyethylene glycol solution, isotonic saline, 5% aqueous glucose, and the like.
  • Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired.
  • Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water and mixing with a viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents.
  • solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration.
  • liquid forms include solutions, suspensions, and emulsions.
  • These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
  • Waxes, polymers, microparticles, and the like can be utilized to prepare sustained-release dosage forms.
  • osmotic pumps can be employed to deliver the active compound uniformly over a prolonged period.
  • the pharmaceutical preparations of the invention are preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
  • the therapeutically effective dose of a compound of Formula I will generally be from about 1 mg/kg to about 100 mg/kg of body weight per day. Typical adult doses will be about 50 mg to about 800 mg per day.
  • the quantity of active component in a unit dose preparation may be varied or adjusted from about
  • composition can, if desired, also contain other compatible therapeutic agents.
  • a subject in need of treatment with a compound of Formula I is administered a dosage of about 1 mg to about 500 mg per day, either singly or in multiple doses over a 24-hour period.
  • the compounds of the present invention are capable of binding to and inhibiting the activity of proteins having the ability to phosphorylate other proteins, such as cdks, PDGFr, FGFr, c-Src, and EGFr-FL.
  • Cdks form complexes with cyclins, and these complexes phosphorylate key proteins allowing cells to proceed through the cell cycle (Meijer L., Progress in Cell Cycle Research, 1995;1:351-363).
  • the compounds of this invention inhibit this phosphorylation and therefore can be used as anti-proliferative agents for the treatment of cancer and/or restenosis and other proliferative diseases.
  • the compounds of the present invention are also useful research tools for studying the mechanism of action of those kinases, both in vitro and in vivo.
  • a 4-substituted amino-2-methansulfanyl- pyrimidine-5-carboxaldehyde is reacted with an organometallic compound, such as, for example, a Grignard reagent, to afford the corresponding secondary alcohol.
  • an organometallic compound such as, for example, a Grignard reagent
  • the alcohol is subsequently oxidized to the ketone.
  • the ketone is then reacted with a trialkyl phosphonoacetate in the presence of base to produce the corresponding 8-substituted-5 -alkyl-2-methylsulfanyl-8H-pyrido [2,3 -d]pyrimidin- 7-one.
  • the pyrido-pyrimidine then can be halogenated at the 6-position with a common halogenating agent, such as, for example, N-bromosucccinimide (NBS).
  • N-bromosucccinimide N-bromosucccinimide
  • the 2-methylsulfanyl derivative is oxidized to the corresponding methylsulfoxide, which is subsequently treated with a desired aniline to afford the 2-phenylamino invention compound.
  • a common halogenating agent such as, for example, N-bromosucccinimide (NBS).
  • N-bromosucccinimide (NBS) N-bromosucccinimide
  • the 2-methylsulfanyl derivative is oxidized to the corresponding methylsulfoxide, which is subsequently treated with a desired aniline to afford the 2-phenylamino invention compound.
  • reactive groups such as amines, alcohols, and acids
  • protecting groups simply avoid unwanted side reactions.
  • Use of protecting groups is common in the art of organic
  • Typical hydroxy protecting groups include either forming groups such as benzyl, and acyl groups such as tert-butoxycarbonyl(Boc), formyl, and acetyl.
  • Amino protecting groups include benzyl, acyl such as acetyl, and trialkylsilyl groups.
  • Carboxylic acid groups typically are protected by conversion to an ester that can be easily hydrolyzed, for example, trichloroethyl, tert-butyl, benzyl, and the like.
  • Some of the invention compounds have one or more chiral centers, and thus can exist as individual optical isomers and mixtures thereof.
  • Compound 246 (Table 1), for example, can exist as an RS racemate, or as the individual R or S isomer. All individual isomers and mixtures thereof are included in this invention. Individual isomers are readily prepared by a chiral synthesis, or by conventional resolution techniques well-known to those skilled in the art. The invention is illustrated further by the following detailed examples which are not to be construed as limiting the invention in scope or spirit to the specific procedures described in them. The starting materials and various intermediates utilized in the synthesis of invention compounds may be obtained from commercial sources, prepared from commercially available organic compounds, or prepared using well-known synthetic methods. The disclosures in this application of all articles and references, including patents, are incorporated herein by reference.
  • the crude product is purified by silica gel chromatography (eluting with 80%-100% ethyl acetate in hexanes) to provide the sulfoxide product as a white solid (0.55 g, 86%).
  • 6-Bromo-8-cyclopentyl-5-methyl-2-methylsulfanyl-8H- pyrido[2,3-d]pyrimidin-7-one is oxidized as described in Example 2.
  • the sulfoxide is reacted with 4-(N-Boc-piperazin-l-yl)aniline as described in Example 3.
  • N-Boc protecting group is removed by hydrolysis as described above for 8-cyclopentyl-6-fluoro-5-methyl-2-methylsulfanyl-8H- pyrido[2,3-d]pyrimidin-7-one to provide 6-Bromo-8-cyclopentyl-5-methyl- 2-(4-piperazin-l-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (compound 35).
  • Mp >200°C (dec).
  • N-methyl morpholine oxide (1.07 g, 8.6 g), and tetrapropylammonium perruthenate (0.227 g, 0.645 mmol).
  • the reaction mixture is stirred at 24°C for 2 hours, and small amounts of additional catalyst are periodically added.
  • the reaction mixture is then run through a silica column (1:1, ethyl acetate :hexanes) to yield the titled compound as a light yellow solid (0.74 g, 70%).
  • reaction mixture was cooled to room temperature and partitioned between water and EtOAc. The organic layer was washed with brine then dried over MgS ⁇ 4. After filtration and concentrate in vacuo, orange solid was obtained which was purified by column chromatography to yield the product as a yellow solid (0.160 g, 47%).
  • EXAMPLE 18 The following compounds are prepared essentially according to the procedures described in Examples 1 to 17 and as illusfrated in Schemes 1 and 2: (a) 8-Cyclopentyl-5-methyl-2-(4-piperazin-l -yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one trifluoroacetic acid salt (Compound 1), mp >215°C (dec);
  • the reaction is terminated by addition of 0.1 mL 20% TCA.
  • the plate is kept at 4°C for at least 1 hour to allow the substrate to precipitate.
  • the wells are then washed five times with 0.2 mL 10% TCA, and 32p incorporation is determined with a beta plate counter (Wallac Inc., Gaithersburg, MD).
  • the Cdk4 enzyme assay for IC50 determination and kinetic evaluation is performed as follows. 96-well filter plates (Millipore MADVN6550) are used. The total volume is 0.1 mL containing a final concentration of 20 mM TRIS (tris[hydroxymethyl]aminomethane) (pH 7.4), 50 mM NaCl, 1 mM dithiothreitol,
  • PDGFr PDGF receptor
  • FGFr FGF receptor
  • the fragment is inserted into a baculoviras vector, cotransfected with AcMNPV DNA, and the recombinant virus is isolated.
  • SF9 insect cells are infected with the virus to overexpress the protein, and the cell lysate is used for the assay.
  • PDGFr and FGFr enzyme assays are performed in 96-well plates (100 ⁇ L/incubation/well), and conditions are optimized to measure the incorporation of 32p from [ ⁇ 3 2p]ATP into a glutamate-tyrosine co-polymer substrate.
  • c-Src protein kinase assay is carried out as follows. c-Src kinase is purified from baculovirus infected insect cell lysates using an antipeptide monoclonal antibody directed against the N-terminal amino acids (amino acids
  • the antibody covalently linked to 0.65 ⁇ m latex beads, is added to a suspension of insect cell lysis buffer comprised of 150 mM NaCl, 50 mM Tris (pH 7.5), 1 mM DTT, 1% NP-40, 2 M EGTA, 1 mM sodium vanadate, 1 mM PMSF, 1 ⁇ g/mL each of leupeptin, pepstatin, and aprotinin.
  • Insect cell lysate containing c-Src protein is incubated with these beads for 3 to 4 hours at 4°C with rotation.
  • the beads are rinsed three times in lysis buffer, resuspended in lysis buffer containing 10% glycerol, and frozen. These latex beads are thawed, rinsed three times in assay buffer (40 mM Tris (pH 7.5), 5 mM ⁇ g CI2) and suspended in the same buffer.
  • assay buffer 40 mM Tris (pH 7.5), 5 mM ⁇ g CI2
  • assay buffer 40 mM Tris (pH 7.5), 5 mM ⁇ g CI2
  • ATP containing 0.2 ⁇ Ci [32p]ATP, 5 ⁇ L DMSO containing inhibitors or as a solvent control, and buffer to make the final volume 125 ⁇ L.
  • the reaction is started at room temperature by addition of ATP and quenched 10 minutes later by the addition of 125 ⁇ L 30% TCA, 0.1 M sodium pyrophosphate for 5 minutes on ice.
  • the plate is then filtered and the wells washed with two 250-mL aliquots of
  • the invention compounds will typically be formulated with common excipients, diluents, and carriers to provide compositions that are well-suited for convenient administration to mammals.
  • the following examples illustrate typical compositions that are provided in a further embodiment of this invention.
  • Compound 12 is mixed with the lactose and cornstarch (for mix) and blended to uniformity to a powder.
  • the cornstarch (for paste) is suspended in 6 mL of water and heated with stirring to form a paste.
  • the paste is added to the mixed powder, and the mixture is granulated.
  • the wet granules are passed through a No. 8 hard screen and dried at 50°C.
  • the mixture is lubricated with 1% magnesium stearate and compressed into a tablet.
  • the tablets are administered to a patient at the rate of 1 to 4 each day for prevention and treatment of atherosclerosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Disclosed are compounds of the formula (I) wherein: R2 is hydrogen, alkyl, or cycloalkyl; R3 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro, -COR4, -CO2R?4, -CONR4R5, -CONR4OR5, -SO¿2NR?4R5, -SO¿2NR?4R5, -SO¿2R4, -SO3R4, formula (II), or -NR4R5; Y is N or CR7; R9 is lower alkyl, haloalkyl, or aryl; X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NR4R5, -N(O)R?4R5, -NR4R5R6W, -SR4¿, -C(O)R4, -CO2R?4, -CONR4R5, -SO¿2NR?4R5, -SO¿2R4, -SO3R4, P(O)(OR4)(OR5), -T(CH¿2)mQR?4, -C(O)T(CH¿2)mQR?4, or -NR4C(O)T(CH¿2)mQR?5; m is 1 to 6. These compounds are useful for treating cell proliferative disorders, such as cancer, atherosclerosis, and restenosis. These compounds are potent inhibitors of cyclin-dependent kinases (cdks) and growth factor-mediated kinases.

Description

5-ALKYLPYRIDO[2,3-d]PYRIMIDINES TYROSINE KINASE INHIBITORS
FIELD OF THE INVENTION
This invention relates to 5-alkylpyridopyrimidines as inhibitors of cyclin- dependent kinases, particularly cyclin-dependent kinase 4. The compounds of the invention are useful for the treatment of inflammation, cell proliferative diseases such as cancer and restenosis, and neurodegenerative diseases such as Alzheimer's disease.
SUMMARY OF THE RELATED ART
Cyclin-dependent kinases and related serine/threonine protein kinases are cellular enzymes that perform essential functions in regulating cell division and proliferation. The cyclin-dependent kinase catalytic units, of which nine have been identified, are activated by regulatory units known as cy dines. The cyclin- dependent kinases include (Cdk) Cdkl, Cdk2, Cdk4, Cdk5, Cdk6, and Wee- 1 kinase. Increased activity or temporally abnormal activation of these kinases results in development of human tumors and other proliferative disorders such as restenosis. Compounds that inhibit Cdks, either by blocking the interaction between a cyclin and its kinase partner, or by binding to and inactivating the kinase, cause inhibition of cell proliferation and thus are useful for treating tumors and other abnormally proliferating cells.
Several compounds that inhibit Cdks have demonstrated both preclinical and clinical anti-tumor activity. For example, flavopiridol is a flavonoid that is a potent inhibitor of Cdk2 and Cdk4, and has been shown to inhibit several types of breast and lung cancer cells (Kaur et al, J Natl. Cancer Inst., 1992;84:1736-1740; Kaur et al., Int. J. Oncol, 1996;9:1143-1168). In addition, Olomoucine
[2-(hydroxyethylamine)-6-benzylamine-9-methylpurme] is a potent inhibitor of Cdk2 and Cdk5 (Vesely et al, Eur. J. Biochem., 1994;224:771-786), and has been shown to inhibit proliferation of approximately 60 different human tumor cell lines used by the National Cancer Institute (NCI) to screen for new cancer therapies (Abraham et al., Biol. Cell, 1995;83:105-120).
In addition to treating cancer, Cdk inhibitors have been shown to treat cardiovascular disorders such as restenosis and atherosclerosis. Other diseases in which Cdk inhibitors are useful include those caused by a variety of infectious agents, including DNA and RNA viruses, and inflammatory disorders such as rheumatoid arthritis.
An object of this invention is to provide a group of small molecular weight organic compounds that are potent Cdk inhibitors, and as such are useful for preventing and treating diseases caused by abnormally proliferating cells.
SUMMARY OF THE INVENTION
This invention provides 5 -alkyl pyridopyrimidines that are useful for treating inflammation, cell proliferative diseases such as cancer and restenosis, and neurodegenerative diseases such as Alzheimer's disease. The compounds of the invention display unexpected improvements in pharmacokinetic properties over prior art compounds, including unanticipated metabolic stability and low clearance rates. In addition, the compounds of the invention are unexpectedly selective inhibitors of Cdk4. The compounds of the invention are readily synthesized, and can be administered to patients by a variety of methods.
The compounds of the invention are those having the structure of Formula I:
Figure imgf000003_0001
and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein:
R2 is (a) hydrogen; (b) lower alkyl optionally substituted with one, two, or three groups independently selected from halogen, hydroxy, lower alkoxy, amino, mono- or dialkylamino, carboxy, alkoxycarbonyl, thio alkyl, nitrile, aryl, heteroaryl, or a carbocyclic group containing from 3 to 7 members, up to two of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen; or
(c) a carbocyclic group containing from 3 to 7 members, up to two of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, lower alkyl, lower alkoxy, amino, mono- or dialkylamino, aryl, and heteroaryl;
R3 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro, -COR4, -CO2R4, -CONR4R5,
CONOR5, -SO2NR4R5, -SO2R4, -SO3R4, P(O)(OR4)(OR5), or
I
R4
-NR4R5; Y is N or CR7;
R9 is lower alkyl, haloalkyl, or aryl;
X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NR4R5, -N(0)R4R5,
-NR R5R6W, -SR4, -C(O)R4, -CO2R4, -CONR4R5, -S02NR R5, -SO2R4, -SO3R4, P(O)(OR4)(OR5), -T(CH2)mQR4,
-C(O)T(CH2)mQR4, or -NR4C(O)T(CH2)mQR5; m is 1-6; n is 0-6;
T is O, S, NR4, N(0)R4 NR4R5W, or CR4R5; Q is O, S, NR4, N(O)R4 NR4R5W, C02, or a carbocyclic group containing from
3 to 7 members, up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono or dialkylamino;
R6 is lower alkyl, haloalkyl, or aryl;
R7 is NR4R5, N(0)R4R5, NR4R5R9χ, OH, OR4, SR4, halo, COR4, (CH2)nR4,
C0 R4, CONR4R5, C(0)NR SO2R5, S(0)R4, S02R4, S02NR R5, SO3R4, (CH2)nP(0)(OR4)2, NR SO2R5, aldehyde, nitrile, nitro, alkyl, alkoxyalkyl, T(CH2)mQR4, C(0)T(CH2)mQR4, NR4C(0)T(CH2)mQR5, or T(CH2)mC02R4;
W is an anion;
R4 and R5 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (CH2)nAr, arylalkyl, aryl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or heteroaryl, or R4 and R5 together with the nitrogen to which they are attached form a carbocyclic ring containing 3 to 8 members, up to four of which members are optionally carbonyl groups or heteroatoms independently selected from oxygen, sulfur, S(O), S(0)2, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, three, or four groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, aminoalkylcarbonyl, trifluoromethyl, trifluoromethylalkyl, trifluoromethylalkylaminoalkyl, amino, mono- or dialkylamino, N-hydroxyacetamido, aryl, heteroaryl, carboxyalkyl, NR10SO2R! l, C(O)NR10R1 , NR10C(O)Rl 1, C(O)OR 0, C(0)NR10SO2R11, (CH2)nS(O)nRl0, (CH2)n-heteroaryl, O(CH2)n-heteroaryl, (CH^C^NR1^1 1, O(CH2)nC(0)OR10; and R4 additionally can be lower alkyl unsubstituted or substituted with one, two, or three groups independently selected from halogen, 5-oxo-4,5-dihydro- lH-l,2,4-triazol-3-yl-sulfanyl, 5-oxo-4,5-dihydro-lH-l,2,4-triazol-3-yl- sulfϊnyl, 5-oxo-4,5-dihydro-lH-l,2,4-triazol-3-yl-sulfonyl, or a carbocyclic group containing from 3 to 7 members, up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono- or dialkylamino; and when Y is CR7, it is part of the part structure
wherein R7 and Z are as defined above, or can be taken
Figure imgf000006_0001
together with the carbons to which they are attached to form
Figure imgf000006_0002
wherein:
G and J are independently CΗ2, NH, or O; B is NH, S, CH2, or O;
D is C or N, provided that Rl 0 is nothing when D is N; and RlO and Rl 1 are independently hydrogen, halogen, lower alkyl, lower alkoxy, or alkylcarbonyl.
Preferred compounds have Formula I wherein Y is CR7. Of this group, preferred compounds are those wherein R7 is NR R5, and R4 and R5 are taken together with the N to which they are attached to form a ring such as piperazine, piperidine, pyrrolidine, morpholine, each of which can be optionally substituted.
The present invention also provides pharmaceutical compositions that comprise a compound of Formula I together with a pharmaceutically acceptable diluent, carrier, or excipient.
The present invention also provides methods for inhibiting cyclin- dependent kinase and growth factor-mediated kinase enzymes.
The present invention also provides a method of treating subjects suffering from diseases caused by cellular proliferation. The method entails inhibiting proliferation of tumorigenic cells of epithelial origin and vascular smooth muscle proliferation, and/or cellular migration by administering a therapeutically effective amount of a compound of Formula I to a subject in need of treatment.
The invention also provides compounds useful in the diagnosis and treatment of cancer, psoriasis, vascular smooth muscle cell proliferation associated with atherosclerosis and postsurgical vascular stenosis and restenosis in mammals.
The present invention also provides a method of treating subjects suffering from diseases caused by DNA tumor viruses such as herpes viruses.
DETAILED DESCRIPTION OF THE INVENTION
The novel compounds encompassed by the instant invention are those described by the general Formula I set forth above, and the pharmaceutically acceptable salts, esters, amides, and prodrugs thereof.
In addition to the compounds of Formula I, the invention encompasses, in a preferred embodiment, compounds of Formula II:
Figure imgf000007_0001
wherein X, Y, Z, and R^ are as defined above for Formula I. Preferred compounds of Formula II are those in which X and Z are independently hydrogen, Cl, or F; Y is CR7; and R^ is hydrogen, Cl, F, Br, or CN.
In addition, the present invention also encompasses preferred compounds of the Formula III:
Figure imgf000008_0001
Especially preferred compounds of Formula III are those in which X and Z are independently hydrogen, Cl, or F; Y is CR7; and R^ is hydrogen, Cl, F, Br, or CN.
In addition, the present invention also encompasses, as a further preferred embodiment, compounds of the Formula IV:
Figure imgf000008_0002
Preferred compounds of Formula IV are those in which X and Z are independently hydrogen, Cl, or F; Y is CR7; and R^ is hydrogen, Cl, F, Br, or CN. The most preferred invention compounds have the Formula V
Figure imgf000009_0001
wherein:
R2 is alkyl or cycloalkyl;
R3 is hydrogen or halo;
R9 is alkyl;
X and Z independently are hydrogen or halo;
R7 is NR4R5; and
R4 and R5 are taken together with the nitrogen to which they are attached to form a 5- or 6-membered carbocyclic ring, optionally containing an oxygen, nitrogen, or sulfur heteroatom, and optionally substituted with alkyl or substituted alkyl groups.
Especially preferred compounds of Formula V are those wherein R7 is
s and such groups are optionally
Figure imgf000009_0002
substituted by alkyl, acyl, amide, or the like. Unless otherwise expressly stated, the following definitions are adhered to throughout this disclosure.
By "alkyl," "lower alkyl," and " \-CI Q alkyl" in the present invention is meant a straight or branched hydrocarbon radical having from 1 to 10 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, iso-pentyl, n-hexyl, and the like. By the term "halogen" in the present invention is meant fluorine, bromine, chlorine, and iodine.
"Alkenyl" means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and one double bond and includes ethenyl, 3-buten-l-yl, 2-ethenylbutyl, 3-hexen-l-yl, and the like.
"Alkynyl" means straight and branched hydrocarbon radicals having from 2 to 6 carbon atoms and one triple bond and includes ethynyl, 3-butyn-l-yl, propynyl, 2-butyn-l-yl, 3-pentyn-l-yl, and the like.
"Cycloalkyl" means a monocyclic or polycyclic hydrocarbyl group such as cyclopropyl, cycloheptyl, cyclooctyl, cyclodecyl, cyclobutyl, adamantyl, norpinanyl, decalinyl, norbornyl, cyclohexyl, and cyclopentyl. Such groups can be substituted with groups such as hydroxy, keto, amino, alkyl, and dialkylamino, and the like. Also included are rings in which 1 to 3 heteroatoms replace carbons. Such groups are termed "heterocyclyl," which means a cycloalkyl group also bearing at least one heteroatom selected from O, S, or N, examples being oxiranyl, pyrrolidinyl, piperidyl, tetrahydropyran, and morpholine.
By "alkoxy," "lower alkoxy," and "C^-Ci Q alkoxy" is meant straight or branched chain alkoxy groups having 1-10 carbon atoms, such as, for example, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, pentoxy, 2-pentyloxy, isopentoxy, neopentoxy, hexoxy, 2-hexoxy, 3-hexoxy, and
3-methylpentoxy. In addition, alkoxy refers to polyethers such as -0-(CH )2-0- CH3, and the like.
"Alkanoyl" groups are alkyl groups linked through a carbonyl, i.e., C1 -C5-C(0)-. Such groups include formyl, acetyl, propionyl, butyryl, and isobutyryl.
"Acyl" means an alkyl or aryl (Ar) group bonded through a carbonyl group, i.e., R-C(O)-. For example, acyl includes a C1 -C alkanoyl, including substituted alkanoyl, wherein the alkyl portion can be substituted by NR4R5or a carboxylic or heterocyclic group. Typical acyl groups include acetyl, benzoyl, and the like.
"Amide" is an amino carbonyl group such as -CONR4R5. The alkyl, alkenyl, alkoxy, and alkynyl groups described above are optionally substituted, preferably by 1 to 3 groups selected from NR4R5, phenyl, substituted phenyl, thio Cj-Cg alkyl, C^-Cβ alkoxy, hydroxy, carboxy,
Ci -Cg alkoxycarbonyl, halo, nitrile, cycloalkyl, and a 5- or 6-membered carbocyclic ring or heterocyclic ring having 1 or 2 heteroatoms selected from nitrogen, substituted mtrogen, oxygen, and sulfur. "Substituted nitrogen" means nitrogen bearing Cι -Cg alkyl or (CH )nPh where n is 1, 2, or 3. Perhalo and polyhalo substitution is also included.
Examples of substituted alkyl groups include 2-aminoethyl, 2-hydroxyethyl, pentachloroethyl, trifluoromethyl, 2-diethylaminoethyl,
2-dimethylaminopropyl, ethoxycarbonylmethyl, 3-phenylbutyl, methanylsulfanylmethyl, methoxymethyl, 3-hydroxypentyl, 2-carboxybutyl, 4-chlorobutyl, 3-cyclopropylpropyl, pentafluoroethyl, 3-mo holinopropyl, piperazinylmethyl, and 2-(4-methylpiperazinyl)ethyl. Examples of substituted alkynyl groups include 2-methoxyethynyl,
2-ethylsulfanylefhynyl, 4-( 1 -piperazinyl)-3 -(butynyl), 3 -phenyl-5-hexynyl, 3-diethylamino-3-butynyl, 4-chloro-3 -butynyl, 4-cyclobutyl-4-hexenyl, and the like.
Typical substituted alkoxy groups include aminomethoxy, trifluoromethoxy, 2-diethylaminoethoxy, 2-ethoxycarbonylethoxy,
3-hydroxypropoxy, 6-carboxlιexyloxy, and the like.
Further, examples of substituted alkyl, alkenyl, and alkynyl groups include dimethylaminomethyl, carboxymethyl, 4-dimethylamino-3-buten-l-yl, 5-ethylmethylamino-3-pentyn-l-yl, 4-morpholinobutyl, 4-tetrahydropyrinidylbutyl, 3-imidazolidin-l-ylpropyl, 4-tetrahydrothiazol-3-yl- butyl, phenylmethyl, 3-chlorophenylmethyl, and the like.
The term "anion" means a negatively charged counterion such as chloride, bromide, trifluoroacetate, and triethylammonium.
By "heteroaryl" is meant one or more aromatic ring systems of 5-, 6-, or 7-membered rings containing at least one and up to four heteroatoms selected from nitrogen, oxygen, or sulfur. Such heteroaryl groups include, for example, thienyl, furanyl, thiazolyl, triazolyl, imidazolyl, (is)oxazolyl, oxadiazolyl, tetrazolyl, pyridyl, thiadiazolyl, oxadiazolyl, oxathiadiazolyl, thiatriazolyl, pyrimidinyl, (iso)quinolinyl, napthyridinyl, phthalimidyl, benzimidazolyl, and benzoxazolyl. A preferred heteroaryl is pyridine.
By "aryl" is meant an aromatic carbocyclic group having a single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or multiple condensed rings in which at least one is aromatic, (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl, anthryl, or phenanthryl), which can be mono-, di-, or trisubstituted with, e.g., halogen, lower alkyl, lower alkoxy, lower alkylthio, trifluoromethyl, lower acyloxy, aryl, heteroaryl, and hydroxy. A preferred aryl is phenyl. The term "cancer" includes, but is not limited to, the following cancers: breast, ovary, cervix, prostate, testis, esophagus, glioblastoma, neuroblastoma, stomach, skin, keratoacanthoma, lung, epidermoid carcinoma, large cell carcinoma, adenocarcinoma, bone, colon, adenocarcinoma, adenoma, pancreas, adenocarcinoma, thyroid, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder carcinoma, liver carcinoma and biliary passages, kidney carcinoma, myeloid disorders, lymphoid disorders, Hodgkin's, hairy cells, buccal cavity and pharynx (oral), lip, tongue, mouth, pharynx, small intestine, colon-rectum, large intestine, rectum, brain and central nervous system, and leukemia. The term "pharmaceutically acceptable salts, esters, amides, and prodrugs" as used herein refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "salts" refers to the relatively nontoxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. Representative salts include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate mesylate, glucoheptonate, lactobionate and laurylsulphonate salts, and the like. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations including, but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like. (See, for example, Berge S.M. et al, "Pharmaceutical Salts," J Pharm. Sci, 1977;66:1-19 which is incorporated herein by reference.) Examples of pharmaceutically acceptable, non-toxic esters of the compounds of this invention include C^-Cg alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C5-C7 cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. C1 -C4 alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.
Examples of pharmaceutically acceptable, non-toxic amides of the compounds of this invention include amides derived from ammonia, primary Cι -C5 alkyl amines and secondary C^-Cg dialkyl amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C1 -C3 alkyl primary amines and
Ci-C2 dialkyl secondary amines are preferred. Amides of the compounds of the invention may be prepared according to conventional methods.
The term "prodrug" refers to compounds that are rapidly transformed in vivo to yield the parent compound of the above formulae, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuclii and V. Stella, "Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987, both of which are hereby incorporated by reference.
Representative compounds of the invention are shown below in Table 1. TABLE1
Figure imgf000014_0001
Figure imgf000014_0002
12 13
Figure imgf000014_0003
16 17 TABLE 1 (cont)
Figure imgf000015_0001
19 22
Figure imgf000015_0002
27
Figure imgf000015_0003
34 35 TABLE 1 (cont)
Figure imgf000016_0001
36 37
Figure imgf000016_0002
38 40 TABLE 1 (cont)
Figure imgf000017_0001
Al 54
TABLE 1 (cont)
Figure imgf000018_0001
74 86
Figure imgf000018_0002
91 102 TABLE 1 (cont)
Figure imgf000019_0001
110
Figure imgf000019_0002
118
Figure imgf000019_0003
TABLE 1 (cont)
Figure imgf000020_0001
Figure imgf000021_0001
192
Figure imgf000021_0002
TABLE 1 (cont)
Figure imgf000022_0001
Figure imgf000023_0001
TABLE 1 (cont)
Figure imgf000024_0001
TABLE 1 (cont)
Figure imgf000025_0001
TABLE 1 (cont)
Figure imgf000026_0001
Figure imgf000026_0002
TABLE 1 (cont)
Figure imgf000027_0001
Figure imgf000027_0002
Figure imgf000027_0003
TABLE 1 (cont)
Figure imgf000028_0001
The compounds of the present invention are useful for treating cancer (for example, leukemia and cancer of the lung, breast, prostate, and skin such as melanoma) and other proliferative diseases including but not limited to psoriasis,
HSV, HIV, restenosis, and atherosclerosis. To utilize a compound of the present invention to treat cancer, a patient having cancer is administered a therapeutically effective amount of a pharmaceutically acceptable composition comprising an invention compound. A further embodiment of this invention is a method of treating subjects suffering from diseases caused by vascular smooth muscle cell proliferation. Compounds within the scope of the present invention effectively inhibit vascular smooth muscle cell proliferation and migration. The method entails inhibiting vascular smooth muscle proliferation, and/or migration by administering an effective amount of a compound of Formula I to a subj ect in need of treatment. .
The compounds of the present invention can be formulated and administered in a wide variety of oral and parenteral dosage forms, including transdermal and rectal administration. It will be recognized to those skilled in the art that the following dosage forms may comprise as the active component, either a compound of Formula I or a corresponding pharmaceutically acceptable salt, ester, amide, prodrug, or solvate of a compound of Formula I.
A further embodiment of this invention is a pharmaceutical composition comprising a compound of Formula I together with a pharmaceutically acceptable carrier, diluent, or excipient therefor. For preparing pharmaceutical compositions with the compounds of the present invention, pharmaceutically acceptable carriers can be either a solid or liquid. Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispensable granules. A solid carrier can be one or more substances which may also act as diluents, flavoring agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier is a finely divided solid such as talc or starch which is in a mixture with the finely divided active component. In tablets, the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
The compositions of this invention preferably contain from about 5% to about 70% or more of the active compound. Suitable carriers include magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. A preferred form for oral use are capsules, which include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component with or without other carriers, is surrounded by a carrier, which is thus in association with it. Similarly, cachets and lozenges are included. Tablets, powders, capsules, pills, cachets, and lozenges can be used as solid dosage forms suitable for oral administration.
For preparing suppositories, a low melting wax, such as a mixture of fatty acid glycerides or cocoa butter, is first melted and the active component is dispersed homogeneously therein, as by stirring. The molten homogenous mixture is then poured into convenient size molds, allowed to cool, and thereby to solidify.
Liquid form preparations include solutions, suspensions, and emulsions such as water or water/propylene glycol solutions. For parenteral injection, liquid preparations can be formulated in solution in aqueous polyethylene glycol solution, isotonic saline, 5% aqueous glucose, and the like. Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing and thickening agents as desired. Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water and mixing with a viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, or other well-known suspending agents. Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for oral administration. Such liquid forms include solutions, suspensions, and emulsions. These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like. Waxes, polymers, microparticles, and the like can be utilized to prepare sustained-release dosage forms. Also, osmotic pumps can be employed to deliver the active compound uniformly over a prolonged period. The pharmaceutical preparations of the invention are preferably in unit dosage form. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.
The therapeutically effective dose of a compound of Formula I will generally be from about 1 mg/kg to about 100 mg/kg of body weight per day. Typical adult doses will be about 50 mg to about 800 mg per day. The quantity of active component in a unit dose preparation may be varied or adjusted from about
0.1 mg to about 500 mg, preferably about 0.5 mg to 100 mg according to the particular application and the potency of the active component. The composition can, if desired, also contain other compatible therapeutic agents. A subject in need of treatment with a compound of Formula I is administered a dosage of about 1 mg to about 500 mg per day, either singly or in multiple doses over a 24-hour period.
The compounds of the present invention are capable of binding to and inhibiting the activity of proteins having the ability to phosphorylate other proteins, such as cdks, PDGFr, FGFr, c-Src, and EGFr-FL. Cdks form complexes with cyclins, and these complexes phosphorylate key proteins allowing cells to proceed through the cell cycle (Meijer L., Progress in Cell Cycle Research, 1995;1:351-363). The compounds of this invention inhibit this phosphorylation and therefore can be used as anti-proliferative agents for the treatment of cancer and/or restenosis and other proliferative diseases.
Because of their inhibitory activity against cdks and other kinases, the compounds of the present invention are also useful research tools for studying the mechanism of action of those kinases, both in vitro and in vivo.
The examples presented below are intended to illustrate particular embodiments of the invention, and are not intended to limit the scope of the specification or the claims in any way.
An illustration of the preparation of compounds of the present invention is shown in Schemes 1 and 2.
Scheme 1
Figure imgf000032_0001
(EtO)2P(0)CH2C02Et NaH
Figure imgf000032_0002
Scheme 2
Figure imgf000033_0001
Figure imgf000033_0002
Those having skill in the art will recognize that the starting materials may be varied and additional steps employed to produce compounds encompassed by the present invention, as demonstrated by the following examples.
As shown in Schemes 1 and 2, a 4-substituted amino-2-methansulfanyl- pyrimidine-5-carboxaldehyde is reacted with an organometallic compound, such as, for example, a Grignard reagent, to afford the corresponding secondary alcohol. The alcohol is subsequently oxidized to the ketone. The ketone is then reacted with a trialkyl phosphonoacetate in the presence of base to produce the corresponding 8-substituted-5 -alkyl-2-methylsulfanyl-8H-pyrido [2,3 -d]pyrimidin- 7-one. The pyrido-pyrimidine then can be halogenated at the 6-position with a common halogenating agent, such as, for example, N-bromosucccinimide (NBS). The 2-methylsulfanyl derivative is oxidized to the corresponding methylsulfoxide, which is subsequently treated with a desired aniline to afford the 2-phenylamino invention compound. When carrying out various reactions to prepare invention compounds, it may be desirable to derivatize reactive groups such as amines, alcohols, and acids, with protecting groups that are readily removed when desired. Such protecting groups simply avoid unwanted side reactions. Use of protecting groups is common in the art of organic chemistry, as described by Greeve and Wuts in Protective Groups in Organic Synthesis, John Wiley and Sons, New York (2nc^ ed, 1991).
Typical hydroxy protecting groups include either forming groups such as benzyl, and acyl groups such as tert-butoxycarbonyl(Boc), formyl, and acetyl. Amino protecting groups include benzyl, acyl such as acetyl, and trialkylsilyl groups. Carboxylic acid groups typically are protected by conversion to an ester that can be easily hydrolyzed, for example, trichloroethyl, tert-butyl, benzyl, and the like.
Some of the invention compounds have one or more chiral centers, and thus can exist as individual optical isomers and mixtures thereof. Compound 246 (Table 1), for example, can exist as an RS racemate, or as the individual R or S isomer. All individual isomers and mixtures thereof are included in this invention. Individual isomers are readily prepared by a chiral synthesis, or by conventional resolution techniques well-known to those skilled in the art. The invention is illustrated further by the following detailed examples which are not to be construed as limiting the invention in scope or spirit to the specific procedures described in them. The starting materials and various intermediates utilized in the synthesis of invention compounds may be obtained from commercial sources, prepared from commercially available organic compounds, or prepared using well-known synthetic methods. The disclosures in this application of all articles and references, including patents, are incorporated herein by reference.
EXAMPLE 1 8-Cyclopentyl-6-fluoro-5-methyl-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-
7-one
Figure imgf000035_0001
NaH (771 mg, 19.3 mmol) is suspended in dry THF (20 mL), and the mixture is cooled to 0°C in an ice bath. Triethyl 2-fluoro-2-phosphonoacetate (3.9 mL, 19.3 mmol) is added dropwise with stirring, and the solution is stirred at room temperature for 30 minutes. A solution of l-(4-cyclopentylamino- 2-methylsulfanyl-pyrimidin-5-yl)-ethanone in dry THF (40 mL) is added via a cannula, and the reaction mixture is stirred at 24°C for 12 hours. The reaction is quenched by the addition of H2O (0.5 mL), and the THF is evaporated in vacuo. The residue is partitioned between ethyl acetate and saturated aqueous sodium chloride. The aqueous layer is extracted twice with fresh ethyl acetate, and the combined organic layers are dried over MgSO_{.. After removal of the drying agent and evaporation of the solvent, the crude product is purified by chromatography on silica gel (eluting with 20%-30% ethyl acetate in hexanes) to give the titled compound as a colorless solid (0.61 g, 23%). EXAMPLE 2 8~Cyclopentyl~6-fluoro-2-methanesulfinyl-5-methyl-8H-pyrido[2,3-d]pyrimidin- 7-one
Figure imgf000036_0001
8-Cyclopentyl-6-fluoro-5-methyl-2-methylsulfanyl-8H- pyrido[2,3-d]pyrimidin-7-one (0.61 g, 2.08 mmol) from Example 1 and 3-phenyl- 1-p-nitrophenylsulfonyloxaziridine (0.65 g, 2.5 mmol) are dissolved in CH2CI2
(20 mL) and stirred for 12 hours at 24°C. Following evaporation of the solvent, the crude product is purified by silica gel chromatography (eluting with 80%-100% ethyl acetate in hexanes) to provide the sulfoxide product as a white solid (0.55 g, 86%).
EXAMPLE 3 4-[4-(8-Cyclopentyl-6-fluoro-5-methyl- 7-oxo- 7, 8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperazine-l-carboxylic acidtert- butyl ester
Figure imgf000036_0002
8-Cyclopentyl-6-fluoro-2-methanesulfinyl-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (0.3 g, 0.97 mmol) from Example 2 and 4-(N-Boc- piperazin-l-yl)aniline (0.548 g, 1.94 mmol) are suspended in 1,4-dioxane (5 mL) and heated to 80°C for 12 hours. Anhydrous DMSO (2.5 mL) is added, and the temperature is raised to 100°C. Heating is continued for 24 hours, after which the reaction mixture is cooled to 24°C and partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The organic layer is separated and washed with H2O, and then with saturated aqueous sodium chloride. After drying over anhydrous MgSO the solvent is evaporated, and the residue is purified by silica gel chromatography to provide the titled compound as a yellow solid (0.23 g, 45%).
EXAMPLE 4 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-piperazin-l-yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one
Figure imgf000037_0001
4-[4-(8-Cyclopentyl-6-fluoro-5-methyl-7-oxo-7,8-dihydro- pyrido [2,3 -d]pyrimidin-2-ylamino)-phenyl] -piperazine- 1 -carboxylic acid tert- butyl ester (0.23 g, 0.44 mmol) from Example 3 is dissolved in a 1 :1 mixture of trifluoroacetic acid (TFA)/CH2Cl2 (20 mL) and stirred at room temperature for 1 hour. Evaporation of the solvents, followed by the addition of anhydrous diethyl ether, gave an orange solid (compound 34) that is collected by. filtration (0.21 g, 74%). Mp 254-255°C. C 3H27N6OF-1.93 TFA: Calcd C, 50.21; H, 4.54; N, 13.08. Found: C, 49.83; H,
4.45; N, 12.99.
EXAMPLE 5 6-Bromo-8-cyclopentyl-5-methyl~2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin- 7-one
Figure imgf000038_0001
8-Cyclopentyl-5-methyl-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin- 7-one (1 g, 3.64 mmol) is dissolved in dry DMF (15 mL) and N-bromosuccinimide (0.97 g, 5.45 mmol) is added followed by benzoylperoxide (0.13 g, 0.5 mmol). The resulting solution is stirred for 12 hours at 24°C. The mixture is then partitioned between ethyl acetate and H2O. The organic layer is washed with H2O, and then with saturated aqueous sodium chloride solution and dried over MgSO Removal of the drying agent and evaporation of the solvent gave the desired title product (0.86 g, 66%) which is used without further purification.
EXAMPLE 6 6-Bromo-8-cyclopentyl-5-methyl-2-(4-piperazin-l-yl-phenylamino)-8H~ pyrido[2,3-d]pyrimidin-7-one
Figure imgf000039_0001
6-Bromo-8-cyclopentyl-5-methyl-2-methylsulfanyl-8H- pyrido[2,3-d]pyrimidin-7-one is oxidized as described in Example 2. The sulfoxide is reacted with 4-(N-Boc-piperazin-l-yl)aniline as described in Example 3. The N-Boc protecting group is removed by hydrolysis as described above for 8-cyclopentyl-6-fluoro-5-methyl-2-methylsulfanyl-8H- pyrido[2,3-d]pyrimidin-7-one to provide 6-Bromo-8-cyclopentyl-5-methyl- 2-(4-piperazin-l-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (compound 35). Mp >200°C (dec).
C23H27N6OBr 1.9 TFA: Calcd C, 45.90; H, 4.15; N, 11.97. Found: C, 45.53; H, 4.09; N, 11.76.
EXAMPLE 7 l-(4-Cyclopentylamino-2-methylsulfanyl-pyrimidin-5-yl)-ethan-l-ol
Figure imgf000039_0002
4-Cyclopentylamino-2-methanesulfanyl-pyrimidine-5-carboxaldehyde (1.1 g, 4.64 mmol) is dissolved in tefrahydrofuran (30 mL) under nitrogen and then cooled with an ice bath. To this clear solution is slowly added methyl magnesium bromide (4.4 mL, 13.2 mmol, 3 M in ether). The reaction is stirred for 1 hour with the ice bath still in place. The reaction is quenched with a small amount of saturated aqueous ammonium chloride and then partitioned between water and ethyl acetate. The layers are separated, and the aqueous layer is extracted with ethyl acetate. The combined organic layers are washed with brine and then dried over magnesium sulfate. After filtration, the solvent is removed in vacuo to yield the titled compound as an oil (1.09 g, 90%). H NMR
(400 MHz, CDC13): δ 1.42-1.59 (m, 5H), 1.60-1.76 (m, 4H), 2.04-2.06 (m, 2H),
2.49 (s, 3H), 4.38-4.43 (m, IH), 4.69-4.74 (m, IH), 6.28-6.30 (d, IH), 7.57 (s, IH).
EXAMPLE 8 l-(4-Cyclopentylamino-2-methylsulfanyl-pyrimidin-5-yl)-ethanone
Figure imgf000040_0001
1 -(4-Cy clopentylamino-2-methylsulfanyl-pyrimidin-5-yl)-ethan- 1 -ol (1.09 g, 4.3 mmol) from Example 7 is dissolved in 100 mL of dichloromethane. The solution is purged by bubbling nitrogen gas through it for 2 minutes. To the reaction solution are added, in order: powdered molecular sieves (4 angstrom),
N-methyl morpholine oxide (1.07 g, 8.6 g), and tetrapropylammonium perruthenate (0.227 g, 0.645 mmol). The reaction mixture is stirred at 24°C for 2 hours, and small amounts of additional catalyst are periodically added. The reaction mixture is then run through a silica column (1:1, ethyl acetate :hexanes) to yield the titled compound as a light yellow solid (0.74 g, 70%). *H ΝMR (400 MHz, CDC13): δ 1.51-1.78 (m, 6H), 2.02-2.08 (m, 2H), 2.49 (s, 3H), 2.53 (s, 3H), 4.47-4.53 (m, 1H), 8.53 (s, 1H), 9.21 (s, IH); MS (M+l) 252.2.
EXAMPLE 9 8-Cyclopentyl-5-methyl-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin-7-one
Figure imgf000041_0001
A cooled (5°C) flask containing tetrahydrofuran (50 mL) is charged with sodium hydride (1.05 g, 26.3 mmol, 60% dispersion in mineral oil) under nitrogen, and 1.0 g of triethyl phosphonoacetate is added. The cooling bath is removed, and the mixture is stirred at 24°C until it becomes a homogeneous solution. The solution is diluted by the dropwise addition of a solution of
1 -(4-cyclopentylamino-2-methylsulfanyl-pyrimidin-5-yl)-ethanone (3.0 g, 11.9 mmol) in tetrahydrofuran (25 mL). The reaction mixture is heated to reflux for 2 hours. The reaction mixture is cooled to 24° C, and diluted 50 mL of water and 50 mL of ethyl acetate. Following separation of the layers, the organic layer is dried over magnesium sulfate and concentrated in vacuo to near dryness. Hexane is added, and the solid is stirred vigorously for 5 minutes before being filtered to yield the titled compound as a light pale orange solid (3.01 g, 92%). H NMR (400 MHz, CDCI3): δ 1.63-2.36 (m, 8H), 2.38 (s, 3H), 2.59 (s, 3H), 5.84-5.93 (m,
IH), 6.39 (s, IH), 8.66 (s, IH). EXAMPLE 10 8-Cyclopentyl-2-methanesulfinyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
Figure imgf000042_0001
8-Cyclopentyl-5-methyl-2-methylsulfanyl-8H-pyrido[2,3-d]pyrimidin- 7-one (1.0 g, 3.63 mmol) from Example 9 is dissolved in dichloromethane (15 mL), and (±)-trαrø-2-(phenylsulfonyl)-3-phenyloxaz_ridine is added. The reaction mixture is stirred at 24°C for 12 hours, and then the solution is passed through a silica column (2% MeOH in CH2CI2) to yield the titled sulfoxide as a white solid (0.67 g, 64%). H NMR (400 MHz, DMSO- 76): δ 1.53-2.19 (m, 8H), 2.45 (s, 3H), 2.87 (s, 3H), 5.75-5.84 (m, IH), 6.64 (s, IH), 9.19 (s, IH).
EXAMPLE 11 4-[4-(8-Cyclopentyl-5-methyl- 7-oxo- 7, 8-dihydro-pyrido[2,3-d]pyrimidin- 2-ylamino)-phenyl]-piperazine-l-carboxylic acid tert-butyl ester
Figure imgf000042_0002
8-Cyclopentyl-2-methanesulfinyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-
7-one (0.7 g, 2.4 mmol) from Example 10 and 4-(4'-N-Boc-piperazinyl)-aniline are dissolved in dimethylsulfoxide (8 mL) and heated to 90°C overnight. The reaction mixture is cooled to room temperature and partitioned between water and ethyl acetate. The organic layer is washed with sodium hydrogen carbonate, brine, and then dried over magnesium sulfate. Removal of the drying agent and concentration in vacuo gives the titled product as a yellow solid that is recrystalhzed from water and acetonitrile (0.55 g, 45%). IH NMR (400 MHz, CDC1 ): δ 1.45 (s, 9H), 1.56-1.87 (m, 6H), 2.23-2.28 (m, 2H), 2.31 (s, 3H),
3.07 (m, 4H), 3.55 (m, 4H), 5.77-5.81 (m, IH), 6.19 (s, IH), 6.90 (d, 2H), 7.42-7.44 (d, 2H), 7.47 (s, IH), 8.55 (s, IK); MS (M+1) 505.1. The Boc protecting group is removed by stirring in a 1 :1 mixture of trifluoroacetic acid/dichloromethane to give (Compound 1). Mp >215°C (dec).
EXAMPLE 12 8-Cyclopentyl-5-ethyl-2-(4-piperazin-l-yl-phenylamino)-8H-pyrido[2,3- aJpyrimidin-7-one (Compound 193)
Figure imgf000043_0001
1 -(4-Cyclopentylamino-2-methylsulfanyl-pyrimidin-5-yl)-propan- 1 -ol. 4-Cyclopentylamino-2-methylsulfanyl-pyrimidine-5-carbaldehyde (4.07 g, 17.1 mmol) was dissolved in THF (60 mL) under nitrogen then cooled with an ice bath. To this clear solution EtMgBr (13.4 mL, 40.3 mmol, Aldrich 3M in ether) was slowly added. The reaction was stirred for 15 minutes with the ice bath still in place. The reaction was quenched with a small amount of sat. aq. NH4CI then partitioned between water and EtOAc. The layers were separated, the organic layer dried over MgSθ4, and after filtration, the solvent was removed in vacuo to yield l-(4-cyclopentylamino-2-methylsulfanyl-pyrimidin-5-yl)-propan-l-ol as an oil (4.55 g, 99%) which was used without further purification. l-(4-Cyclopentylamino-2-methylsulfanyl-pyrimidin-5-yl) -propan-1 -one. 1 -(4-Cyclopentylamino-2-methylsulfanyl-pyrimidin-5-yl)-propan- 1 -ol (4.55 g, 17.1 mmol) was dissolved in toluene (80 mL) to which manganese (IV) oxide (3.72 g, 42.8 mmol, Aldrich <5 micron, activated, -85%) was subsequently added. The reaction was brought to reflux for 16 hours. The reaction was cooled to room temperature and filtered though a celite pad. The filtrate then was concentrated in vacuo to yield the product as a light yellow oil (3.79 g, 84%).
8-Cyclopentyl-5-ethyl-2-methylsulfanyl-8H-pyrido[2,3-dJpyrimidin-7-one. Under nitrogen, a cooled flask with THF (50 mL) was charged with NaH (1.23 g, 30.7 mmol, 60% dispersion in mineral oil) to which was added triethyl phosphonoacetate (6.09 mL, 30.7 mmol). The cooling bath was removed, and the reaction mixture was stirred at ambient temperature until everything dissolved. A solution of the 1 -(4-cyclopentylamino-2-methylsulfanyl-pyrimidin-5-yl)-propan- 1-one (3.0 g, 11.9 mmol) in THF (70 mL) was slowly added to the preformed anion. Then the reaction mixture was brought to reflux for 60 hours. The reaction was cooled to room temperature and diluted with water and EtOAc. The layers were separated, and the aqueous layer was extracted with EtOAc. The combined organic extracts were washed with brine, dried over MgSθ4, filtered, and concentrated in vacuo to give a waxy solid. The solid residue was triturated with hexanes to give a white solid after filtration (2.67 g, 66%).
8-Cyclopentyl-5-ethyl-2-methanesulfinyl-8H-pyrido[2,3-d]pyrimidin- 7 -one. 8-Cyclopentyl-5-ethyl-2-methylsulfanyl-8H-pyrido[2,3-_/]pyrimidin-7-one (2.57 g, 8.88 mmol) was dissolved in CH2CI2 (50 L), and 2-benzene-sulfonyl-
3-phenyl-oxaziridine was added. The reaction mixture was stirred for 16 hours at room temperature. Then the solution was evaporated in vacuo to give an orange oil. EtOAc was added and a white precipitate formed. This precipitate was filtered and washed with hexanes to yield a white solid (2.12 g, 78%).
4-[4-(8-Cyclopentyl-5-ethyl- 7-oxo-7, 8-dihydro-pyrido[2, 3-d]pyrimidin- 2-ylamino)-phenyl]-piperazine-l -carboxylic acid tert-butyl ester. The sulfoxide, 8-cyclopentyl-5-ethyl-2-methanesulfinyl-8H-pyrido[2,3-_ ]pyrimidin-7-one (0.2 g, 0.654 mmol) and 4-(4'-N-Boc-piperazinyl)-aniline were dissolved in DMSO (5 mL) and heated to 70°C for 16 hours. The reaction mixture was cooled to room temperature and partitioned between water and EtOAc. The organic layer was washed with brine then dried over MgSθ4. After filtration and concentrate in vacuo, orange solid was obtained which was purified by column chromatography to yield the product as a yellow solid (0.160 g, 47%).
8-Cyclopentyl-5-ethyl-2-(4-piperazin-l-yl-phenylamino)~8H- pyrido[2,3-d]pyrimidin-7-one _?55)-4-[4-(8-Cyclopentyl-5-ethyl-7-oxo- 7, 8-dihydro-pyrido [2,3 -_ ]pyrimidm-2-ylammo)-phenyl]-piperaz_ne- 1 -carboxylic acid tert-butyl ester was dissolved in dichloromethane (2 mL), and trifluoroacetic acid (0.5 mL) was added. This mixture was stirred at room temperature for 15 hours. The solvent was evaporated, then the solid was suspended in diethyl ether and filtered to give a fluffy gray solid (128 mg, 75%). 1H ΝMR (400 MHz, DMSO-d6): δ 1.17 (m, 3H), 1.52-1.83 (m, 6H), 2.20 (m, 2H), 2.75 (m, 2H), 3.22 (m, 4H), 5.78 (m, IH), 6.10 (s, IH), 6.95 (d, 2H), 7.53 (d, 2H), 8.73 (s, 2H),
8.79 (s, IH), 9.76 (s, IH); CHΝ for C23H30Ν6O + 1.21 TFA.
EXAMPLE 13 2-[4-(4-Acetyl-piperazin-l-yl)-phenylamino]-8-cyclopentyl-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 198)
Figure imgf000045_0001
l-[4-(4-Amino-phenyl)-piperazin-l-yl]-ethane (0.075 g, 0.343 mmol) and 8-cyclopentyl-5-methyl-2-methanesulfinyl-8H-pyrido[2,3-cT|pyrimidin-7-one (0.100 g, 0.343 mmol) were dissolved in DMSO (5 mL) and heated to 70°C for 16 hours. At this point, 20 mg more of the aniline was added, and heating was continued for an additional 4 hours. The reaction was cooled to room temperature and partitioned between water and EtOAc. The organic layer was washed with brine then dried over MgSθ4. Filtration and concentration in vacuo gave an orange solid which was purified by column chromatography to yield a yellow solid (0.049 g, 32%). Mp 261-263°C.
EXAMPLE 14 2-[4-((3R,4S)-Aminomethyl-trifluoromethyl-pyrrolidin-l-yl)-phenylamino)- 8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 216)
Figure imgf000046_0001
[(3R,4S)-l-(4-Amino-phenyl)-trifluoromethyl-pyrrolidin-3-ylmethyl]- carbamic acid tert-butyl ester. ((3S,4S)-4-Trifluoromethyl-pyrrolidin-3-ylmethyl)- carbamic acid tert-butyl ester (1.0 g, 3.72 mmol), j_>-fluoro-nitrobenzene (0.36 mL, 3.38 mmol) and diisopropyl ethyl amine (0.65 mL, 3.72 mmol) were dissolved in acetonitrile (10 mL) and refluxed for 24 hours. The solvent was removed, and the mixture was triturated with hexanes and filtered to yield a crude yellow solid (1.4 g). This product was dissolved in THF and treated with Raney Nickel under a hydrogen atmosphere until no further change in pressure was observable. Following removal of the catalyst by filtration, the product aniline was obtained by evaporation of the solvent and used without further purification.
{(3R, 4S)-[4-(8-Cyclopentyl-5~methyl-7-oxo-7, 8-dihydro- pyrido[2,3~a]pyrimidin-2-ylamino)-phenyl]-trifluoromethyl-pyrrolidin- 3 -ylmethyl} -carbamic acid tert-butyl ester (222). [(3R,4S)-l-(4-Amino-phenyl)- trifluoromethyl-pyrrolidin-3-ylmethyl] -carbamic acid tert-butyl ester and 8-cyclopentyl-5-methyl-2-methanesulfinyl-8H-pyrido[2,3-(i]ρyrimidin-7-one were coupled and deprotected as previously described for Example 11. CΗN for C25Η29N601F3 + 1.6 TFA, mp >130°C (dec).
EXAMPLE 15
8-Cyclopentyl-5-methyl-2-{4-[2-(4H~[l,2,4]triazol-3-ylsulfanyl)-ethyl]- phenylamino}-8H-pyrido[2,3-dJpyrimidin- 7-one (Compound 222)
Figure imgf000047_0001
4-[2(4H-[l,2,4]triazol-3-ylsulfanyl)-ethyl]-phenylamine. To a suspension of hexane rinsed 60% sodium hydride (0.83 g), in dimethylformamide (5 mL) at
0°C, was added a solution of 3-mercapto-l,2,4-triazole (2.0 g) in dimethylformamide (10 mL) in portions. After 45 minutes 4-nitrophenethyl bromide (4.1 g) was added, and the reaction mixture was stirred at room temperature for 18 hours. 1 M Hydrochloric acid (70 mL) was added and the aqueous phase was extracted with diethyl ether (3 x 100 mL), and the combined organic extracts were concentrated to dryness. The resulting solid was collected, washed with diethyl ether (2 x 10 mL) and dried to yield the nitrobenzene intermediate (3.17 g). MS: MH+, 251; MH- 248.9. A solution of this intermediate (1.0 g) was reduced using Raney Nickel (0.5 g) and hydrogen in THF (100 mL). The sample was concentrated to dryness to yield the title compound (0.88 g), MS:
MH+, 221; MH-, 219.
8~Cyclopentyl-5-methyl-2-{4-[2-(4H-[l,2,4]triazol-3-ylsulfanyl)-ethyl]~ phenylamino}-8H-pyrido[2,3-d]pyrimidin~7-one. A solution of 8-cyclopentyl- 5-methyl-2-methanesulfmyl-8H-pyrido[2,3-c ]ρyrimidin-7-one (0.02 g), 4-[2(4H- [l,2,4]triazol-3-ylsulfanyl)-ethyl]-phenylamine (0.0166 g) and trifluoroacetic acid (0.06 mL) in acetonitrile (2 mL) was heated at 80°C for 18 hours. The reaction mixture was cooled and the solvent removed in vacuo. 1 M Sodium hydroxide (4 mL) was added and the aqueous phase was extracted with diethyl ether (3 x 4 mL); sodium chloride (20 mg) was added after the first extraction. The aqueous layer was acidified to pH = 1 and extracted with a mixture of ethyl acetate/dichloromethane (9:1) (3 x 4 mL). The combined ethyl acetate/dichloromethane extracts were concentrated to dryness and purified by column chromatography using a gradient of ethyl acetate 60% to 100% in hexanes. Concentration of the appropriate fractions yielded Compound 222
(0.014 g). !H NMR (d6.DMSO): δ 1.58 (2H, m), 1.7 (2H, m), 1.88 (2H, m),
2.2 (2H5 m), 2.38 (3H, s), 2.9 (2H, m), 3.4 (2H, m), 5.7 (IH, s), 5.8 (IH, m), 7.18 (2H, d, J = 9), 7.6 (2H, d, J = 9), 8.78 (IH, s).
EXAMPLE 16 8-Cyclopentyl-5-methyl-2-[4-(lH-[l,2,4]triazol-3-ylsulfanyl)-phenylamino]-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 223)
Figure imgf000048_0001
4-(lH-[l,2,4]triazol-3-ylsulfanyl)-phenylamine. To a suspension of hexanes rinsed 60% sodium hydride (1.16 g) in dimethylformamide (10 mL) at 0°C was added a solution of 3-mercapto-l,2,4-triazole (4.0 g) in dimethylformamide (20 mL) dropwise. After 20 minutes, l-fluoro-4-nitrobenzene (5 g) in dimethylformamide (20 mL) was added, and the reaction mixture was stirred at room temperature for 2 hours, then at 60°C for 18 hours. 1 M Hydrochloric acid (100 mL) was added, and the solid was collected and dried. A second crop of solid (2.1 g) was recovered by crystallization from the mother liquors. To the combined solids was added dichloromethane (300 mL) and 1 M sodium hydroxide (200 mL). The dichloromethane was further extracted with 1 M sodium hydroxide (100 mL). The combined aqueous phases were extracted with dicliloromethane (2 x 300 mL) then acidified to pH = 1. The solid formed was collected and dried to yield the nitrobenzene derivative (1.96 g). This product was reduced using Raney Nickel and hydrogen in tetrahydrofuran (100 mL). Following removal of the catalyst, the sample was concentrated to dryness to yield the desired product (1.7 g), MS: MH+, 192.9; MH-, 190.0.
8-Cyclopentyl-5-methyl-2-[4-(lH-[l, 2, 4]triazol-3-ylsulfanyl)- phenylaτnino]-8H-pyrido[2, 3-dJpyrimidin- 7 -one. This compound was prepared from 4-(lH-[l,2,4]triazol-3-ylsulfanyl)-phenylamine and 8-cyclopentyl-5-methyl- 2-methanesulfinyl-8H-pyrido[2,3- ]pyrimidin-7-one by the procedure of
Example 15 to give Compound 223. *ΗNMR (D6-DMSO): δ 1.58 (2H, m),
1.75 (2H, m), 1.90 (2H, m), 2.2 (2H, m), 2.38 (3H, s), 5.82 (IH, m), 6.20 (IH, s), 7.4 (2H, d, J = 9), 7.73 (2H, d, J = 9), 8.85 (IH, bs), 8.82 (IH, s).
EXAMPLE 17 8-Cyclopentyl-5-methyl-7-oxo-2-(4-piperazin-l-yl-phenylamino)-7,8-dihydro- pyrido[2,3-d]pyrimidine-6-carboxylic acid methyl ester (Compound 224)
Figure imgf000049_0001
4-[4-(6-Bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido [2,3 -<fJpyrimidin-2-ylamino)-phenyl]-piperazine- 1 -carboxylic acid tert-butyl ester (300 mg, 0.515 mmol), Pd(OAc) (23 mg, 0.05 mmol), l,2-bis(diphenylphosphino)-propane 64 mg, 0.155 mmol), and triethylamine (0.18 mL, 1.29 mmol) were combined in methanol and pressurized to 500 PSI in CO gas. The reaction mixture was heated to 100°C and stirred for 14 hours, then allowed to cool to 24°C. Evaporation of the solvent, followed by chromatography on Siθ2 (45%-50% EtOAc in Hexanes) gave a yellow oil. This oil was dissolved in CH2CI2 (10 mL) and treated with 2 M HCl in diethyl ether (10 mL) at room temperature. A white precipitate formed. After stirring for 3 hours at room temperature, the solvent was evaporated. The residue was re-suspended in anhydrous diethyl ether and filtered to give the titled compound as a yellow solid
(34 mg), mp 195-205°C. *H MR (d6-DMSO): δ 1.52 (br s, 2H), 1.71 (br s, 2H),
1.82 (br s, 2H), 2.14 (br s, 2H), 2.30 (s, 3H), 3.18 (s, 4H), 3.27 (s, 4H), 3.76 (s, 3H), 5,8 (s, IH), 6.96 (d, J = 8 Hz, 2H), 7.53 (d, J = 8 Hz, 2H), 8.85 (s, IH),
9.04 (s, IH), 9.97 (s, IH).
EXAMPLE 18 The following compounds are prepared essentially according to the procedures described in Examples 1 to 17 and as illusfrated in Schemes 1 and 2: (a) 8-Cyclopentyl-5-methyl-2-(4-piperazin-l -yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one trifluoroacetic acid salt (Compound 1), mp >215°C (dec);
(b) 8-(l-Methylethyl)-5-methyl-2-(4-piperazin-l-yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 2), mp >235°C (dec); (c) 8-CycIopentyl-5-methyl-2-(4-fluoro-3-methylphenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 3);
(d) 8-(l-Methylethyl)-5-methyl-2-(4-fluoro-3-methylphenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 4);
(e) 8-Cyclohexyl-5-methyl-2-(4-fluoro-3-methylphenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 5);
(f) 8-Cyclohexyl-5-methyl-2-[4-(4-propanoylpiperazin-
1 -yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 6);
(g) 8-Cyclopentyl-5-methyl-2-[4-(4-propanoylρiperazin- l-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetic acid salt (Compound 7), mp 235-237°C; (h) 8-(l -Methylethyl)-5-methyl-2-[4-(4-propanoylpiperazin- l-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 8);
(i) 8-Cyclohexyl-5 -methyl-2-(4-ρiρerazin- 1 -yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 9); (j) 8-Cyclopentyl-5-methyl-2-(4-:pyridylphenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 10);
(k) 8-(l -Methylethyl)-5-methyl-2-(4-pyridylphenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 11);
(1) 8-Cyclopentyl-5-methyl-2-[4-(3-aminopyrrolidinyl)phenylamino]-8H- pyrido[2,3-d]pyrimidin-7-one trifluoroacetic acid salt (Compound 12), mp >195°C (dec);
(m) 8-(l-Methylethyl)-5-methyl-2-[4-(3-aminopyriOlidinyl)phenylamino]- 8H-ρyrido[2,3-d]pyrimidin-7-one (Compound 13), mp >227-229°C;
(n) N-(l-{4-[(8-cyclopentyl-5-methyl-7-oxo(8-hydropyridino[2,3-d]- pyrimidin-2-yl))amino]phenyl}pyrrolidin-3-yl)-3,3-dimethylbutanamide
(Compound 14);
(o) N-(l-{4-[(5-methyl-8-(l-methylethyl)-7-oxo(8-hydropyridino[2,3-d]- pyrimidin-2-yl))amino]phenyl}pyrrolidin-3-yl)-3,3-dimethylbutanamide (Compound 15); (p) 8-Cyclopentyl-5-methyl-2-(3-chloro-4-piperazin-l-yl-phenylamino)-
8H-pyrido[2,3-d]pyrimidin-7-one (Compound 16), mp 234-237°C;
(q) 8-Cyclohexyl-5-methyl-2-(3-chloro-4-piperazin-l-yl-phenylamino)- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 17);
(r) 8-(l -Methylethyl)-5 -methyl-2-(3 -chloro-4-piperazin- 1 -yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 18);
(s) 8-Cyclopentyl-6-fluoro-5-methyl-2-(3-chloro-4-piperazin-l-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 19);
(t) 8-Cyclohexyl-6-fluoro-5-methyl-2-(3-chloro-4-piperazin-l-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 21); (u) 8-(l -Methylethyl)-6-fluoro-5 -methyl-2-(3 -chloro-4-piperazin- 1 -yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 20); (v) 8-Cyclopentyl-5-methyl-2-(3-chloro-4-morpholin-4-yl-phenylamino)- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 22);
(w) 8-(l-Methylethyl)-5-methyl-2-(3-chloro-4-morpholin-4-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 23); (x) 8-Cyclohexyl-5-methyl-2-(3-chloro-4-morpholin-4-yl-phenylamino)-
8H-pyrido[2,3-d]pyrimidin-7-one (Compound 24);
(y) 2-({3-chloro-4-[4-(3-morpholin-4-ylpropyl)piperidyl]ρhenyl}amino)- 8-cyclopentyl-5-methyl-8-hydropyridino[2,3-dJpyrimidin-7-one (Compound 25); (z) 2-( { 3 -chloro-4-[4-(3 -morpholin-4-ylpropyl)piperidyl]phenyl} amino)- 8-(l-methylethyl)-5-methyl-8-hydropyridino[2,3-d]pyrimidin-7-one
(Compound 26);
(aa) 2-({3-chloro-4-[4-(3-morpholin-4-ylpropyl)piperidyl]phenyl}amino)- 8-cyclohexyl-5-methyl-8-hydropyridino[2,3-d]pyrimidin-7-one (Compound 27); (bb) 2-({3-chloro-4-[4-(3-piperazinylpropyl)piperidyl]phenyl}amino)- 8-cyclopentyl-6-fluoro-5-methyl-8-hydropyridino[2,3-d]pyrimidin-7-one
(Compound 28);
(cc) 2-( { 3 -chloro-4- [4-(3 -piperazinylpropyl)piperidyl]phenyl } amino)- 8-(l-methylethyl)-6-fluoro-5-methyl-8-hydropyridino[2,3-d]pyrimidin-7-one (Compound 29); (dd) 2-({3-chloro-4-[4-(3-piperazinylpropyl)piperidyl]phenyl}amino)-
8-cyclohexyl-6-fluoro-5-methyl-8-hydropyridino[2,3-d]pyrimidin-7-one (Compound 30), mp >80°C (dec);
(ee) 2-( { 3 -chloro-4- [4-(3 -piperazinylpropy l)piperidy l]phenyl } amino)- 8-cyclopentyl-5-methyl-8-hydropyridino[2,3-d]pyrimidin-7-one (Compound 31); (ff) 2-({3-chloro-4-[4-(3-piperazinylpropyl)piperidyl]phenyl}amino)-
8-(l-methylethyl)-5-methyl-8-hydropyridino[2,3-d]ρyrimidin-7-one (Compound 32);
(gg) 2-( {3 -chloro-4- [4-(3 -piperazinylpropyl)ρiperidyl]phenyl } amino)- 8-cyclohexyl-5-methyl-8-hydropyridino[2,3-d]pyrimidin-7-one (Compound 33); (gg2) 8-Cyclopentyl-2-[4-(piperazin-l-yl)-phenylamino]-6-fluoro-5- methyl-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 34), mp 254-255°C; (gg3) 8-Cyclopentyl-2-[4-(piperazin-l-yl)-phenylamino]-6-bromo-5- methyl-8H-pyrido[2,3-d]ρyrimidin-7-one trifluoroacetate (Compound 35), mp >200°C;
(hh) 8-Cyclopentyl-2-[4-(3,5-dimethyl-piperazin-l-yl)-phenylamino]- 6-fluoro-5-methyl-8H-pyrido [2,3-d]pyrimidin-7-one hydrochloride
(Compound 36), mp >220°C;
(ii) 8-Cyclopentyl-2-(3 -fluoro-4-piρerazin- 1 -yl-phenylamino)-5 -methyl- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 37);
(jj) 6-Bromo-8-cyclopentyl-2-[4-(3,5-dimethyl-piperazin-l-yl)- ρhenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride
(Compound 38), mp >230°C;
(kk) 8-Cyclopentyl-6-fluoro-2-(3-fluoro-4-piperazin-l-yl-phenylamino)- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 39);
(11) 6-Bromo-8-cyclopentyl-2-(3-fluoro-4-piperazin- 1 -yl-phenylamino)- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 40);
(mm) 8-Cyclopentyl-2-[4-(3,5-dimethyl-piperazin-l-yl)-phenylamino]- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride (Compound 41);
(nn) 2-(3-Chloro-4-piperazin-l-yl-phenylamino)-8-cyclopentyl-5-methyl- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 42); (oo) 2-(3-Chloro-4-piperazin-l-yl-phenylamino)-8-cyclopentyl-6-fluoro-
5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 43);
(pp) 6-Bromo-2-(3-chloro-4-piperazin- 1 -yl-phenylamino)-8-cyclopentyl- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 44);
(qq) 8-Cyclopentyl-5-methyl-2-(4-morpholin-4-yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 45), mp 227-229°C;
(rr) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-morpholin-4-yl-phenylamino)- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 46);
(ss) 6-Bromo-8-cyclopentyl-5-methyl-2-(4-morpholin-4-yl-phenylamino)- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 47); (tt) 8-Cyclopentyl-2-(3-fluoro-4-morpholin-4-yl-phenylamino)-5-methyl-
8H-pyrido[2,3-d]ρyrimidin-7-one (Compound 48); (uu) 8-Cyclopentyl-6-fluoro-2-(3-fluoro-4-morpholin-4-yl-phenylamino)- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 49);
(w) 6-Bromo-8-cyclopentyl-2-(3-fluoro-4-morpholin-4-yl-phenylamino)- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 50); (ww) 2-(3-Chloro-4-morpholin-4-yl-phenylamino)-8-cycloρentyl-
5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 51);
(xx) 2-(3-Chloro-4-morpholin-4-yl-phenylamino)-8-cyclopentyl-6-fluoro- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 52);
(yy) 6-Bromo-2-(3 -chloro-4-morpholin-4-yl-phenylamino)-8-cyclopentyl- 5 -methyl-8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 53) ;
(zz) 8-Cyclopentyl-5-methyl-2-{4-[4-(2,2,2-trifluoro-ethyl)-piρerazin- 1 -yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 54), mp 198-199°C;
(aaa) 8-Cyclopentyl-6-fluoro-5-methyl-2-{4-[4-(2,2,2-trifluoro-ethyl)- piperazin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 55);
(bbb) 6-Bromo-8-cycloρentyl-5-methyl-2-{4-[4-(2,2,2-trifluoro-ethyl)- piperazin- 1 -yl] -phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 56);
(ccc) 8 -Cyclopentyl-5 -methyl-2- {4- [4-(3 -piperazin- 1 -yl-propyl)- piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 57), mp >80°C (dec);
(ddd) 8-Cyclopentyl-6-fluoro-5 -methyl-2- {4-[4-(3 -piperazin- 1 -yl-propyl)- piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 58), mp >230°C;
(eee) 6-Bromo-8-cyclopentyl-5-methyl-2-{4-[4-(3-piperazin-l-yl-propyl)- piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 59);
(fff) 8-Cyclopentyl-5-methyl-2- {4-[4-(3-morpholin-4-yl-propyl)- piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 60);
(ggg) 8-Cyclopentyl-6-fluoro-5-methyl-2-{4-[4-(3-morpholin-4-yl- propyl)-piperidin- 1 -yl]-phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 61); (hhh) 6-Bromo-8-cyclopentyl-5-methyl-2-{4-[4-(3-morpholin-4-yl- propyl)-piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 62);
(iii) 6-Bromo-8-cyclopentyl-5-methyl-2-{4-[4-(3-mo holin-4-yl-propyl)- piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 63);
(jjj) 2-(4- {4-[3 -(3 - Amino-pyrrolidin- 1 -yl)-propyl]-piperidin- 1 -yl} - phenylamino)-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 64);
(kkk) 2-(4-{4-[3-(3-Amino-pyrrolidin-l-yl)-propyl]-piperidin-l-yl}- phenylamino)-8-cyclopentyl-6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 65);
(111) 2-(4-{4-[3-(3-Amino-pyrrolidin-l-yl)-propyl]-piperidin-l-yl}- phenylamino)-6-bromo-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 66); (irimm) 8-Cyclopentyl-2-{3-fluoro-4-[4-(3-piperazin-l-yl-propyl)- piperidin- 1 -yl] -phenylamino } -5 -methyl- 8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 67);
(nnn) 8-Cyclopentyl-6-fluoro-2-{3-fluoro-4-[4-(3-piperazin-l-yl-propyl)- piρeridin-l-yl]-phenylamino}-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 68);
(ooo) 6-Bromo-8-cyclopentyl-2-{3-fluoro-4-[4-(3-piperazin-l-yl-propyl)- piperidin-l-yl]-phenylamino}-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 69);
(ppp) 8-Cyclopentyl-2-{3-fluoro-4-[4-(3-morpholin-4-yl-propyl)- piperidin-l-yl]-phenylamino}-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 70);
(qqq) 8-Cyclopentyl-6-fluoro-2-{3-fluoro-4-[4-(3-morpholin-4-yl- propyl)-piperidin-l-yl]-phenylamino}-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 71); (rrr) 6-Bromo-8-cyclopentyl-2- {3 -fluoro-4- [4-(3 -morpholin-4-yl-propyl)- piperidin-l-yl]-phenylamino}-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 72); (sss) 2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-cyclopentyl- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 73), mp >215°C (dec);
(ttt) 2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-8-cyclopentyl- 6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 74); (uuu) 2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-6-bromo-
8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 75);
(vw) 2-[4-(3-Amiιιo-pyrrolidin-l-yl)-3-fluoro-phenylamino]- 8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 76); (www) 2-[4-(3-Amino-pyrrolidin-l-yl)-3-fluoro-phenylamino]- 8-cyclopentyl-6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 77);
(xxx) 2-[4-(3-Amino-pyrrolidin-l-yl)-3-fluoro-phenylamino]-6-bromo- 8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 78); (yyy) 8-Cyclopentyl-5-methyl-2-{4-[3-(2,2,2-trifluoro-ethylamino)- pyrrolidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate
(Compound 79), mp >160°C (dec);
(zzz) 8-Cyclopentyl-6-fluoro-5-methyl-2-{4-[3-(2,2,2-trifluoro- ethylamino)-pyrrolidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 80); (aaaa) 6-Bromo-8-cyclopentyl-5-methyl-2-{4-[3-(2,2,2-trifluoro- ethylamino)-pyrrolidin- 1 -yl]-phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 81);
(bbbb) 2- [4-(3 - Amino-pyrrolidin- 1 -yl)-3 -chloro-phenylamino] - 8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 82), mp >215°C (dec);
(cccc) 2- [4-(3 -Amino-pyrrolidin- 1 -yl)-3 -chloro-phenylamino] - 8-cyclopentyl-6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 83), mp 221 °C;
(dddd) 2-[4-(3 -Amino-pyrrolidin- 1 -yl)-3 -chloro-phenylamino] -6-bromo- 8-cycloρentyl-5-methyl-8H-ρyrido[2,3-d]pyrimidin-7-one (Compound 84); (eeee) 2-[4-(3-Aminomethyl-4-trifluoromethyl-pyrrolidin-l-yl)- phenylamino] - 8 -cy clopentyl-5 -methyl- 8H-py rido [2,3 -d]pyrimidin-7-one (Compound 85);
(ffff) 2- [4-(3 - Aminomethyl-4-trifluoromethyl-pyrrolidin- 1 -yl)- phenylamino]-8-cyclopentyl-6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 86);
(gggg) 2-[4-(3-Aminomethyl-4-trifluoromethyl-pyrrolidin-l-yl)- phenylamino]-6-bromo-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 87); (hhhh) 2-[4-(3-Trifloroethylaminomethyl-pyrrolidin-l -yl)-phenylamino]-
8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 88);
(iiii) 2-[4-(3-Trifloroethylaminomethyl-pyrrolidin-l-yl)-phenylamino]- 8-cyclopentyl-6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 89); (jjjj) 2-[4-(3-TrifloiOethylaminomethyl-pyrrolidin-l-yl)-phenylamino]-
6-bromo-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 90);
(kkkk) 8-Cyclopentyl-2-[4-(3,3-dimethyl-piperazin-l-yl)-phenylamino]- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride (Compound 91), mp >150°C (dec);
(llll) 8-Cyclopentyl-2-[4-(3,3-dimethyl-piperazin-l-yl)-phenylamino]- 6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 92);
(rnminm) 6-Bromo-8-cyclopentyl-2- [4-(3 ,3 -dimethyl-piperazin- 1 -yl)- phenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride (Compound 93), mp >200°C (dec);
(nnnn) 8-Cyclopentyl-5-methyl-2-[4-(3,3,4-trimethyl-piperazin-l-yl)- phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 94);
(oooo) 8-Cyclopentyl-6-fluoro-5-mefhyl-2- [4-(3 ,3 ,4-trimethyl-piperazin- l-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 95); (PPPP) 6-Bromo-8-cyclopentyl-5-methyl-2-[4-(3,3,4-trimethyl-piperazin- l-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 96); (qqqq) 2- [4-(4- Acetyl-piperazin- 1 -yl)-phenylamino] - 8 -cyclopentyl- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 97);
(rrrr) 2-[4-(4-Acetyl-piperazin-l-yl)-phenylamino]-8-cyclopentyl- 6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 98), mp 267-269°C;
(ssss) 2-[4-(4-Acetyl-piperazin-l-yl)-phenylamino]-6-bromo- 8-cycloρentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 99);
(tttt) 8-Cyclopentyl-2- {4- [4-(2-hydroxy-ethyl)-3 ,5-dimethyl-piperazin- 1 -yl] -phenylamino } -5 -methyl- 8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 100), mp 156-159°C;
(uuuu) 8-Cyclopentyl-6-fluoro-2-{4-[4-(2-hydroxy-ethyl)-3,5-dimethyl- piperazin-l-yl]-phenylamino}-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 101);
(vvw) 6-Bromo-8-cyclopentyl-2-{4-[4-(2-hydroxy-ethyl)-3,5-dimethyl- piperazin-l-yl]-phenylamino}-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 102);
(wwww) 8-Cyclopentyl-5-methyl-2-(4-perhydro-l,4-diazepin-l-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride (Compound 103), mp 172°C (dec); (xxxx) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-perhydro-l,4-diazepin-l-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride (Compound 104), mp 192°C (dec);
(yyyy) 6-Bromo-8-cyclopentyl-5-methyl-2-(4-perhydro- 1 ,4-diazepin- 1 -yl- phenylamino)-8H-ρyrido[2,3-d]pyrimidin-7-one (Compound 105); (zzzz) 8-Cyclopentyl-5-methyl-2-[4-(4-methyl-piperazin-l ~yl)- phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 106), m 211-213°C;
(aaaaa) 8-Cyclopentyl-6-fluoro-5-methyl-2-[4-(4-methyl-piperazin-l-yl)- phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 107); (bbbbb) 6-Bromo-8-cyclopentyl-5-methyl-2-[4-(4-methyl-piperazin-l-yl)- phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 108); (ccccc) 8-Cyclopentyl-5-methyl-2- [4-(4-methyl-perhydro- 1 ,4-diazepin- l-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 109), mp >185°C (dec);
(ddddd) 8-Cyclopentyl-6-fluoro-5-methyl-2-[4-(4-methyl-perhydro- 1 ,4-diazepin- 1 -yl)-pheny lamino] - 8H-pyrido [2,3 -d]pyrimidin-7-one
(Compound 110);
(eeeee) 6-Bromo-8-cyclopentyl-5-methyl-2-[4-(4-methyl-perhydro- l,4-diazepin-l-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 111); (fffff) {4-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido [2,3 -d]pyrimidin-2-ylamino)-phenyl] -piperazin- 1 -yl} -acetic acid (Compound 112);
(ggggg) {4-[4-(8-Cyclopentyl-6-fluoro-5-methyl-7-oxo-7,8-dihydro- pyrido [2,3 -d]pyrimidin-2-ylamino)-phenyl] -piperazin- 1 -y 1 } -acetic acid (Compound 113);
(Mihhh) {4-[4-(6-Bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperazin-l-yl}-acetic acid (Compound 114);
(iiiii) 8-Cyclopentyl-5-methyl-2-(4-{4-[3-(lH-tetrazol-5-yl)-propyl]- piperidin-l-yl}-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 115);
(iujj) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-{4-[3-(lH-tetrazol-5-yl)- propyl]-piperidin-l-yl}-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 116); (kkkkk) 6-Bromo-8-cyclopentyl-5-methyl-2-(4-{4-[3-(lH-tetrazol-5-yl)- propyl]-piperidin-l-yl}-ρhenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 117);
(lllll) 8-Cyclopentyl-5-methyl-2-(4-{4-[3-(5-oxo-4,5-dihydro-lH- l,2,4-triazol-3-ylsulfanyl)-propyl]-piperidin-l-yl}-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 118); (lnmmmin) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-{4-[3-(5-oxo- 4,5-dihydro-lH-l,2,4-triazol-3-ylsulfanyl)-propyl]-piperidin-l-yl}-phenylamino)- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 119);
(rinnnn) 6-Bromo-8-cyclopentyl-5-methyl-2-(4-{4-[3-(5-oxo-4,5-dihydro- 1 H- 1 ,2,4-triazol-3 -ylsulfanyl)-propyl] -piperidin- 1 -yl} -phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 120);
(ooooo) 8-Cyclopentyl-5 -methyl-2-(4- {4- [3 -(5-oxo-4,5 -dihydro- 1 H- l,2,4-triazole-3-sulfmyl)-propyl]-piperidin-l-yl}-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 121); (PPPPP) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-{4-[3-(5-oxo-4,5-dihydro-
1 H- 1 ,2,4-triazole-3-sulfinyl)-propyl]-piperidin- 1 -yl} -phenylamino)-8H- pyrido[2,3-d]pyrimidin-7~one (Compound 122);
(qqqqq) 6-Bromo-8-cyclopentyl-5-methyl-2-(4-{4-[3-(5-oxo-4,5-dihydro- lH-l,2,4-triazole-3-sulfinyl)-propyl]-piperidin-l-yl}-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 123);
(rrrrr) 8-Cyclopentyl-5-methyl-2-(4-{4-[3-(5-oxo-4,5-dihydro-lH- l,2,4-triazole-3-sulfonyl)-propyl]-piperidin-l-yl}-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 124);
(sssss) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-{4-[3-(5-oxo-4,5-dihydro- lH-l,2,4-triazole-3-sulfonyl)-propyl]-piperidin-l-yl}-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 125);
(ttttt) 6-Bromo-8-cycloρentyl-5-methyl-2-(4-{4-[3-(5-oxo-4,5-dihydro- lH-l,2,4-triazole-3-sulfonyl)-propyl]-piperidin-l-yl}-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 126); (uuuuu) N-(2-{l-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidin-4-yl}-ethyl)-N-hydroxy- acetamide (Compound 127);
(wwv) N-(2-{ 1 -[4-(8-Cyclopentyl-6-fluoro-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidin-4-yl}-ethyl)-N-hydroxy- acetamide (Compound 128);
(wwwww) N-(2-{l-[4-(6-Bromo-8-cyclopentyl-5-methyl-7-oxo- 7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidin-4-yl}-ethyl)- N-hydroxy-acetamide (Compound 129); (xxxxx) N-(3-{l-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidin-4-yl}-propyl)-N-hydroxy- acetamide (Compound 130);
(yyyyy) N-(3-{ 1 -[4-(8-Cyclopentyl-6-fluoro-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidin-4-yl}-propyl)-N-hydroxy- acetamide (Compound 131);
(zzzzz) N-(3-{l-[4-(6-Bromo-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidin-4-yl}-propyl)-N-hydroxy- acetamide (Compound 132); (aaaaaa) 2-(Benzofixran-5-ylamino)-8-cyclopentyl-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 133);
(bbbbbb) 8-Cyclopentyl-2-(lH-indol-5-ylamino)-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 134);
(cccccc) 2-(Benzo[b]thiophen-5-ylamino)-8-cyclopentyl-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 135);
(dddddd) 8-Cyclopentyl-2-(2,3 -dimethyl- 1 H-indol-5-ylamino)-5 -methyl- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 136);
(eeeeee) 2-(9H-Carbazol-3-ylamino)-8-cyclopentyl-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 137); (ffffff) 8-Cyclopentyl-2-(lH-indazol-5-ylamino)-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 138);
(gggggg) 2-(2-Acetyl-benzofuran-5-ylamino)-8-cyclopentyl-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 139);
(hhhhhh) 8-Cyclopentyl-5-methyl-2-(4-morpholin-4-yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 140), mp 227-229°C;
(iiiiii) 8-Cyclopentyl-2-[4-(3,5-dimethyl-piperazin-l-yl)-phenylamino]- 5-methyl-8H-p rido[253-d]pyrimidin-7-one (Compound 141);
(jjjjjj) 2-(3-Chloro-4-piperazin- 1 -yl-phenylamino)-8-cyclopentyl- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 142), mp 234-237°C;
(kkkkkk) 8-Cyclopentyl-5-methyl-2-(4-piperidin-l-yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 143); (111111) 8-Cyclopentyl-5-methyl-2-[4-(4-methyl-piperazin- 1 -yl)- phenylamino]-8H-pyrido[2,3-d]ρyrimidin-7-one (Compound 144);
(mmmminm) N- { 1 -[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidin-4-yl}-acetamide (Compound 145);
(nnnnnn) 8-Cyclopentyl-5-methyl-2-(4-piperazin- 1 -yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 146), mp 237-240°C;
(oooooo) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-piperazin-l-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 147), mp 254-255°C;
(pppppp) 6-Iodo-8-cyclopentyl-5-methyl-2-(4-piperazin-l-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 148);
(qqqqqq) 2-[3-Chloro-4-(3-amino-pyrrolidin- 1 -yl)-phenylamino]-8- cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 149), mp >215°C (dec);
(rrrrrr) 8-Cyclopentyl-5-methyl-2-[4-(4-(2,2,2-trifluoroethyl)-piperazin- 1 - yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 150), mp 198-199°C;
(ssssss) 8-Cyclopentyl-2-(4-fluoro-phenylamino)-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 151), mp 217-220°C;
(tttttt) 8-Cyclopentyl-5~methyl-2-phenylamino-8H-pyrido[2,3- d]ρyrimidin-7-one (Compound 152), mp 180-183°C;
(uuuuuu) 8-Cyclopentyl-2-(3,4-dichlorophenylamino)-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 153), mp 225-230°C; (www) 8-Isopropyl-5-methyl-2-(4-piperazin-l -yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 154), mp >235°C (dec);
(wwwwww) 8-Isopropyl-5-methyl-2-[4-(4-propionyl-piperazin-l -yl)- phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 155); (xxxxxx) 8-Cyclohexyl-5-methyl-2-(4-piperazin-l-yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 156); (yyyyyy) 2-{4-[4-(3~Morpholin-4-yl-propyl)-piperidin-l-yl]- phenylamino}-8-cyclohexyl-6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 157), mp 206-209°C;
(zzzzzz) 8-Cycloρentyl-5-methyl-2-[4-(2H-l ,2,4-triazol-3- ylsulfanylmethyl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 158);
(aaaaaaa) 8-Cyclopentyl-5-methyl-2-[4-(2H-l,2,4-triazole-3- sulfinylmethyl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 159); (bbbbbbb) 8-Cyclopentyl-5-methyl-2-[4-(2H-l,2,4-triazole-3- sulfonylmethyl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 160);
(ccccccc) 8-Cyclopentyl-5-methyl-2-[4-(5-oxo-4,5-dihydro-l,2,4- oxadiazol-3 -ylmethyl)-phenylamino] -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 161);
(ddddddd) 8-Cyclopentyl-5-methyl-2-{4-[2-(2H-l,2,4-triazol-3- ylsulfanyl)-ethyl]-phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 162);
(eeeeeee) 8-Cyclopentyl-5-methyl-2-{4-[2-(2H-l,2,4-triazole-3-sulfinyl)- ethyl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 163);
(fffffff) 8-Cyclopentyl-5-methyl-2-{4-[2-(2H-l,2,4-triazole-3-sulfonyl)- ethyl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 164);
(ggggggg) 8-Cyclopentyl-5-methyl-2-{4-[2-(5-oxo-4,5-dihydro- 1 ,2,4- oxadiazol-3 -yl)-ethyl]-phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 165);
(hhhhhhh) 8-Cyclopentyl-5-methyl-2-[4-(3H-l ,2,3-triazol-4~ ylsulfanylmethyl)-phenylamino]-8H-ρyrido[2,3-d]pyrimidin-7-one (Compound 166);
(iiiiiii) 8-Cyclopentyl-5-methyl-2-{4-[2-(3H-l,2,3-triazol-4-ylsulfanyl)- ethyl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 167); (jjjjjjj) 8-Cyclopentyl-5-methyl-2-{4-[4-(5-oxo-4,5-dihydro-l,2,4- oxadiazol-3 -yl)-piperidin- 1 -yl]-phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 168);
(kkkkkkk) 8-Cyclopentyl-5-methyl-2-{4-[4-(2H-l,2,4-triazol-3- ylsulfanyl)-piperidin- 1 -yl] -phenylamino } - 8H-pyrido [2,3 -d]pyrirnidin-7-one
(Compound 169);
(1111111) 8-Cyclopentyl-5-methyl-2-{4-[4-(2H-l,2,4-triazole-3-sulfinyl)- piperidin- 1 -yl] -phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 170); (mmmmmmm) 8-Cycloρentyl-5-methyl-2-{4-[4-(2H-l,2,4-triazole-3- sulfonyl)-piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 171), mp 235-237°C;
(nimmmn) 8-Cyclopentyl-5-methyl-2-{4-[4-(2H-tetrazol-5-yl)-piperidin- 1 -yl]-ρhenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 172); (ooooooo) 1 -[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3- d]pyrimidin-2-ylamino)-phenyl]-piperidine-4-carboxylic acid (lH-tetrazol-5-yl)- amide (Compound 173);
(ppppppp) 8-Cyclopentyl-5-methyl-2- {4- [4-(3H- 1 ,2,3 -triazol-4- ylsulfanyl)-piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 173);
(qqqqqqq) 3-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3- d]pyrimidin-2-ylamino)-phenyl]-N-(lH-tetrazol-5-yl)-propionamide (Compound 174);
(rrrrrrr) 2-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3- d]pyrimidin-2-ylamino)-phenoxy]-N-(lH-tetrazol-5-yl)-acetamide
(Compound 175);
(sssssss) 8-Cyclopentyl-5-methyl-2-[4-(5-oxo-4,5-dihydro-l,2,4- oxadiazol-3-ylmethoxy)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 176), mp >195°C (dec); (ttttttt) 8-Cyclopentyl-5-methyl-2-(4-{4-[2-(2H-l ,2,4-triazole-3-sulfinyl)- ethyl]-piperidin- 1 -yl } -phenylamino)-8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 177); (uuuuuuu) 8-Cyclopentyl-5-methyl-2-(4-{4-[2-(2H-l,2,4-triazole-3- sulfonyl)-ethyl]-piperidin-l-yl}-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 178);
(wwwv) 8-Cyclopentyl-5-methyl-2-(4-{4-[2-(3H-l ,2,3-triazol-4- ylsulfanyl)-ethyl]-piperidin-l-yl}-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 179);
(wwwwwww) 8-Cyclopentyl-5-methyl-2-(4-{4-[2-(2H-l ,2,4-triazol-3- ylsulfanyl)-ethyl]-piperidin-l-yl}-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 180), mp 234-237°C; (xxxxxxx) 8-Cycloρentyl-5-methyl-2-(4-{4-[2-(5-oxo-4,5-dihydro-l,2,4- oxadiazol-3-yl)-ethyl]-piperidin-l-yl}-phenylamino)-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 181);
(yyyyyyy) 8-Cycloρentyl-5-methyl-2-{4-[4-(2-oxo-2,3-dihydro-l,2,3,5- oxathiadiazol-4-yl)-piperidin- 1 -yl] -phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7- one (Compound 182);
(zzzzzzz) 8-Cyclopentyl-2-{4-[4-(2,2-dioxo-2,3-dihydro-l,2,3,5- oxathiadiazol-4-yl)-piperidin-l-yl]-phenylamino}-5-methyl-8H-pyrido[2,3- d]pyrimidin-7-one (Compound 183);
(aaaaaaaa) 8-Cyclopentyl-5-methyl-2-{4-[4-(l-oxo-2,5-dihydro-lH- 1 ,2,3 ,5-thiatriazol-4-yl)-piperidin- 1 -yl]-phenylamino } -8H-pyrido [2,3 - d]ρyrimidin-7-one (Compound 184);
(bbbbbbbb) 8-Cyclopentyl-2-{4-[4-(l,l-dioxo-2,5-dihydro-lH-l,2,3,5- thiatriazol-4-yl)-piperidin- 1 -yl] -phenylamino } -5-methyl-8H-pyrido [2,3 - d]pyrimidin-7-one (Compound 185); (cccccccc) N-{l-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido [2,3 -d]ρyrimidin-2-ylamino)-phenyl]-piperidine-4-carbonyl} - methanesulfonamide (Compound 186);
(dddddddd) 8-Cyclopentyl-5-methyl-2-{4-[3-(2H-l ,2,4-triazol-3- ylsulfanyl)-pyrrolidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 187); (eeeeeeee) 8-Cyclopentyl-5-methyl-2-{4-[3-(2H-l,2,4-triazole-3- sulfinyl)-pyrrolidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 188);
(ffffffff) 8-Cyclopentyl-5-methyl-2-{4-[3-(2H-l,2,4-triazole-3-sulfonyl)- pyrrolidin- 1 -yl] -phenylamino } - 8H-pyrido [2,3 -d]pyrimidin-7-one
(Compound 189);
(gggggggg) 8-Cyclopentyl-5-methyl-2-{4-[3-(3H-l,2,3-triazol-4- ylsulfanyl)-pyrrolidin- 1 -yl] -phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 190); (hhhhhhhh) 8-Cyclopentyl-5-methyl-2-{4-[3-(5-oxo-4,5-dihydro-l,2,4- oxadiazol-3 -yl)-pyrrolidin- 1 -yl] -phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 191);
(iiiiiiii) 8-Cyclopentyl-5-methyl-2- {4- [4-(3 -hydroxypropyl)piperidin- 1 - yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 192), mp 180-184°C;
(jjjjjjjj) 8-Cyclopentyl-5-propyl-2-(4-piperazin- 1 -yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 193);
(kkkkkkkk) 8-Cyclopentyl-5-ethyl-2-(4-piperazin- 1 -yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 194); (11111111) 8-(l-Methylethyl)-5-ethyl-2-(4-piperazin-l-yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 195), mp >235°C (dec);
(miximmmmmm) 8-(l-Methylethyl)-5-ethyl-2-(4-piperazin-l-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 196), mp >235°C (dec); (rinnnnnnn) 8-Cyclopentyl-5-methyl-2-[4-(3-hydroxypyrrolidin-l- yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 197), mp 225-226°C;
(oooooooo) 8-Cyclopentyl-5-ethyl-2-[4-(4-acetylpiperazin-l- yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 198); (PPPPPPPP) 8-Cyclopentyl-5-methyl-6-fluoro-2-[4-(4-acetylpiperidin-l - yl)ρhenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 199), mp 267-269°C; (qqqqqqqq) 8-Cyclopropyl-5-methyl-2-[4-(4-acetamidopiperidin-l- yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 200), mp 221°C (dec);
(qqqqqqqr) 8-Cyclopropyl~5-methyl-6-fluoro-2-[4-(4-acetarnidopiperidin- 1-yl) phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 201), mp >250°C;
(rrrrrrrr) 8-Cyclopentyl-5-methyl-2-[4-(homopiperazin- 1 - yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride (Compound 202), mp 172°C (dec); (ssssssss) 8-Cyclopentyl-5-methyl-6-fluoro-2-[4-(homopiperazin-l- yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride (Compound 203), mp 192°C (foam);
(tttttttt) 8-Cyclopentyl-5-methyl-6-fluoro-2-[4-(3,3-dimethyl-4- acetylpiperazin-l-yl)phenylamino]-8H-pyrido[253-d]pyrimidin-7-one (Compound 204), mp 200-204°C;
(uuuuuuuu) 8-Cyclopentyl-5-methyl-2-[4-(3,3-dimethyl-4- acetylpiperazin-l-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 205), mp 192-196°C;
(wvwvvv) 8-Cyclopentyl-5-methyl-6-fluoro-2-[4-(4-methylpiperazin-l - yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate
(Compound 206);
(wwwwwwww) 8-Cyclopentyl-5-methyl-2-[4-(N- methylacetamido)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 207), mp 185-187°C; (xxxxxxxx) 8-Cyclopentyl-5-methyl-2-{4-[2-(2- hydroxyethoxy)ethylamino]phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 208), mp 122-126°C;
(yyyyyyyy) 8-Cyclopentyl-5-methyl-2-[4-(3-oxopiperazin-l- yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 209), mp >235°C (dec); (zzzzzzzz) 8-Cyclopentyl-5-methyl-2-[4-(2- methoxyethoxy)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 210), mp 156-157°C;
(aaaaaaaaa) 8-Cyclopentyl-5-methyl-2-(9H carbazol-3-yl amino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 211);
(bbbbbbbbb) 8-Cyclopentyl-5-methyl-2-(lH-indazol-5-yl)amino-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 212);
(ccccccccc) 8-Cyclopentyl-5-methyl-2-(2-acetylbenzofuran-5-yl)amino- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 213); (ddddddddd) 8-Cyclopentyl-5-methyl-2-[(4-piperidin- 1 -yl)phenylamino]-
8H-pyrido[2,3-d]pyrimidin-7-one (Compound 214);
(eeeeeeeee) 8-Cyclopentyl-5-methyl-2-(2,3-dimethylindol-5-yl)amino- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 215);
(fffffffff) 8-Cycloρentyl-5-isopropyl-2-[4-(3,5-methyl-4R- aminomethylpyrrolidin-l-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 216);
(ggggggggg) 8-Cyclopentyl-5-methyl-2-{4-[4-(2-hydroxyethyl)piperazin- l-yl)]phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 217), mp 171-173°C; (hhlmhhhhli) 8-Cyclopentyl-5-methyl-2-{4-[4-(3- morpholinopropyl)piperidin- 1 -yl]phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7-one trifuoroacetic acid salt (Compound 218), mp 178-181°C;
(iiiiiiiii) 8-Cyclopentyl-5-methyl-2-(benzofuran-5-yl)amino-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 219); Ojjjjjjjj) 8-Cyclopentyl-5-methyl-2-(indol-5-yl)amino-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 220); and
(l l dc) 8-Cyclopentyl-5-methyl-2-(thionaphthen-5-yl)amino-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 221);.
8-Cyclopentyl-6-iodo-5-methyl-2-(4-piperazin-l-yl-phenylamino)-8H- pyrido[2,3-^]pyrimidin-7-one (Compound 225), mp 185-198°C (dec); 8-Cy clopentyl-2- {4- [1 -(3 ,5-dimethyl-piperazin- 1 -yl)-methanoyl]- phenylamino}-5-methyl-8H-pyrido[2,3-^pyrimidin-7-one (Compound 226), mp 181 (foam);
8-Cyclopentyl-2-[4-(3,5-dimethyl-piperazin-l-yl)-phenylamino]-5- trifluoromethyl-8H~pyrido[2,3-^pyrimidin-7-one (Compound 227), mp 200(foam);
6-Bromo-8-cyclopentyl-2-[4-(3,3-dimethyl-piperazin-l-yl)-phenylamino]- 5-methyl-8H-pyrido[2,3-_ lpyrimidin-7-one (Compound 228), mp >200 (dec);
8-Cyclopentyl-2-[4-(3,5-dimethyl-piperazin-l-yl)-phenylamino]-6-iodo-5- methyl-8H-pyrido[2,3- ]pyrimidin-7-one (Compound 229), mp 225-226°C (dec);
6-Chloro-8-cyclopentyl-2-[4-(3,5-dimethyl-piperazin-l-yl)-phenylamino]- 5~methyl-8H-pyrido[2,3-< ]pyrimidin-7-one (Compound 230), mp >250°C;
8-Cyclopentyl-5-methyl-2-[4-(lΗ-[l,2,4]triazol-3-ylsulfanyl)- phenylamino]-8H-pyrido[2,3-<f|pyrimidin-7-one (Compound 231); 4-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3-(3]pyrimidin-
2-ylamino)-phenyl]-piperazine-l-carbaldehyde (Compound 232), mp 244-247°C;
8-Cyclopentyl-2-(4-piperazin-l-yl-phenylamino)-5-trifluoromethyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 233), mp >275°C (dec);
8-( 1 -Ethyl-propyl)-5-methyl-2-(4-piperazin- 1 -yl-phenylamino)-8H- ρyrido[2,3-φyrimidin-7-one (Compound 234), p >180°C (dec);
[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3-tf]pyrimidin-2- ylamino)-benzyl]-phosphonic acid (Compound 235), mp >250°C;
6-Chloro-8-cyclopentyl-5-methyl-2-(4-piperazin-l-yl-phenylamino)-8H- pyrido[2,3-i ]pyrimidin-7-one (Compound 236), mp 188°C (dec); 2-[4-(3,5-Dimethyl-ρiperazin-l-yl)-phenylamino]-8-(l-ethyl-propyl)-5- methyl-8H-pyrido[2,3-ύT]pyrimidin-7-one (Compound 237), mp >185°C (dec);
8-Cyclopentyl-2-[4-(2-hydroxy-ethylamino)-phenylamino]-5-methyl-8H- pyrido[2,3- yrimidin-7-one (Compound 238), mp 197-200°C;
3-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[233-_ ]pyrimidin- 2-ylamino)-phenyl]-N,N-diethyl-piOpionamide (Compound 239), mp 138-140°C;
8-Cyclopentyl-6-fluoro-2-[4-(2-hydroxy-ethyl)-phenylamino]-5-methyl- 8H-pyrido[2,3- yrimidin-7-one (Compound 240), mp 241-244°C; 8-Cyclopentyl-2-[4-(2-hydroxy-ethyl)-phenylamino]-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 241), mp 191-194°C;
4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3-i Ipyrimidin-2- ylamino)-benzoic acid (Compound 242); 8-Cyclopentyl-2-[4-(3,3-dimethyl-piperazin-l-yl)-phenylamino]-5-methyl-
8H-pyrido[2,3-^pyrimidin-7-one (Compound 243), mp >150°C (dec);
[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3-t_]pyrimidin-2- ylamino)-benzyl]-phosphonic acid diethyl ester (Compound 244), mp >250°C (foam); 8-Cyclopentyl-6-fluoro-2-[4-(2-methoxy-ethylamino)-phenylamino]-5- methyl-8H-pyrido[2,3-^pyrimidin-7-one (Compound 245), mp 147-149°C;
(S)-2-Amino-3-[4-(8-cyclopentyl-6-fluoro-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-tf]pyrimidin-2-ylamino)-phenyl]-propionic acid (Compound 246), mp 238°C (dec); 8-Cyclopentyl-2-[4-(2-methoxy-ethoxy)-phenylamino]-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 247), mp 156-157°C;
8-Cyclopentyl-2-(4-isopropylamino-phenylamino)-5-methyl-8H- pyrido[253-d]ρyrimidin-7-one (Compound 248), mp 216-220°C;
8-Cyclopentyl-2-(4-hydroxy-3,5-dimethyl-phenylamino)-5-methyl-8H- pyrido[2,3-d]ρyrimidin-7-one (Compound 249), mp 252-254°C;
8-Cyclopentyl-6-fluoro-2-(4-hydroxy-3,5-dimethyl-phenylamino)-5- methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 250), mp 241-248°C;
8-Cyclopentyl-6-fluoro-2-(4-hydiOxy-3,5-dimethyl-phenylamino)-5- methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 251), mp 240°C (dec).
EXAMPLE 19
Biological Assays
Several of the invention compounds have been evaluated in standard assays routinely used to measure inhibition of cyclin-dependent kinase enzymes and other serine/threonine protein kinases. The assays were carried out as follows: Cdkl and Cdk2 enzyme assays for IC50 determinations and kinetic evaluation are performed as follows. 96-well filter plates (Millipore MADVN6550) are used. The total volume is 0.1 mL 20 mM TRIS (pH 7.4), 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 12 mM ATP containing
0.25 μCi [32P]ATP, 20 ng enzyme (Cdk2/cyclin E, Cdk2/cyclin A, or Cdkl/cyclin B), 1 μg retinoblastoma protein, and appropriate dilutions of the particular invention compound. All components except the ATP are added to the wells, and the plate is placed on a plate mixer for 2 minutes. The reaction is initiated by addition of [32p]ATP, and the plate is incubated at 25 °C for
15 minutes. The reaction is terminated by addition of 0.1 mL 20% TCA. The plate is kept at 4°C for at least 1 hour to allow the substrate to precipitate. The wells are then washed five times with 0.2 mL 10% TCA, and 32p incorporation is determined with a beta plate counter (Wallac Inc., Gaithersburg, MD).
The Cdk4 enzyme assay for IC50 determination and kinetic evaluation is performed as follows. 96-well filter plates (Millipore MADVN6550) are used. The total volume is 0.1 mL containing a final concentration of 20 mM TRIS (tris[hydroxymethyl]aminomethane) (pH 7.4), 50 mM NaCl, 1 mM dithiothreitol,
10 mM MgCl2, 25 μM ATP containing 0.25 μCi [32P]ATP, 20 ng Cdk4, 1 μg retinoblastoma protein, and appropriate dilutions of a compound of the present invention. All components except the ATP are added to the wells, and the plate is placed on a plate mixer for 2 minutes. The reaction is started by adding [32p]ATP, and the plate is incubated at 25°C for 15 minutes. The reaction is terminated by addition of 0.1 mL 20% trichloroacetic acid (TCA). The plate is kept at 4°C for at least 1 hour to allow the substrate to precipitate. The wells are then washed five times with 0.2 mL 10% TCA, and 3 incorporation is determined with a beta plate counter (Wallac Inc., Gaithersburg, MD). For PDGF receptor (PDGFr) and FGF receptor (FGFr) tyrosine kinase assays, full-length cDNAs for the mouse PDGF-β and human FGF 1 (fig) receptor tyrosine kinases are obtained from J. Escobedo and prepared as described previously (Escobedo et al, J. Biol. Chem., 1988;262:1482-1487). PCR primers are designed to amplify a fragment of DNA that codes for the intracellular tyrosine kinase domain. The fragment is inserted into a baculoviras vector, cotransfected with AcMNPV DNA, and the recombinant virus is isolated. SF9 insect cells are infected with the virus to overexpress the protein, and the cell lysate is used for the assay.
PDGFr and FGFr enzyme assays are performed in 96-well plates (100 μL/incubation/well), and conditions are optimized to measure the incorporation of 32p from [γ32p]ATP into a glutamate-tyrosine co-polymer substrate. Briefly, to each well is added 82.5 μL incubation buffer containing - 25 mM Hepes (pH 7.0), 150 mM NaCl, 0.1% Triton X-100, 0.2 mM PMSF, 0.2 mM Na3V04, 10 mM MnC„2, and 750 μg/mL Poly (4:1) glutamate-tyrosine followed by 2.5 μL inhibitor and 5 μL enzyme lysate (7.5 μg/μL FGFr or 6.0 μg/μL PDGFr) to initiate the reaction. Following a 10-minute incubation at
25°C, 10 mL [γ 2P]ATP (0.4 μCi plus 50 μM ATP) is added to each well, and samples are incubated for an additional 10 minutes at 25°C. The reaction is terminated by the addition of 100 μL 30% trichloroacetic acid (TCA) containing 20 mM sodium pyrophosphate and precipitation of material onto glass fiber mats (Wallac). Filters are washed three times with 15% TCA containing 100 mM sodium pyrophosphate, and the radioactivity retained on the filters is counted in a Wallac 1250 Betaplate reader. Nonspecific activity is defined as radioactivity retained on the filters following incubation of samples with buffer alone (no enzyme). Specific enzymatic activity (enzyme plus buffer) is defined as total activity minus nonspecific activity. The concentration of a compound that inhibited specific activity by 50% (IC50) is determined based on the inhibition curve.
The c-Src protein kinase assay is carried out as follows. c-Src kinase is purified from baculovirus infected insect cell lysates using an antipeptide monoclonal antibody directed against the N-terminal amino acids (amino acids
2-17) of c-Src. The antibody, covalently linked to 0.65 μm latex beads, is added to a suspension of insect cell lysis buffer comprised of 150 mM NaCl, 50 mM Tris (pH 7.5), 1 mM DTT, 1% NP-40, 2 M EGTA, 1 mM sodium vanadate, 1 mM PMSF, 1 μg/mL each of leupeptin, pepstatin, and aprotinin. Insect cell lysate containing c-Src protein is incubated with these beads for 3 to 4 hours at 4°C with rotation. At the end of the lysate incubation, the beads are rinsed three times in lysis buffer, resuspended in lysis buffer containing 10% glycerol, and frozen. These latex beads are thawed, rinsed three times in assay buffer (40 mM Tris (pH 7.5), 5 mM μg CI2) and suspended in the same buffer. In a Millipore 96-well plate with a 0.65 μm polyvinylidine membrane bottom are added the reaction components: 10 μL c-Src beads, 10 μL 2.5 mg/mL poly GluTyr substrate, 5 μM
ATP containing 0.2 μCi [32p]ATP, 5 μL DMSO containing inhibitors or as a solvent control, and buffer to make the final volume 125 μL. The reaction is started at room temperature by addition of ATP and quenched 10 minutes later by the addition of 125 μL 30% TCA, 0.1 M sodium pyrophosphate for 5 minutes on ice. The plate is then filtered and the wells washed with two 250-mL aliquots of
15% TCA, 0.1 M pyrophosphate. The filters are then punched, counted in a liquid scintillation counter, and the data examined for inhibitory activity in comparison to a known inhibitor such as erbstatin. The method has been described by Thompson et al., J Med. Chem., 1994;37:598-609. The results of the foregoing assays for several representative invention compounds are presented in Table 1. The metabolic stability of representative Compounds was evaluated in human liver microsomes (HLM) and is given in Table 1 as the time in minutes (T Half) required for one-half of the parent compound to disappear after being added to a HLM homogluate.
Figure imgf000074_0002
Figure imgf000074_0001
Figure imgf000075_0002
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000076_0002
Various properties of preferred 5-methylpyridoρyrimidin-7-ones such as 8-cyclopentyl-5-methyl-2-[(4-piperazinylphenyl)-amino]-8-hydropyridino[2,3- d]pyrimidin-7-one (Compound 1), including IC50, stability, and clearance rate, are displayed in Table 2.
Table 2
Compound 5-Me ιc50 (μ ) T/z in Clearance
Cdkl/ Cdk2/ Cdk2/ Cdk4 FGFr c-Src PDGFr HLM (mL/min/kg) cyclin B cyclin A cyclin E (min)
1 Yes >5 >5 >5 0.007 1.077 83 25.5 (n = 2)
57 Yes >5 >5 >5 0.151 6.08
73 Yes >1.7 >1.7 >5 0.061 >5 80
79 Yes >5 >5 >5 0.975 NA 34 8
152 Yes >1.7 4.91 >5 2.15 NA >50 4
From the results displayed in Table 2, it is clear that Compound 1 and other invention compounds specifically inhibit Cdk4, and has relatively little effect on Cdkl and Cdk2. Furthermore, Compound 1 is relatively more stable, and cleared at a slower rate, compared to prior art compounds. These results indicate that the methyl group in the 5 -position confers unique properties onto the pyridopyrimidine and is a preferred embodiment.
Formulation Examples
As noted above, the invention compounds will typically be formulated with common excipients, diluents, and carriers to provide compositions that are well-suited for convenient administration to mammals. The following examples illustrate typical compositions that are provided in a further embodiment of this invention.
EXAMPLE 20
Tablet Formulation
Ingredient Amount
Compound 12 50 mg
Lactose 80 mg
Cornstarch (for mix) 10 mg
Cornstarch (for paste) 8 mg
Magnesium Stearate (1%) 2 mg
150 mg
Compound 12 is mixed with the lactose and cornstarch (for mix) and blended to uniformity to a powder. The cornstarch (for paste) is suspended in 6 mL of water and heated with stirring to form a paste. The paste is added to the mixed powder, and the mixture is granulated. The wet granules are passed through a No. 8 hard screen and dried at 50°C. The mixture is lubricated with 1% magnesium stearate and compressed into a tablet. The tablets are administered to a patient at the rate of 1 to 4 each day for prevention and treatment of atherosclerosis.
EXAMPLE 21
Parenteral Solution
In a solution of 700 mL of propylene glycol and 200 mL of water for injection is added 20.0 g of Compound 38. The mixture is stirred and the pH is adjusted to 5.5 with hydrochloric acid. The volume is adjusted to 1 00 mL with water for injection. The solution is sterilized, filled into 5.0 mL ampoules, each containing 2.0 mL (40 mg of Compound 38), and sealed under nitrogen. The solution is administered by injection to a patient suffering from cancer and in need of treatment.
The invention and the manner and process of making and using it, are now described in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, to make and use the same. It is to be understood that the foregoing describes preferred embodiments of the present invention and that modifications may be made therein without departing from the spirit or scope of the present invention as set forth in the claims. To particularly point out and distinctly claim the subject matter regarded as invention, the following claims conclude this specification.

Claims

CLAIMSWhat is claimed is:
1. A compound of the formula
Figure imgf000080_0001
and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein:
R2 is (a) hydrogen; (b) lower alkyl optionally substituted with one, two, or three groups independently selected from halogen, hydroxy, lower alkoxy, amino, mono- or dialkylamino, carboxy, alkoxycarbonyl, thioalkyl, nitrile, aryl, heteroaryl, or a carbocyclic group containing from 3 to 7 members, up to two of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen; or
(c) a carbocyclic group containing from 3 to 7 members, up to two of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from consisting of halogen, hydroxy, lower alkyl, lower alkoxy, amino, mono- or dialkylamino, aryl, and heteroaryl; R-3 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro, -COR4, -C02R4, -CONR4R5, CONR4OR5, -S02NR4R5, -S02R4, -SO3R4,
R4
P(O)(OR4)(OR5), or -NR4R5;
Y is N or CR7;
R° is lower alkyl, haloalkyl, or aryl;
X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NR4R5, -N(0)R4R5,
-NR R5R6W, -SR4, -C(0)R4, -C02R4, -CONR4R5,
-S0 NR4R5, -S02R4, -S03R4, P(0)(OR4)(OR5),
-T(CH2)mQR4, -C(0)T(CH2)mQR4, or -NR4C(0)T(CH2)mQR5; m is 1 to 6; T is O, S, NR4, N(O)R4 NR4R5 W, or CR4R5;
Q is O, S, NR4, N(O)R4, NR4R5w, C02, or a carbocyclic group containing from 3 to 7 members, up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono or dialkylamino; R6 is lower alkyl, haloalkyl, or aryl;
R? is NR4R5, N(O)R4R5, NR4R5R9W, OH, OR4, SR4, halo, COR4,
(CH2)nR4, (CH2)nR4, C02R4, CONR4R5, C(0)NR4SO2R5,
S(0)R4, S02R4, SO2NR4R5, SO3R4 (CH )nP(O)(OR4)2,
NR4S02R5, aldehyde, nitrile, nitro, alkyl, alkoxyalkyl, T(CH2)mQR4, C(O)T(CH2)mQR4, NR C(0)T(CH2)mQR5, or
T(CH2)mCO2R4; n is 0 to 6; W is an anion; R4 and R^ are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (CH2)nAr, arylalkyl, aryl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or heteroaryl, or R4 and R^ together with the nitrogen to which they are attached form a carbocyclic ring containing 3 to 8 members, up to four of which members are optionally carbonyl groups or heteroatoms independently selected from oxygen, sulfur, S(O), S(0)2, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, three, or four groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, aminoalkylcarbonyl, trifluoromethyl, trifluoromethylalkyl, trifluoromethylalkylaminoalkyl, mono- or dialkylamino, N-hydroxyacetamido, aryl, heteroaryl, carboxyalkyl,
NR10SO2Rπ, C(0)NRl°Rl l, NR1°C(0)RH, C^OR1^ C(0)NR! 0SO2R! 1 , (CH^S^R1 °, (CH2)n-heteroaryl,
0(CH2)n-heteroaryl, (CH2)nC(0)NRlθRΪ l, 0(CH2)nC(0)ORl°; and R4 additionally can be lower alkyl unsubstituted or substituted with one, two, or three groups independently selected from halogen, 5-oxo-4,5-dihydiO-lH-l,2,4-triazol-3-yl-sulfanyl, 5-oxo- 4,5-dihydro-lH-l52,4-triazol-3-yl-sulfmyl, 5-oxo-4,5-dihydro-lH- l,2,4-triazol-3-yl-sulfonyl, or a carbocyclic group containing from 3 to 7 members, up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono- or dialkylamino; and
RIO and RU are independently hydrogen, halogen, lower alkyl, lower alkoxy, or alkylcarbonyl.
A compound of the Formula II
Figure imgf000083_0001
and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein:
R3 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro, -COR4, -C02R4, CONR4R5,
CONR OR5, -S02NR4R5, -S02R4, -SO3R4, -P(O)(OR )(OR5), I
R4 or -NR4R5;
Y is N or CR7;
X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NR4R5, -N(0)R4R5,
-NR4R5R6W, -SR4, -C(0)R4 -C02R4, -CONR4R5, -SO2NR4R5, -S02R4, -SO3R4, P(O)(OR4)(OR5),
-T(CH2)mQR4, -C(0)T(CH2)mQR4, or -NR4C(O)T(CH2)mQR5; m is 1 to 6; T is O, S, NR4, N(0)R4, NR R5W, or CR4R5; Q is O, S, NR4, N(0)R4, NR4R5W, CO2, or a carbocyclic group containing from 3 to 7 members, up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono or dialkylamino; R6 is lower alkyl, haloalkyl, or aryl;
R7 is NR4R5, N(0)R4R5, NR R R9 , OH, OR4, SR4, halo, COR4, (CH2)nR4, C02R4, CONR R5, C(0)NR S02R5, S(0)R4, S02R4, S02NR R5, SO3R4, (CH2)nP(0)(OR4)2, NR S02R5, aldehyde, nitrile, nitro, alkyl, alkoxyalkyl, T(CH2)mQR9, C(0)T(CH2)mQR9, NR9C(O)T(CH2)mQRl0, or
T(CH2)mC02R4; n is 0 to 6; W is an anion;
R4 and R are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (CH2)nAr, arylalkyl, aryl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or heteroaryl, or R4 and R together with the nitrogen to which they are attached form a carbocyclic ring containing 3 to 8 members, up to four of which members are optionally carbonyl groups or heteroatoms independently selected from oxygen, sulfur, S(O), S(0)2, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, three, or four groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, aminoalkylcarbonyl, trifluoromethyl, trifluoromethylalkyl, trifluoromethylalkylaminoalkyl, amino, mono- or dialkylamino, N-hydroxyacetamido, aryl, heteroaryl, carboxyalkyl,
NR1OSO2R1 !, C^NRiOR11, Rl0C(O)Rl !, C(O)OK.10, C(O)NRl0SO2Rl l, (CH2)nS(0)nRlO, (CH2)n-heteroaryl, 0(CH2)n-heteroaryl, (CH2)nC(O)NR1 OR11 , O(CH2)nC(0)OR1 °;
R is lower alkyl, haloalkyl, or aryl; and R additionally can be lower alkyl unsubstituted or substituted with one, two, or three groups independently selected from halogen, 5-oxo-4,5-dihydro-lH-l,2,4-triazol-3-yl-sulfanyl, 5-oxo-4,5- dihydro-lH-l,2,4-triazol-3-yl-sulfinyl, 5-oxo-4,5-dihydro-lH- l,2,4-triazol-3-yl-sulfonyl, or a carbocyclic group containing from 3 to 7 members, up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono- or dialkylamino; and when Y is CR7, it is part of the part structure
ΛΛΛΛΛΛ,
W / \ wh _erein R 7' and Z are as defined above, or can be
R 7; Z taken together with the carbons to which they are attached to form
Figure imgf000085_0001
wherein: G and J are independently CH2, NH, or O;
B is NH, S, CH2, or O;
D is C or N, provided that R1^ 1S nothing when D is N; and
RIO and Rl 1 are independently hydrogen, halogen, lower alkyl, lower alkoxy, or alkylcarbonyl.
A compound of the Formula III
Figure imgf000086_0001
and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein:
R3 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro, -COR4, -C02R4, -CONR4R5,
CONR OR5, -S02NR4R5, -SO2R4, -SO3R4 P(0)(OR )(OR5),
I
R4 or -NR4R5;
Y is N or CR7;
X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NR4R5, -N(0)R4R5,
-NR4R5R6W, -SR4, -C(0)R4, -C02R4, -CONR4R5.
-S02NR R5, -S0 R4, -SO3R4, P(O)(OR4)(OR5),
-T(CH2)mQR4, -C(O)T(CH2)mQR4, or -NR4C(0)T(CH2)mQR.5; m is 1 to 6; T is O, S, NR4, N(0)R4, NR4R5W, or CR R5; Q is O, S, NR4, N(O)R4, NR4R5W, CO2, or a carbocyclic group containing from 3 to 7 members, up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono or dialkylamino; R6 is lower alkyl, haloalkyl, or aryl;
R7 is NR4R5, N(0)R4R5, NR4R5R9χ, OH, OR4, SR4, halo, COR4, (CH2)nR4, C02R4, CONR4R5, C(0)NR4S02R5, S(0)R4, S02R4, S02NR R5, SO3R4, (CH2)nP(0)(OR4)2, NR4S02R5, aldehyde, nitrile, nitro, alkyl, alkoxyalkyl, T(CH2) QR9, C(O)T(CH2)mQR9, NR9C(O)T(CH2)mQRl0, or
T(CH2)mC02R4; n is 0 to 6; W is an anion;
R4 and R5 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (CH2)nAr, arylalkyl, aryl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or heteroaryl, or R4 and R together with the nitrogen to which they are attached form a carbocyclic ring containing 3 to 8 members, up to four of which members are optionally carbonyl groups or heteroatoms independently selected from oxygen, sulfur, S(O), S(0)2, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, three, or four groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, trifluoromethylalkyl, trifluoromethylalkylaminoalkyl, amino, mono- or dialkylamino, N-hydroxyacetamido, aryl, heteroaryl, carboxyalkyl, NR1 OSO^11 , C^NR1 °R! 1 , NR1 °C(0)R11 , C(O)ORl , C(O)NRl0so2Rl l, (CH2)nS(0)nRlO, (CH2)n- heteroaryl, 0(CH2)n-heteroaryl, (CH2)nC(0)NR1 OR11 , O(CH2)nC(O)ORlO;
and R4 additionally can be lower alkyl unsubstituted or substituted with one, two, or three groups independently selected from halogen, 5-oxo-4,5-dihydro-lH-l,2,4-triazol-3-yl-sulfanyl, 5-oxo- 4,5-dihydro-lH-l,2,4-triazol-3-yl-sulfmyl, 5-oxo-4,5-dihydro-lH- 1 ,
2,4-triazol-3-yl-sulfonyl, or a carbocyclic group containing from
3 to 7 members, up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono- or dialkylamino; and when Y is CR7, it is part of the part structure
ΛAΛΛΛΛ
/ \ wherein R7 and Z are as defined above, or can be
R 77 Z taken together with the carbons to which they are attached to form
Figure imgf000088_0001
wherein:
G and J are independently CΗ2, NH, or O; B is NH, S, CH2, or O;
D is C or N, provided that R1^ is nothing when D is N; and
R9 is lower alkyl, haloalkyl, or aryl;
RIO and Rl 1 are independently hydrogen, halogen, lower alkyl, lower alkoxy, or alkylcarbonyl.
4. A compound of the Formula IV
Figure imgf000089_0001
and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein:
R3 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro, -COR4, -C02R4, C0NR4R5,
-C0NR40R5, -S02NR R5, -S02R4, -SO3R4, P(0)(0R4)(0R5),
I
R4 or -NR4R5;
Y is N or CR7;
X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NR R5, -N(0)R R5, -NR R R6W, -SR4, -C(O)R4, -C02R4, -CONR4R5, -S02NR R5, -S02R4, -SO3R4, P(0)(0R4)(0R5),
-T(CH2)mQR4, -C(0)T(CH2)mQR4, or -NR4C(0)T(CH2)mQR5; m is 1 to 6;
T is O, S, NR4, N(0)R4 NR4R5W, or CR4R5; Q is O, S, NR4, N(0)R4, NR4R5 , C02, or a carbocyclic group containing from 3 to 7 members, up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono or dialkylamino;
R6 is lower alkyl, haloalkyl, or aryl;
R7 is NR4R5, N(0)R4R5, NR R5R9χ, OH, OR4, SR4, halo, COR4, (CH2)nR4, C02R4, CONR4R5, C(0)NR4S0 R5, S(O)R4,
S02R4, S02NR4R5, SO3R4, (CH2)nP(0)(OR )2, NR S02R5, aldehyde, nitrile, nitro, alkyl, alkoxyalkyl, T(CH2)mQR9, C(0)T(CH2)mQR9, NR9c(0)T(CH2)mQRlO, or T(CH2)mC02R4; n is O to ό;
W is an anion;
R4 and R are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (CH2)nAr, arylalkyl, aryl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or heteroaryl, or R4 and R together with the nitrogen to which they are attached form a carbocyclic ring containing 3 to 8 members, up to four of wliich members are optionally carbonyl groups or heteroatoms independently selected from oxygen, sulfur, S(O), S(0)2, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, three, or four groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, aminoalkylcarbonyl, trifluoromethyl, trifluoromethylalkyl, trifluoromethylalkylaminoalkyl, amino, mono- or dialkylamino, N-hydroxyacetamido, aryl, heteroaryl, carboxy alkyl, NR^SO^11, C(0)NR1( Rl I, NRIOC^R1 i,
C(O)NRl°S02R1 l, (CH2)nS(0)nR10, (CH2)n-heteroaryl,
0(CH2)n-heteroaryl, (CH2)nC(O)NR10R1 1, 0(CH2)nC(0)OR10; and R4 additionally can be lower alkyl unsubstituted or substituted with one, two, or three groups independently selected from halogen,
5-oxo-4, 5 -dihydro-lH-1 ,2,4-triazol-3-yl-sulfanyl, 5-oxo- 4,5-dihydiO-lH-l,2,4-triazol-3-yl-sulfinyl, 5-oxo-4,5-dihydro-lH- l,2,4-triazol-3-yl-sulfonyl, or a carbocyclic group containing from 3 to 7 members, up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono- or dialkylamino; and when Y is CR7, it is part of the part structure
Figure imgf000091_0001
taken together with the carbons to which they are attached to form
Figure imgf000091_0002
wherein:
G and J are independently CΗ2, NH, or O;
B is NH, S, CH2, or O;
D is C or N, provided that Rl 0 is nothing when D is N; R9 is lower alkyl, haloalkyl, or aryl; and
RIO and R^ are independently hydrogen, halogen, lower alkyl, lower alkoxy, or alkylcarbonyl.
A compound of Formula V
Figure imgf000092_0001
and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof, wherein: R2 is (a) hydrogen; ( ) lower alkyl optionally substituted with one, two, or three groups independently selected from halogen, hydroxy, lower alkoxy, amino, mono- or dialkylamino, carboxy, alkoxycarbonyl, thioalkyl, nitrile, aryl, heteroaryl, or a carbocyclic group containing from 3 to 7 members, up to two of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen; or
(c) a carbocyclic group containing from 3 to 7 members, up to two of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from consisting of halogen, hydroxy, lower alkyl, lower alkoxy, amino, mono- or dialkylamino, aryl, and heteroaryl;
R3 is hydrogen, lower alkyl, lower alkoxy, halogen, trifluoromethyl, lower alkynyl, lower alkenyl, nitrile, nitro, -COR4, -CO2R4, -CONR4R5, CONR OR5, -S02NR R5, -S02R4, -SO3R4,
I
R4 P(O)(OR )(OR5), or -NR R5;
R is lower alkyl, haloalkyl, or aryl; X and Z are independently hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, hydroxy, nitrile, nitro, -NR4R5, -N(0)R4R5, -NR4R5R°W, -SR4, -C(0)R4, -C02R4, -CONR4R5, -SO2NR R5, -S02R4, -SO3R4, P(0)(OR4)(OR5), -T(CH2)mQR4, -C(0)T(CH2)mQR4, or -NR4C(O)T(CH2)mQR5; m is l to 6;
T is O, S, NR4, N(0)R4, NR R5W, or CR R5;
Q is O, S, NR4, N(0)R4, NR4R5W, C02, or a carbocyclic group containing from 3 to 7 members, up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono or dialkylamino;
R6 is lower alkyl, haloalkyl, or aryl;
R7 is NR4R5, N(0)R R5, NR4R5R9W, OH, OR4, SR4, halo, COR4, (CH2)nR4, (CH2)nR4, C02R4 CONR4R5, C(0)NR4S02R5 5
S(0)R4, SO2R4, SO2NR4R5, SO3R4, (CH2)nP(O)(OR4)2, NR4S02R5, aldehyde, nitrile, nitro, alkyl, alkoxyalkyl, T(CH2)mQR4, C(0)T(CH2)mQR4, NR C(0)T(CH2)mQR5, or
T(CH2)mC02R4; n is 0 to 6; W is an anion; R4 and R5 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, (CH2)nAr, arylalkyl, aryl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocycloalkyl, or heteroaryl, or R4 and R together with the nitrogen to which they are attached form a carbocyclic ring containing 3 to 8 members, up to four of which members are optionally carbonyl groups or heteroatoms independently selected from oxygen, sulfur, S(O), S(O) , and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, - three, or four groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, aminoalkylcarbonyl, trifluoromethyl, trifluoromethylalkyl, trifluoromethylalkylaminoalkyl, mono- or dialkylamino, N-hydroxyacetamido, aryl, heteroaryl, carboxyalkyl,
NR10SO R1 *, C(O)NR!0R! !, NR^C^R11, C(O)ORl0, C(0)NRl °S02Rl 1 , (CH2)nS(0)nR1 °, (CH2)n-heteroaryl,
0(CH2)n-heteroaryl, (CH2)nC(O)NR10R11, 0(CH2)nC(0)OR10; and R4 additionally can be lower alkyl unsubstituted or substituted with one, two, or three groups independently selected from halogen, 5-oxo-4,5-dihydro-lH-l,2,4-triazol-3-yl-sulfanyl, 5-oxo- 4,5-dihydro-lH-l,2,4-triazol-3-yl-sulfιnyl, 5-oxo-4,5-dihydro-lH- l,2,4-triazol-3-yl-sulfonyl, or a carbocyclic group containing from 3 to 7 members, up to four of which members are optionally heteroatoms independently selected from oxygen, sulfur, and nitrogen, wherein the carbocyclic group is unsubstituted or substituted with one, two, or three groups independently selected from halogen, hydroxy, hydroxyalkyl, lower alkyl, lower alkoxy, alkoxycarbonyl, alkylcarbonyl, alkylcarbonylamino, aminoalkyl, trifluoromethyl, N-hydroxyacetamide, trifluoromethylalkyl, amino, or mono- or dialkylamino; and
RIO and RU are independently hydrogen, halogen, lower alkyl, lower alkoxy, or alkylcarbonyl.
6. A compound according to Claim 5 wherein R7 is selected from
Figure imgf000095_0001
and wherein such groups are optionally substituted by alkyl, aryl, or amide.
7. A compound selected from the group consisting of:
(a) 8-Cyclopentyl-5-methyl-2-(4-piperazin- 1 -yl-phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 1);
(b) 8-(l-Methylethyl)-5-methyl-2-(4-piρerazin-l-yl-phenylamino)- 8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 2);
(c) 8-Cyclopentyl-5-methyl-2-(4-fluoro-3-methylphenylamino)- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 3);
(d) 8-(l -Methylethyl)-5-methyl-2-(4-fluoro- 3-methylphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 4); (e) 8-Cyclohexyl-5-methyl-2-(4-fluoro-3-methylphenylamino)-
8H-pyrido[2,3-d]pyrimidin-7-one (Compound 5);
(f) 8 -Cy clohexyl-5 -methyl-2- [4-(4-propanoylpiperazin- l-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 6);
(g) 8-Cyclopentyl-5-methyl-2-[4-(4-propanoylpiperazin- l-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 7);
(h) 8-(l -Methylethyl)-5-methyl-2-[4-(4-propanoylpiperazin- l-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 8); (i) 8-Cyclohexyl-5-methyl-2-(4-piperazin- 1 -yl-phenylamino)-8H- pyrido[253-d]pyrimidin-7-one (Compound 9);
(j) 8-Cyclopentyl-5-methyl-2-(4-pyridylphenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 10); (k) 8-(l-Methylethyl)-5-methyl-2-(4-pyridylphenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 11);
(1) 8-Cyclopentyl-5-methyl-2-[4-(3-aminopyrrolidinyl)- phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 12);
(m) 8-(l-Methylethyl)-5-methyl-2-[4-(3-aminopyrrolidinyl)- phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 13);
(n) N-( 1 - {4- [(8-cyclopentyl-5-methyl-7-oxo(8-hydropyridino- [2,3-d]pyrimidin-2-yl))amino]phenyl}pyrrolidin-3-yl)- 3,3-dimethylbutanamide (Compound 14);
(o) N-(l-{4-[(5-methyl-8-(l-methylethyl)-7-oxo(8- hydropyridino[2,3-d]pyrimidin-2-yl))amino]phenyl}pyrrolidin-3-yl)-
3,3-dimethylbutanamide (Compound 15);
(p) 8-Cyclopentyl-5 -methyl -2-(3 -chloro-4-piperazin- 1 -yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 16); (q) 8-Cyclohexyl-5 -methyl-2-(3 -chloro-4-piperazin- 1 -yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 17);
(r) 8-(l -Methylethyl)-5-methyl-2-(3-chloro-4-piperazin-l -yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 18);
(s) 8-Cyclopentyl-6-fluoro-5-methyl-2-(3-chloro-4-piperazin-l-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 19); (t) 8-Cyclohexyl-6-fluoro-5-methyl-2-(3-chloro-4-piperazin-l-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 21);
(u) 8-(l-Methylethyl)-6-fluoro-5-methyl-2-(3-chloro-4-piperazin- 1 -yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 20); (v) 8-Cyclopentyl-5-methyl-2-(3-chloro-4-morpholin-4-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 22);
(w) 8-(l -Methylethyl)-5-methyl-2-(3-chloro-4-morpholin-4-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 23); (x) 8-Cyclohexyl-5-methyl-2-(3-chloro-4-morpholin-4-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 24); (y) 2-({3-chloro-4-[4-(3-morpholin-4-ylpropyl)piperidyl]- phenyl}amino)-8-cycloρentyl-5-methyl-8-hydropyridino[2,3-d]pyrimidin- 7-one (Compound 25);
(z) 2-( { 3 -chloro-4- [4-(3 -morpholin-4-ylpropyl)piperidyl] - phenyl}amino)-8-(l-methylethyl)-5-methyl-8-hydropyridino[2,3-d]- pyrimidin-7-one (Compound 26);
(aa) 2-({ 3 -chloro-4- [4-(3 -morpholin-4-ylpropyl)piperidyl]- phenyl}amino)-8-cyclohexyl-5-methyl-8-hydropyridino[2,3-d]pyrimidin-
7-one (Compound 27);
(bb) 2-({3-chloro-4-[4-(3-piperazinylpropyl)piperidyl]phenyl}- amino)-8-cyclopentyl-6-fluoro-5-methyl-8- hydropyridino[2,3-d]pyrimidin-7-one (Compound 28); (cc) 2-({3-chloro-4-[4-(3-piperazinylpropyl)piperidyl]- phenyl}amino)-8-(l-methylethyl)-6-fluoro-5-methyl-8-hydropyridino- [2,3-d]pyrimidin-7-one (Compound 29);
(dd) 2-({3-chloro-4-[4-(3-piperazinylpropyl)piperidyl]- phenyl}amino)-8-cyclohexyl-6-fluoro-5-methyl-8-hydropyridino- [2,3-d]pyrimidin-7-one (Compound 30);
(ee) 2-({3-chloro-4-[4-(3-piperazinylpropyl)piperidyl]- phenyl}amino)-8-cyclopentyl-5-methyl-8-hydropyridino[2,3-d]pyrimidin- 7-one (Compound 31);
(ff) 2-( { 3 -chloro-4-[4-(3 -piperazinylpropyl)piperidyl]- phenyl} amino)-8-(l -methylethyl)-5-methyl-8-hydropyridino-
[2,3-d]pyrimidin-7-one (Compound 32);
(gg) 2-({3-chloro-4-[4-(3-piperazinylproρyl)piperidyl]- phenyl}amino)-8-cyclohexyl-5-methyl-8-hydropyridino[2,3-d]pyrimidin- 7-one (Compound 33); (gg2) 8-Cyclopentyl-2-[4-(piperazin-l-yl)-phenylamino]-6-fluoro-
5-methyl-8H-pyrido [2,3 -d]pyrimidin- 7-one trifluoroacetate (Compound 34); (gg3) 8-Cyclopentyl-2-[4-(piperazin-l-yl)-phenylamino]-6-bromo- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 35);
(hh) 8-Cyclopentyl-2- [4-(3 ,5-dimethyl-piperazin- 1 -yl)- ρhenylamino]-6-fluoro-5-methyl-8H-ρyrido[2,3-d]pyrimidin-7-one hydrochloride (Compound 36);
(ii) 8-Cyclopentyl-2-(3 -fluoro-4-piperazin- 1 -yl-phenylamino)- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 37);
(jj) 6-Bromo-8-cyclopentyl-2-[4-(3 ,5-dimethyl-piperazin- 1 -yl)- phenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin- 7-one hydrochloride
(Compound 38);
(kk) 8-Cyclopentyl-6-fluoro-2-(3 -fluoro-4-piperazin- 1 -yl- phenylamino)-5-methyl-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 39); (11) 6-Bromo-8-cyclopentyl-2-(3-fluoro-4-piperazin-l-yl- phenylamino)-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 40);
(mm) 8-Cyclopentyl-2-[4-(3,5-dimethyl-piperazin-l-yl)- phenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 41);
(nn) 2-(3-Chloro-4-piperazin-l-yl-phenylamino)-8-cyclopentyl- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 42);
(oo) 2-(3-Chloro-4-piperazin-l-yl-phenylamino)-8-cyclopentyl- 6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 43); (pp) 6-Bromo-2-(3-chloro-4-piperazin-l-yl-phenylamino)-
8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 44);
(qq) 8-Cyclopentyl-5-methyl-2-(4-morpholin-4-yl-phenylamino)- 8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 45); (rr) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-morpholin-4-yl- phenylamino)-8H-ρyrido[2,3-d]pyrimidin-7-one (Compound 46);
(ss) 6-Bromo-8-cyclopentyl-5-methyl-2-(4-morpholin-4-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 47); (tt) 8-Cyclopentyl-2-(3-fluoro-4-morpholin-4-yl-phenylamino)- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 48);
(uu) 8-Cyclopentyl-6-fluoro-2-(3-fluoro-4-morpholin-4-yl- ρhenylamino)-5-methyl-8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 49);
(w) 6-Bromo-8-cyclopentyl-2-(3-fluoro-4-morpholin-4-yl- phenylamino)-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 50);
(ww) 2-(3-Chloro-4-morpholin-4-yl-phenylamino)-8-cyclopentyl- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 51);
(xx) 2-(3 -Chloro-4-morpholin-4-yl-phenylamino)-8-cyclopentyl- 6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 52);
(yy) 6-Bromo-2-(3 -chloro-4-morpholin-4-yl-phenylamino)- 8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 53);
(zz) 8-Cycloρentyl-5-methyl-2-{4-[4-(2,2,2-trifluoro-ethyl)- piperazin- 1 -yl] -phenylamino } - 8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 54);
(aaa) 8-Cyclopentyl-6-fluoro-5-methyl-2-{4-[4-(2,2,2-trifluoro- ethyl)-piperazin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 55);
(bbb) 6-Bromo-8-cyclopentyl-5-methyl-2-{4-[4-(2,2,2-trifluoro- ethyl)-piperazin- 1 -yl] -phenylamino } - 8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 56); (ccc) 8-Cyclopentyl-5-methyl-2-{4-[4-(3-piperazin-l-yl-propyl)- piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 57);
(ddd) 8-Cyclopentyl-6-fluoro-5-methyl-2-{4-[4-(3-piperazin-l-yl- propyl)-piperidin- 1 -yl] -phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 58);
(eee) 6-Bromo-8-cyclopentyl-5-methyl-2-{4-[4-(3-piperazin-l-yl- propyl)-piperidin- 1 -yl] -phenylamino ] -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 59); (fff) 8-Cyclopentyl-5-methyl-2- {4- [4-(3 -morpholin-4-yl-propyl)- piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 60);
(ggg) 8-Cyclopentyl-6-fluoro-5-methyl-2-{4-[4-(3-morpholin- 4-yl-propyl)-piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-
7-one (Compound 61);
(hhh) 6-Bromo-8-cyclopentyl-5-methyl-2-{4-[4-(3-morpholin- 4-yl-propyl)-piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 62); (iii) 6-Bromo-8-cyclopentyl-5-methyl-2-{4-[4-(3-morpholin-4-yl- propyl)-piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 63);
(jjj) 2-(4-{4-[3-(3-Amino-pyrrolidin-l-yl)-propyl]-piperidin-l-yl}- phenylamino)-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 64);
(kkk) 2-(4- { 4- [3 -(3 -Amino-pyrrolidin- 1 -y l)-propyl] -piperidin- l-yl}-phenylamino)-8-cyclopentyl-6-fluoro-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 65);
(111) 2-(4- {A- [3 -(3 -Amino-pyrrolidin- 1 -yl)-propyl]-piperidin- 1 -yl} - phenylamino)-6-bromo-8-cyclopentyl-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 66);
(mmm) 8-Cyclopentyl-2- {3 -fluoro-4- [4-(3 -piperazin- 1 -yl-propyl)- piperidin- 1 -yl]-phenylamino } -5-methyl-8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 67); (nnn) 8-Cyclopentyl-6-fluoro-2-{3-fluoro-4-[4-(3-piperazin-l-yl~ propyl)-piperidin-l-yl]-phenylamino}-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 68);
(ooo) 6-Bromo-8-cyclopentyl-2-{3-fluoro-4-[4-(3-piperazin-l-yl- propyl)-piperidin- 1 -yl] -phenylamino } -5 -methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 69);
(ppp) 8-Cyclopentyl-2- { 3 -fluoro-4- [4-(3 -morpholin-4-yl-propyl)- piperidin-l-yl]-phenylamino}-5-methyl-8H-ρyrido[2,3-d]pyrimidin-7-one (Compound 70); (qqq) 8-Cyclopentyl-6-fluoro-2- { 3 -fluoro-4- [4-(3 -morpholin-4-yl- propyl)-piperidin-l-yl]-phenylamino}-5-methyl-8H-pyrido[2,3-d]- pyrimidin-7-one (Compound 71);
(rrr) 6-Bromo-8 -cyclopentyl-2- { 3 -fluoro-4- [4-(3 -morpholin-4-yl- propyl)-ρiperidin- 1 -yl] -phenylamino } -5 -methyl- 8H~pyrido [2,3 -d] - pyrimidin-7-one (Compound 72);
(sss) 2-[4-(3-Amino-pyrrolidin-l -yl)-phenylamino]-8-cyclopentyl- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 73);
(ttt) 2-[4-(3-Amino-pyrrolidin-l -yl)-phenylamino]-8-cyclopentyl- 6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 74);
(uuu) 2-[4-(3-Amino-pyrrolidin-l-yl)-phenylamino]-6-bromo- 8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 75);
(vvv) 2-[4-(3-Amino-pyrrolidin-l -yl)-3-fluoro-phenylamino]- 8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 76);
(www) 2-[4-(3-Amino-pyrrolidin-l-yl)-3-fluoro-phenylamino]- 8-cyclopentyl-6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 77); (xxx) 2-[4-(3-Amino-pyrrolidin-l-yl)-3-fluoro-phenylamino]-
6-bromo-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 78);
(yyy) 8-Cyclopentyl-5-methyl-2-{4-[3-(2,2,2-trifluoro- ethylamino)-pyrrolidin- 1 -yl]-phenylamino} -8H-pyrido [2,3 -djpyrimidin- 7-one trifluoroacetate (Compound 79);
(zzz) 8-Cyclopentyl-6-fluoro-5-methyl-2-{4-[3-(2,2,2-trifluoiO- ethylamino)-pyrrolidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 80);
(aaaa) 6-Bromo-8-cyclopentyl-5-methyl-2-{4-[3-(2,2,2-trifluoro- ethylamino)-ρyrrolidin- 1 -yl]-phenylamino } -8H-pyrido [2,3 -d]pyrimidin-
7-one (Compound 81); (bbbb) 2-[4-(3-Amino-pyrrolidin-l -yl)-3 -chloro-phenylamino] - 8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 82);
(cccc) 2- [4-(3 -Amino-pyrrolidin- 1 -yl)-3 -chloro-phenylamino] - 8-cyclopentyl-6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 83);
(dddd) 2- [4-(3 -Amino-pyrrolidin- 1 -yl)-3-chloro-phenylamino]- 6-bromo-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 84); (eeee) 2- [4-(3 - Aminomethyl-4-trifluoromethyl-pyrrolidin- 1 -y 1)- pheny lamino] - 8 -cy clopentyl-5 -methyl-8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 85);
(ffff) 2- [4-(3 - Aminomethyl-4-trifluoromethyl-pyrrolidin- 1 -yl)- phenylamino]-8-cyclopentyl-6-fluoro-5-methyl-8H-pyrido[2,3-d]- pyrimidin- 7-one (Compound 86);
(gggg) 2- [4-(3 - Aminomethyl-4-trifluoromethyl-pyrrolidin- 1 -yl)- phenylamino]-6-bromo-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]- pyrimidin-7-one (Compound 87);
(hhhh) 2-[4-(3-Trifloroethylaminomethyl-pyrrolidin-l-yl)- phenylamino]-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 88);
(iiii) 2- [4-(3 -Trifloroethylaminomethyl-pyrrolidin- 1 -yl)- phenylamino]-8-cyclopentyl-6-fluoro-5-methyl-8H-pyrido[2,3-d]- pyrimidin-7-one (Compound 89); (jjjj) 2-[4-(3-Trifloroethylaminomethyl-pyrrolidin-l-yl)- phenylamino]-6-bromo-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]- pyrimidin-7-one (Compound 90);
(kkkk) 8-Cyclopentyl-2-[4-(3,3-dimethyl-piperazin-l-yl)- phenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride (Compound 91);
(llll) 8-Cyclopentyl-2-[4-(3,3-dimethyl-piperazin-l-yl)- phenylamino]-6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 92); (mmmm) 6-Bromo-8-cyclopentyl-2-[4-(3,3-dimethyl-piperazin- 1 -yl)-phenylamino] -5 -methyl- 8H-pyrido [2,3 -d]pyrimidin-7-one hydrochloric (Compound 93);
(nnrm) 8-Cyclopentyl-5-methyl-2-[4-(3,3,4-trimethyl-piperazin- l-yl)-ρhenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 94);
(oooo) 8-Cyclopentyl-6-fluoro-5-methyl-2-[4-(3,3,4-trimethyl- piperazin-l-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 95);
(pppp) 6-Bromo-8-cyclopentyl-5-methyl-2-[4-(3 ,3 ,4-trimethyl- piperazin-l-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 96);
(qqqq) 2-[4-(4-Acetyl-piperazin-l-yl)-phenylamino]- 8-cyclopentyl-5-methyl-8H-ρyrido[2,3-d]pyrimidin-7-one (Compound 97); (rrrr) 2-[4-(4-Acetyl-piperazin-l-yl)-phenylamino]-8-cyclopentyl-
6-fluoro-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 98); (ssss) 2-[4-(4-Acetyl-piperazin-l -yl)-phenylamino]-6-bromo- 8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 99); (tttt) 8-Cyclopentyl-2-{4-[4-(2-hydroxy-ethyl)-3,5-dimethyl- piperazin- 1 -yl] -phenylamino} -5 -methyl~8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 100);
(uuuu) 8-Cyclopentyl-6-fluoro-2-{4-[4-(2-hydroxy-ethyl)- 3,5-dimethyl-piperazin-l-yl]-phenylamino}-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 101);
(vvw) 6-Bromo-8-cyclopentyl-2- {4-[4-(2-hydroxy-ethyl)~ 3 ,5-dimethyl-piperazin- 1 -yl] -phenylamino} -5-methyl-8H-pyrido[2,3-d]- pyrimidin-7-one (Compound 102);
(wwww) 8-Cyclopentyl-5-methyl-2-(4-perhydro-l ,4-diazepin- 1 -yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride
(Compound 103); (xxxx) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-ρerhydro- 1 ,4-diazepin- 1 -yl-phenylamino)-8H-pyrido [2,3 -d]pyrimidin-7-one hydrochloride (Compound 104);
(yyyy) 6-Bromo-8-cyclopentyl-5-methyl-2-(4-perhydro- l,4-diazepin-l-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 105);
(zzzz) 8-Cyclopentyl-5-methyl-2-[4-(4-methyl-piperazin- 1 -yl)- phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 106); (aaaaa) 8-Cyclopentyl-6-fluoro-5-methyl-2-[4-(4-methyl- piperazin-l-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 107);
(bbbbb) 6-Bromo-8-cyclopentyl-5-methyl-2-[4-(4-methyl- piperazin-l-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 108); (ccccc) 8-Cyclopentyl-5-methyl-2-[4-(4-methyl-perhydro- l,4-diazepin-l-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 109);
(ddddd) 8-Cyclopentyl-6-fluoro-5-methyl-2-[4-(4-methyl- perhydro- 1 ,4-diazepin- 1 -yl)-phenylamino] -8H-pyrido[2,3 -d]pyrimidin- 7-one (Compound 110);
(eeeee) 6-Bromo-8-cyclopentyl-5-methyl-2-[4-(4-methyl- perhydro- 1 ,4-diazepin- 1 -yl)-phenylamino]-8H-pyrido [2,3 -d]pyrimidin- 7-one (Compound 111);
(fffff) {4-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido [2,3 -d]pyrimidin-2-ylamino)-phenyl] -piperazin- 1 -yl } -acetic acid
(Compound 112);
(ggggg) {4-[4-(8-Cyclopentyl-6-fluoro-5-methyl-7-oxo- 7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperazin-l-yl}- acetic acid (Compound 113); (l_l__αhh) {4-[4-(6-Bromo-8-cyclopentyl-5-methyl-7-oxo-
7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperazin- 1 -yl} - acetic acid (Compound 114); (iiiii) 8-Cyclopentyl-5-methyl-2-(4-{4-[3-(lH-tetrazol-5-yl)- propyl]-piperidin-l-yl}-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 115);
(jjjjj) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4- {4- [3 -( 1 H-tetrazol- 5 -yl)-propyl] -piperidin- 1 -yl } -phenylamino)-8H-pyrido [2,3 -d]ρyrimidin-
7-one (Compound 116);
(kkkkk) 6-Bromo-8-cyclopentyl-5-methyl-2-(4-{4-[3-(lH-tetrazol- 5-yl)-propyl]-piperidin-l-yl}-phenylamino)-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 117); (lllll) 8-Cyclopentyl-5-methyl-2-(4-{4-[3-(5-oxo-4,5-dihydro-lH- l,2,4-triazol-3-ylsulfanyl)-propyl]-piperidin-l-yl}-ρhenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 118);
(mmmmm) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-{4-[3-(5-oxo- 4,5-dihydro-lH-l,2,4-triazol-3-ylsulfanyl)-propyl]-piperidin-l-yl}- ρhenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 119);
(nrtnnn) 6-Bromo-8 -cy clopentyl-5 -methyl-2 -(4- { 4- [3 -(5-oxo- 4, 5 -dihy dro- 1 H- 1 ,2,4-triazol-3 -ylsulfanyl)-propyl] -piperidin- 1 -yl } - phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 120);
(ooooo) 8-Cyclopentyl-5-methyl~2-(4-{4-[3-(5-oxo-4,5-dihydro- 1 H- 1 ,2,4-triazole-3 -sulfinyl)-proρyl] -piperidin- 1 -yl} -phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 121);
(ppppp) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-{4-[3-(5-oxo- 4,5-dihydro-lH-l,2,4-triazole-3-sulfinyl)-propyl]-piperidin-l-yl}- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 122); (qqqqq) 6-Bromo-8-cyclopentyl-5-methyl-2-(4-{4-[3-(5-oxo-
4,5-dihydro- 1 H- 1 ,2,4-triazole-3 -sulfinyl)-propyl]-piperidin- 1 -yl} - phenylamino)-8H-ρyrido[2,3-d]pyrimidin-7-one (Compound 123);
(rrriT) 8-Cyclopentyl-5-methyl-2-(4- {4-[3-(5-oxo-4,5-dihydro- 1 H- l,2,4-triazole-3-sulfonyl)-propyl]-piperidin-l-yl}-phenylamino)-8H- pyrido [2,3 -d]ρyrimidin-7-one (Compound 124);
(sssss) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-{4-[3-(5-oxo- 4,5-dihydro- IH- 1 ,2,4-triazole-3-sulfonyl)-propyl]-piperidin- 1 -yl} - phenylamino)-8H-ρyrido[2,3-d]pyrimidin- 7-one (Compound 125); (ttttt) 6-Bromo-8-cyclopentyl-5-methyl-2-(4- {4- [3 -(5-oxo- 4,5-dihydro- 1 H- 1 ,2,4-triazole-3 -sulfonyl)-propyl] -piperidin- 1 -yl} - phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 126);
(uuuuu) N-(2-{ l-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidin-4-yl}-ethyl)-N- hydroxy-acetamide (Compound 127);
(wvw) N-(2-{ 1 -[4-(8-Cyclopentyl-6-fluoro-5-methyl-7-oxo- 7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidin-4-yl}- ethyl)-N-hydroxy-acetamide (Compound 128); (wwwww) N-(2-{l-[4-(6-Bromo-8-cyclopentyl-5-methyl-7-oxo-
7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidin-4-yl}- ethyl)-N-hydroxy-acetamide (Compound 129);
(xxxxx) N-(3-{ 1 -[4-(8-Cycloρentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidin-4-yl}-propyl)-N- hydroxy-acetamide (Compound 130);
(yyyyy) N-(3- { 1 -[4-(8-Cyclopentyl-6-fluoro-5-methyl-7-oxo- 7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-ρiperidin-4-yl}- propyl)-N-hydroxy-acetamide (Compound 131);
(zzzzz) N-(3-{ 1 -[4-(6-Bromo-8-cyclopentyl-5-methyl-7-oxo- 7,8-dihydiO-pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-ρiperidin-4-yl}- ρropyl)-N-hydroxy-acetamide (Compound 132);
(aaaaaa) 2-(Benzofuran-5-ylamino)-8-cyclopentyl-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 133);
(bbbbbb) 8-Cyclopentyl-2-(lH-indol-5-ylamino)-5-methyl-8H- pyrido [2,3 -d]pyrimidin-7-one (Compound 134);
(cccccc) 2-(Benzo[b]thiophen-5-ylamino)-8-cyclopentyl-5-methyl- 8H-pyrido[2,3-d]ρyrimidin-7-one (Compound 135);
(dddddd) 8-Cyclopentyl-2-(2,3-dimethyl-lH-indol-5-ylamino)- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 136); (eeeeee) 2-(9H-Carbazol-3-ylamino)-8-cyclopentyl-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 137);
(ffffff) 8-Cyclopentyl-2-(l H-indazol-5-ylamino)-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 138); (gggggg) 2-(2-Acetyl-ber_zofuran-5-ylamino)-8-cyclopentyl- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 139); (hhhhhh) 8-Cyclopentyl-5-methyl-2-(4-morpholin-4-yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 140); (iiiiii) 8-Cyclopentyl-2-[4-(3,5-dimethyl-piperazin-l-yl)- phenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 141);
(jjjjjj) 2-(3-Chloro-4-piperazin-l-yl-phenylamino)-8-cyclopentyl- 5-methyl-8H-pyrido[2,3-d]ρyrimidin-7-one trifluoroacetate (Compound 142);
(kWckkk) 8-Cyclopentyl-5-methyl-2-(4-piρeridin- 1 -yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 143);
(HUH) 8-Cyclopentyl-5-methyl-2-[4-(4-methyl-piperazin-l-yl)- phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 144); (mmmmmm) N-{l-[4-(8-Cyclopentyl-5-methyl-7-oxo-
7,8-dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piρeridin-4-yl}- acetamide (Compound 145);
(n innn) 8-Cyclopentyl-5-methyl-2-(4-piperazin-l -yl- phenylamino)-8H-pyrido [2,3 -d]pyrimidin-7-one trifluoroacetate (Compound 146);
(oooooo) 8-Cyclopentyl-6-fluoro-5-methyl-2-(4-piperazin- 1 -yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 147);
(pppppp) 6-Bromo-8-cyclopentyl-5-methyl-2-(4-piperazin- 1 -yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 148); (qqqqqq) 2-[3-Chloro-4-(3-amino-pyrrolidin-l-yl)-phenylamino]-
8-cyclopentyl-5-methyl-8H-pyrido [2,3 -d]pyrimidin-7-one trifluoroacetate (Compound 149);
(rrrrrr) 8-Cyclopentyl-5-methyl-2-[4-(4-(2,2,2-trifluoroethyl)- piperazin- 1 -yl)-phenylamino]-8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 150);
(ssssss) 8-Cyclopentyl-2-(4-fluoro-phenylamino)-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 151); (tttttt) 8-Cyclopentyl-5-methyl-2-phenylamino-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 152);
(uuuuuu) 8-Cyclopentyl-2-(3 ,4-dichloroρhenylamino)-5-methyl- 8H-pyrido [2,3 -d]pyrimidin- 7-one (Compound 153); (www) 8-Isopropyl-5-methyl-2-(4-piperazin-l-yl-phenylamino)-
8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 154);
(wwwwww) 8-Isopropyl-5-methyl-2-[4-(4-propionyl-piperazin-l- yl)-phenylamino]-8H-ρyrido[2,3-d]pyrimidin-7-one (Compound 155); (xxxxxx) 8-Cyclohexyl-5-methyl-2-(4-piperazin- 1 -yl- phenylamino)-8H-ρyrido[2,3-d]pyrimidin- 7-one (Compound 156);
(yyyyyy) 2-{4-[4-(3-Morpholin-4-yl-propyl)-piperidin-l-yl]- pheny lamino } - 8-cy clohexyl-6-fluoro-5 -methyl- 8H-pyrido [2,3 - d]pyrimidin-7-one (Compound 157);
(zzzzzz) 8-Cyclopentyl-5-methyl-2-[4-(2H-l ,2,4-triazol-3- ylsulfanylmethyl)-phenylamino]-8H-pyrido [2,3 -d]pyrimidin-7-one
(Compound 158);
(aaaaaaa) 8-Cyclopentyl-5-methyl-2-[4-(2H-l,2,4-triazole-3- sulfinylmethyl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 159); (bbbbbbb) 8-Cyclopentyl-5-methyl-2-[4-(2H-l,2,4-triazole-3- sulfonylmethyl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 160);
(ccccccc) 8-Cyclopentyl-5-methyl-2-[4-(5-oxo-4,5-dihydro-l,2,4- oxadiazol-3 -ylmethyl)-pheny lamino] - 8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 161);
(ddddddd) 8-Cyclopentyl-5-methyl-2-{4-[2-(2H-l ,2,4-triazol-3- ylsulfanyl)-ethyl]-ρhenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 162);
(eeeeeee) 8-Cyclopentyl-5-methyl-2-{4-[2-(2H-l,2,4-triazole-3- sulfinyl)-ethyl]-phenylamino}-8H-pyrido[2,3-d]ρyrimidin- 7-one
(Compound 163); (fffffff) 8-Cyclopentyl-5-methyl-2-{4-[2-(2H- 1 ,2,4-triazole-3- sulfonyl)-ethyl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 164);
(ggggggg) 8-Cyclopentyl-5-methyl-2-{4-[2-(5-oxo-4,5-dihydro- 1 ,2,4-oxadiazol-3 -yl)-ethyl] -phenylamino } - 8H-pyrido [2,3 -d]pyrimidin-7- one (Compound 165);
(hhhhhhh) 8-Cyclopentyl-5-methyl-2-[4-(3H-l ,2,3-triazol-4- ylsulfanylmethyl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 166); (iiiiiii) 8-Cyclopentyl-5-methyl-2-{4-[2-(3H-l,2,3-triazol-4- ylsulfanyl)-ethyl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 167);
(jjjjjjj) 8-Cyclopentyl-5-methyl-2-{4-[4-(5-oxo-4,5-dihydro-l,2,4- oxadiazol-3-yl)-piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 168);
(M kkkkk) 8-Cyclopentyl-5-methyl-2-{4-[4-(2H-l,2,4-triazol-3- ylsulfanyl)-piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7- one (Compound 169);
(1111111) 8-Cyclopentyl-5-methyl-2-{4-[4-(2H-l,2,4-triazole-3- sulfinyl)-piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 170);
(m mmmm ) 8-Cyclopentyl-5-methyl-2-{4-[4-(2H-l,2,4- triazole-3 -sulfonyl)-piperidin- 1 -yl]-phenylamino } -8H- pyrido[2,3-d]pyrimidin-7-one (Compound 171), mp 235-237°C; (nnminnn) 8-Cyclopentyl-5-methyl-2-{4-[4-(2H-tetrazol-5-yl)- piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 172);
(ooooooo) l-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidine-4-carboxylic acid (lH-tetrazol-5-yl)-amide (Compound 173); (ppppppp) 8-Cyclopentyl-5-methyl-2- {4-[4-(3H- 1 ,2,3-triazol-4- ylsulfanyl)-piperidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7- one (Compound 173);
(qqqqqqq) 3-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-N-(lH-tetrazol-5-yl)- propionamide (Compound 174);
(rrrrrrr) 2-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenoxy]-N-(lH-tetrazol-5-yl)- acetamide (Compound 175); (sssssss) 8-Cyclopentyl-5-methyl-2-[4-(5-oxo-4,5-dihydro- 1 ,2,4- oxadiazol-3 -ylmethoxy)-phenylamino] -8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 176);
(ttttttt) 8-Cyclopentyl-5-methyl-2-(4-{4-[2-(2H-l ,2,4-triazole-3- sulfmyl)-ethyl]-piperidin-l-yl}-phenylamino)-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 177);
(uuuuuuu) 8-Cyclopentyl-5-methyl-2-(4-{4-[2-(2H-l,2,4-triazole- 3-sulfonyl)-ethyl]-piperidin-l-yl}-phenylamino)-8H-ρyrido[2,3- d]pyrimidin-7-one (Compound 178);
(wvywv) 8-Cyclopentyl-5-methyι-2-(4-{4-[2-(3H-l,2,3-triazol- 4-ylsulfanyl)-ethyl]-piperidin-l-yl}-phenylamino)-8H-pyrido[2,3- d]pyrimidin-7-one (Compound 179);
(wwwwwww) 8-Cyclopentyl-5-methyl-2-(4-{4-[2-(2H-l,2,4- triazol-3-ylsulfanyl)-ethyl]-piperidin-l-yl}-phenylamino)-8H-pyrido[2,3- d]pyrimidin-7-one (Compound 180); (xxxxxxx) 8-Cyclopentyl-5-methyl-2-(4-{4-[2-(5-oxo-4,5- dihy dro- 1 ,2,4-oxadiazol-3 -yl)-ethyl]-piperidin- 1 -yl} -phenylamino)-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 181);
(yvyyyyy) 8-Cyclopentyl-5-methyl-2-{4-[4-(2-oxo-2,3-dihydro- l,2,3,5-oxathiadiazol-4-yl)-piρeridin-l-yl]-phenylamino}-8H-pyrido[2,3- d]pyrimidin-7-one (Compound 182);
(zzzzzzz) 8-Cyclopentyl-2- {4-[4-(2,2-dioxo-2,3-dihydro- 1 ,2,3 ,5- oxathiadiazol-4-yl)-piperidin-l-yl]-phenylamino}-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 183); (aaaaaaaa) 8-Cyclopentyl-5-methyl-2-{4-[4-(l-oxo-2,5-dihydro- 1 H- 1 ,2,3 ,5-thiatriazol-4-yl)-piperidin- 1 -yl] -phenylamino } -8H-pyrido [2,3 - d]pyrimidin-7-one (Compound 184);
(bbbbbbbb) 8-Cyclopentyl-2-{4-[4-(l ,1 -dioxo-2,5-dihydro-lH- 1,2,3, 5-thiatriazol-4-yl)-piperidin-l-yl]-phenylamino}-5-methyl-8H- pyrido [2,3 -djpyrimidin- 7-one (Compound 185);
(cccccccc) N-{ l-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro- pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperidine-4-carbonyl}- methanesulfonamide (Compound 186); (dddddddd) 8-Cyclopentyl-5-methyl-2-{4-[3-(2H-l,2,4-triazol-3- y lsulfany l)-pyrrolidin- 1 -y 1] -phenylamino } - 8H-pyrido [2,3 -d]pyrimidin-7- one (Compound 187);
(eeeeeeee) 8-Cyclopentyl-5-methyl-2-{4-[3-(2H-l,2,4-triazole-3- sulfinyl)-pyrrolidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 188);
(fflffiffff) 8-Cyclopentyl-5-methyl-2-{4-[3-(2H-l,2,4-triazole-3- sulfonyl)-pyrrolidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 189);
(gggggggg) 8-Cyclopentyl-5-methyl-2-{4-[3-(3H-l,2,3-triazol-4- ylsulfanyl)-pyrrolidin-l-yl]-phenylamino}-8H-pyrido[2,3-d]pyrimidin-7- one (Compound 190);
(hhhlThhhh) 8-Cyclopentyl-5-methyl-2-{4-[3-(5-oxo-4,5-dihydro- 1 ,2,4-oxadiazol-3 -yl)-pyrrolidin- 1 -yl]-phenylamino } -8H-pyrido [2,3 - djpyrimidin- 7-one (Compound 191); (iiiiiiii) 8-Cycloρentyl-5-methyl-2-{4-[4-(3- hydroxypropyl)piperidin- 1 -yl]-ρhenylamino } -8H-pyrido [2,3 -d]pyrimidin- 7-one trifluoroacetate (Compound 192);
(jjjjjjjj) 8-Cyclopentyl-5-methyl-2-(4-piperazin- 1 -yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 193);
(ld__klddckk) 8-Cyclopentyl-5-ethyl-2-(4-piperazin-l -yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 194); (11111111) 8-( 1 -Methylethyl)-5-ethyl-2-(4-piperazin- 1 -yl- phenylamino)-8H-pyrido[253-d]ρyrimidin-7-one (Compound 195);
(n mrnmmmmm) 8-(Methylethyl)-5-ethyl-2-(4-piperazin- 1 -yl- phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one trifluoroacetate (Compound 196);
(nnrnnnnn) 8-Cyclopentyl-5-methyl-2-[4-(3-hydroxypyrrolidin-l - yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 197); (oooooooo) 8-Cyclopentyl-5-methyl-2-[4-(4-acetylpiperazin-l - yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 198); (PPPPPPPP) 8-Cyclopentyl-5-methyl-6-fluoro-2-[4-(4- acetylpiperidin-l-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 199);
(qqqqqqqq) 8-Cyclopropyl-5-methyl-2-[4-(4-acetamidopiperidin- l-yl)phenylamino]-8H-pyrido[2,3-d]ρyrimidin-7-one (Compound 200); (rrrrrrrr) 8 -Cy clopentyl-5 -methyl-2- [4-(homopiperazin- 1 - yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride (Compound 202);
(ssssssss) 8-Cyclopentyl-5-methyl-6-fluoro-2-[4-(homopiperazin- 1 -yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one hydrochloride (Compound 203);
(tttttttt) 8-Cyclopentyl-5-methyl-6-fluoro-2-[4-(3,3-dimethyl-4- acetylpiperazin-l-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 204);
(uuuuuuuu) 8-Cyclopentyl-5-methyl-2- [4-(3 ,3 -dimethyl-4- acetylpiperazin-l-yl)phenylamino]-8H-ρyrido[2,3-d]pyrimidin-7-one
(Compound 205);
(vwwvw) 8-Cyclopentyl-5-methyl-6-fluoro-2-[4-(4- methylpiperazin- 1 -yl)phenylamino]-8H-pyrido [2,3 -d]pyrimidin-7-one (Compound 206); (wwwwwwww) 8-Cyclopentyl-5-methyl-2-[4-(N- methylacetamido)phenylamino]-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 207); (xxxxxxxx) 8-Cyclopentyl-5-methyl-2-{4-[2-(2- hydroxyethoxy)ethylamino]phenylamino}-8H-pyrido[2,3-d]pyrimidin-7- one (Compound 208);
(yyyyyyyy) 8-Cyclopentyl-5-methyl-2-[4-(3-oxoρiperazin-l- yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 209);
(zzzzzzzz) 8-Cyclopentyl-5-methyl-2-[4-(2- methoxyethoxy)phenylamino]-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 210);
(aaaaaaaaa) 8-Cyclopentyl-5-methyl-2-(carbozol-3-yl)amino-8H- pyrido [2,3 -d]pyrimidin-7-one (Compound 211);
(bbbbbbbbb) 8-Cyclopentyl-5-methyl-2-(isoindazol-5-yl)amino- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 212);
(ccccccccc) 8-Cyclopentyl-5-methyl-2-(2-acetylbenzofuran-5- yl)amino-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 213); (ddddddddd) 8-Cyclopentyl-5-methyl-2-[(4-piperidin-l- yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 214);
(eeeeeeeee) 8-Cyclopentyl-5-methyl-2-(2,3-dimethylindol-5- yl)amino-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 215); (fffffffff) 8-Cyclopentyl-5-methyl-2-[4-(3,5-methyl-4R- aminomethylpyrrolidin-l-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7- one (Compound 216);
(ggggggggg) 8-Cyclopentyl-5-methyl-2- {4-[4-(2- hydroxyethyl)piperazin- 1 -yl)]phenylamino } -8H-pyrido [2,3 -d]pyrimidin-7- one (Compound 217); (hhhhhhhhh) 8-Cyclopentyl-5-methyl-2-{4-[4-(3- morpholinopropyl)piperidin- 1 -yljpheny lamino } - 8H- pyrido[2,3-d]pyrimidin-7-one (Compound 218);
(iiiiiiiii) 8-Cyclopentyl-5-methyl-2-(benzofuran-5-yl)amino-8H- pyrido [2,3 -d]pyrimidin- 7-one (Compound 219); (jjjjjjjjj) 8-Cyclopentyl-5-methyl-2-(indol-5-yl)amino-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 220); and
(Udddckkkk) 8-Cyclopentyl-5-methyl-2-(thionaphthen-5- yl)amino-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 221). A compound selected from the group consisting of:
8-Cyclopentyl-6-iodo-5-methyl-2-(4-piperazin- 1 -yl-phenylamino)- 8H-pyrido[2,3-^pyrimidin-7-one (Compound 225);
8-Cyclopentyl-2-{4-[l-(3,5-dimethyl-piperazin-l-yl)-methanoyl]- phenylamino}-5-methyl-8Η-pyrido[2,3-d]pyrimidin-7-one
(Compound 226);
8-Cyclopentyl-2-[4-(3,5-dimethyl-piperazin-l-yl)-phenylamino]-5- trifluoromethyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 227); 6-Bromo-8-cyclopentyl-2-[4-(3,3-dimethyl-piperazin-l-yl)- phenylamino]-5-methyl-8H-pyrido[2,3-(f]pyrimidin- 7-one
(Compound 228);
8-Cyclopentyl-2- [4-(3 ,5-dimethyl-piperazin- 1 -yl)-phenylamino] -6- iodo-5-methyl-8H-pyrido[2,3--^pyrimidin-7-one (Compound 229); 6-Chloro-8-cyclopentyl-2-[4-(3,5-dimethyl-piperazin- 1 -yl)- phenylammo]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
(Compound 230);
8-Cyclopentyl-5-methyl-2-[4-(lΗ-[l,2,4]triazol-3-ylsulfanyl)- phenylamino]-8H-pyrido[2,3-<f]pyrimidin-7-one (Compound 231); 4-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3- ]pyrimidin-2-ylamino)-phenyl]-piperazine- 1 -carbaldehyde
(Compound 232);
8-Cyclopentyl-2-(4-piperazin- 1 -yl-phenylamino)-5- trifluoromethyl-8H-pyrido[2,3-£ ]pyrimidm-7-one (Compound 233); 8-(l -Ethyl-propyl)-5-mefhyl-2-(4-piperazin-l -yl-phenylamino)- 8H-pyrido[2,3-<i]pyrimidm-7-one (Compound 234);
[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3- d]pyrimidin-2-ylamino)-benzyl]-phosphonic acid (Compound 235);
6-Chloro-8-cyclopentyl-5-methyl-2-(4-piperazin-l-yl- phenylamino)-8H-pyrido[2,3-^pyrimidin-7-one (Compound 236); 2-[4-(3,5-Dimethyl-piperazin-l -yl)-phenylamino]-8-(l -ethyl- propyl)-5-methyl-8H-pyrido[2,3-c ]pyrimidin-7-one (Compound 237);
8-Cyclopentyl-2-[4-(2-hydroxy-ethylamino)-ρhenylamino]-5- methyl-8Η-pyrido[2,3-d]pyrimidin-7-one (Compound 238); 3-[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3- d]pyrimidin-2-ylamino)-phenyl]-N,N-diethyl-propionamide (Compound 239);
8-Cyclopentyl-6-fluoro-2-[4-(2-hydroxy-ethyl)-phenylamino]-5- methyl-8H-pyrido [2,3 -d]pyrimidin- 7-one (Compound 240);
8-Cyclopentyl-2-[4-(2-hydroxy-ethyl)-phenylamino]-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 241);
4-(8-Cycloρentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3- d]pyrimidin-2-ylamino)-benzoic acid (Compound 242); 8-Cyclopentyl-2-[4-(3,3-dimethyl-piperazin-l -yl)-phenylamino]-5- methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 243);
[4-(8-Cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido[2,3- d]pyrimidin-2-ylamino)-benzyl]-phosphonic acid diethyl ester (Compound 244); 8-Cyclopentyl-6-fluoro-2-[4-(2-methoxy-ethylamino)- phenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 245);
(S)-2-Amino-3-[4-(8-cyclopentyl-6-fluoro-5-methyl-7-oxo-7,8- dihydro-pyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-propionic acid (Compound 246);
8-Cyclopentyl-2-[4-(2-methoxy~ethoxy)-phenylamino]-5-methyl- 8H-pyrido[2,3-d]pyrimidin-7-one (Compound 247);
8-Cyclopentyl-2-(4-isopropylamino-phenylamino)-5-methyl-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 248); 8-Cyclopentyl-2-(4-hydroxy-3,5-dimethyl-phenylamino)-5-methyl-
8H-pyrido[2,3-d]pyrimidin-7-one (Compound 249);
8-Cyclopentyl-6-fluoro-2-(4-hydroxy-3,5-dimethyl-phenylamino)- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 250);
8-Cyclopentyl-6-fluoro-2-(4-hydroxy-3,5-dimethyl-phenylamino)- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 251).
9. A pharmaceutical composition comprising a compound selected from Claim 1 in combination with a pharmaceutically acceptable carrier, diluent, or excipient.
10. A method for controlling proliferative disorders selected from the group consisting of cancer, psoriasis, vascular smooth muscle proliferation associated with a disorder selected from the group consisting of atherosclerosis, postsurgical vascular stenosis, and restenosis in mammals comprising administering to said mammal a therapeutically effective amount of a compound according to Claim 1.
11. A method of inhibiting a cyclin-dependent kinase comprising contacting the cyclin-dependent kinase with a compound selected from Claim 1.
12. A method of Claim 11 wherein said cyclin-dependent kinase is cdk4.
13. A method of inhibiting a growth factor-mediated tyrosine kinase comprising contacting said growth factor-mediated kinase with a compound selected from Claim 1.
14. A method of Claim 13 wherein said growth factor-mediated tyrosine kinase is platelet derived growth factor (PDGF).
15. A method of Claim 13 wherein said growth factor-mediated tyrosine kinase is fibroblast growth factor (FGF).
16. A method of treating a subject suffering from diseases caused by vascular smooth muscle cell proliferation comprising administering to said subject a therapeutically effective amount of a compound selected from Claim 1.
17. A method of treating a subject suffering from cancer comprising administering to said subject a therapeutically effective amount of a compound selected from Claim 1.
18. 6-Bromo-8-cyclopentyl-2-[4-(3,5-dimethylpipeerazin-l-yl)-phenylamino]- 5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one.
19. 8-Cyclopentyl-6-fluoro-5-methyl-2-[4-(piperazin-l-yl)phenyl__mino]-8H- pyrido[2,3-d]pyrimidin-7-one.
20. 8-Cyclopentyl-5-methyl-2-(carbazol-3-yl)-8H-pyrido[2,3-d]pyrimidin-7- one.
21. A compound selected from
8-Cyclopentyl-5-methyl-2-(carbozol-3-yl)amino-8H~ pyrido [2,3 -d]pyrimidin- 7-one (Compound 211); 8-Cyclopentyl-5-methyl-2-(isoindazol-5-yl)amino-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 212);
8-Cyclopentyl-5-methyl-2-(2-acetylbenzofuran-5-yl)amino-8H- pyrido[2,3-d]ρyrimidin-7-one (Compound 213);
8-Cyclopentyl-5-methyl-2-[(4-piperidin-l-yl)phenylamino]-8H- pyrido [2,3 -d]pyrimidin-7-one (Compound 214);
8-Cyclopentyl-5-methyl-2-(2,3-dimethylindol-5-yl)amino-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 215);
8-Cycloρentyl-5-methyl-2-[4-(3,5-methyl-4R- aminomethylpyrrolidin-l-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7- one (Compound 216);
8-Cyclopentyl-5-methyl-2- {4-[4-(2-hydroxyethyl)piperazin-l - yl)]phenylamino}-8H-pyrido[2,3-d]pyrimidin-7-one (Compound 217);
8-Cyclopentyl-5-methyl-2- {4- [4-(3 -morpholinopropyl)piperidin- 1 - yl]phenylamino}-8H-pyrido[2,3-d]pyrimidin- 7-one (Compound 217); 8-Cyclopentyl-5-methyl-2-(benzofuran-5-yl)amino-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 219);
8-Cyclopentyl-5-methyl-2-(indol-5-yl)amino-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 220); and
8-Cyclopentyl-5-methyl-2-(thionaphthen-5-yl)amino-8H- pyrido[2,3-d]pyrimidin-7-one (Compound 221).
PCT/US2001/002657 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors WO2001070741A1 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SK1247-2002A SK12472002A3 (en) 2000-03-06 2001-01-29 5-Alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
AU2001233028A AU2001233028A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido(2,3-D)pyrimidines tyrosine kinase inhibitors
IL15148001A IL151480A0 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d] pyrimidines tyrosine kinase inhibitors
EEP200200506A EE200200506A (en) 2000-03-06 2001-01-29 5-alkylpyrido [2,3-d] pyrimidines as tyrosine kinase inhibitors
BR0109056-9A BR0109056A (en) 2000-03-06 2001-01-29 5-alkylpyrido [2,3-d] pyrimidines tyrosine kinase inhibitors
KR1020027011627A KR20020075805A (en) 2000-03-06 2001-01-29 5-Alkylpyrido[2,3-d]pyrimidines Tyrosine Kinase Inhibitors
JP2001568942A JP2003528101A (en) 2000-03-06 2001-01-29 5-alkylpyrido [2,3-d] pyrimidine tyrosine kinase inhibitors
DZ013308A DZ3308A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido [2,3-d] pyrimidines tyrosine kinase inhibitors
PL01358271A PL358271A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
APAP/P/2002/002643A AP2002002643A0 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
NZ520962A NZ520962A (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines cyclin-dependent tyrosine kinase inhibitors
EA200200802A EA200200802A1 (en) 2000-03-06 2001-01-29 5-ALKYLPYRIDO [2.3-d] Pyrimidine Thyrosine Kinase Inhibitors
CA002401368A CA2401368A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
MXPA02008535A MXPA02008535A (en) 2000-03-06 2001-01-29 5 alkylpyrido[2,3 d]pyrimidines tyrosine kinase inhibitors.
EP01905114A EP1268476A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
HU0300136A HUP0300136A2 (en) 2000-03-06 2001-01-29 5-alkylpyrido [2,3-d]pyrimidines tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
IS6524A IS6524A (en) 2000-03-06 2002-08-23 5-alkylpyrido (3-3-D) pyrimidine tyrosine kinase inhibitors
NO20024235A NO20024235L (en) 2000-03-06 2002-09-05 5-alkylpyrido (2,3-D) pyrimidine tyrosine kinase inhibitors
BG107161A BG107161A (en) 2000-03-06 2002-10-02 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
HR20020798A HRP20020798A2 (en) 2000-03-06 2002-10-04 5-ALKYLPYRIDO[2,3-d]PYRIMIDINES TYROZINE KINASE INHIBITORS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18712400P 2000-03-06 2000-03-06
US60/187,124 2000-03-06

Publications (1)

Publication Number Publication Date
WO2001070741A1 true WO2001070741A1 (en) 2001-09-27

Family

ID=22687699

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/002657 WO2001070741A1 (en) 2000-03-06 2001-01-29 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors

Country Status (36)

Country Link
EP (1) EP1268476A1 (en)
JP (1) JP2003528101A (en)
KR (1) KR20020075805A (en)
CN (1) CN1422268A (en)
AP (1) AP2002002643A0 (en)
AR (1) AR034119A1 (en)
AU (1) AU2001233028A1 (en)
BG (1) BG107161A (en)
BR (1) BR0109056A (en)
CA (1) CA2401368A1 (en)
CO (1) CO5280200A1 (en)
CR (1) CR6736A (en)
CZ (1) CZ20022929A3 (en)
DZ (1) DZ3308A1 (en)
EA (1) EA200200802A1 (en)
EE (1) EE200200506A (en)
GT (1) GT200100037A (en)
HN (1) HN2001000040A (en)
HR (1) HRP20020798A2 (en)
HU (1) HUP0300136A2 (en)
IL (1) IL151480A0 (en)
IS (1) IS6524A (en)
MA (1) MA26881A1 (en)
MX (1) MXPA02008535A (en)
NO (1) NO20024235L (en)
NZ (1) NZ520962A (en)
OA (1) OA12227A (en)
PA (1) PA8513201A1 (en)
PE (1) PE20011177A1 (en)
PL (1) PL358271A1 (en)
SK (1) SK12472002A3 (en)
SV (1) SV2001000338A (en)
TN (1) TNSN01036A1 (en)
WO (1) WO2001070741A1 (en)
YU (1) YU66502A (en)
ZA (1) ZA200207110B (en)

Cited By (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000270A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidones and uses thereof
WO2003000011A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
WO2003062236A1 (en) * 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
EP1364950A1 (en) * 2001-02-26 2003-11-26 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
US6696566B2 (en) * 2001-02-12 2004-02-24 Syntex (U.S.A.) Llc 6-substituted pyrido-pyrimidines
WO2004065378A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
WO2006021547A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
FR2887882A1 (en) * 2005-07-01 2007-01-05 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
JP2007504160A (en) * 2003-08-29 2007-03-01 エグゼリクシス， インコーポレイテッド c-Kit Regulator and Method of Use
WO2007044813A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
WO2007044698A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
US7323472B2 (en) 2000-10-23 2008-01-29 Smithkline Beecham Corporation 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds
US7348331B2 (en) 2003-11-13 2008-03-25 Roche Palo Alto Llc Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008047307A1 (en) * 2006-10-16 2008-04-24 Gpc Biotech Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
US7423042B2 (en) 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
WO2008153207A1 (en) * 2007-06-15 2008-12-18 Banyu Pharmaceutical Co., Ltd Bicycloaniline derivative
US7479558B2 (en) 2005-03-25 2009-01-20 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
US7544682B2 (en) 2004-07-15 2009-06-09 Sanofi-Aventis Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof
US7585866B2 (en) 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
EP2112150A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Improved raf inhibitors
US7629462B2 (en) 2000-03-02 2009-12-08 Smithkline Beecham Corporation Tetrasubstituted pyrimidine compounds as chemical intermediates
US7629350B2 (en) 2002-04-19 2009-12-08 Smithkline Beecham Corporation Compounds
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
US7629460B2 (en) 2004-08-25 2009-12-08 Boehringer Ingelheim International Gmbh Dihydropteridione derivatives, process for their manufacture and their use as medicament
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
US7674789B2 (en) 2005-03-25 2010-03-09 Glaxo Group Limited Compounds
US7678801B2 (en) 2005-03-25 2010-03-16 Glaxo Group Limited Compounds
US7728003B2 (en) 2005-09-14 2010-06-01 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US7750152B2 (en) 2003-02-26 2010-07-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same
US7759347B2 (en) 2004-06-21 2010-07-20 Boehringer Ingelheim International Gmbh 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7842806B2 (en) 2006-01-13 2010-11-30 Sanofi-Aventis Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof
WO2010141406A2 (en) 2009-06-01 2010-12-09 Osi Pharmaceuticals, Inc. Amino pyrimidine anticancer compounds
WO2011075616A1 (en) 2009-12-18 2011-06-23 Temple University - Of The Commonwealth System Of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
US8058270B2 (en) 2004-08-14 2011-11-15 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
USRE43115E1 (en) 2004-12-02 2012-01-17 Boehringer Ingelheim International Gmbh Process for the manufacture of fused piperazin-2-one derivatives
US8101622B2 (en) 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
US8143247B2 (en) 2004-08-14 2012-03-27 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US8188086B2 (en) 2006-02-08 2012-05-29 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US8193188B2 (en) 2004-07-09 2012-06-05 Boehringer Ingelheim International Gmbh Methods of using pyridodihydropyrazinones
WO2012074951A1 (en) 2010-11-29 2012-06-07 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
US8236811B2 (en) 2006-12-28 2012-08-07 Sanofi Therapeutic use for treating of leukemia
US8273755B2 (en) 2006-09-15 2012-09-25 Pfizer Inc 4-methylpyridopyrimidinone compounds
US8329695B2 (en) 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
US8445675B2 (en) 2004-08-14 2013-05-21 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US8623885B2 (en) 2011-03-23 2014-01-07 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
US8841312B2 (en) 2007-12-19 2014-09-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US8987267B2 (en) 2010-08-05 2015-03-24 Temple University—Of the Commonwealth System of Higher Education 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
RU2619944C2 (en) * 2013-02-21 2017-05-22 Пфайзер Инк. Solid forms of selective cdk4/6 inhibitor
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US9956225B2 (en) 2013-07-26 2018-05-01 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US10233188B2 (en) 2016-08-15 2019-03-19 Pfizer Inc. CDK2/4/6 inhibitors
US11174252B2 (en) 2018-02-15 2021-11-16 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
US11464779B2 (en) 2016-03-29 2022-10-11 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737155B2 (en) * 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
US8138181B2 (en) * 2007-04-03 2012-03-20 Array Biopharma Inc. Imidazo[1,2-a]pyridine compounds as receptor tyrosine kinase inhibitors
WO2011044535A2 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
ES2604191T3 (en) * 2011-05-17 2017-03-03 Principia Biopharma Inc. Tyrosine Kinase Inhibitors
TWI646094B (en) * 2016-06-01 2019-01-01 大陸商貝達藥業股份有限公司 Crystal form of inhibitory protein kinase active compound and application thereof
JP7226804B2 (en) * 2017-03-03 2023-02-21 オークランド ユニサービシズ リミテッド FGFR kinase inhibitor and pharmaceutical use
TW202035406A (en) * 2018-12-07 2020-10-01 大陸商杭州英創醫藥科技有限公司 Heterocyclic compound as CDK-HDAC dual pathway inhibitor
CN112759589B (en) * 2019-11-01 2022-04-08 暨南大学 Pyrimidopyridinones and their use
WO2022188755A1 (en) * 2021-03-08 2022-09-15 暨南大学 Pyridopyrimidine-based compound and application thereof
WO2024056091A1 (en) * 2022-09-16 2024-03-21 华东师范大学 Pyridonopyrimidine derivative as rsk inhibitor and use thereof
WO2024099403A1 (en) * 2022-11-10 2024-05-16 北京普祺医药科技股份有限公司 Thioether compound having soft drug property and use thereof, and pharmaceutical composition and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733914A (en) * 1995-05-03 1998-03-31 Warner-Lambert Company Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
WO1999061444A2 (en) * 1998-05-26 1999-12-02 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5733914A (en) * 1995-05-03 1998-03-31 Warner-Lambert Company Pyrido 2, 3-d!pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
WO1998033798A2 (en) * 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
WO1999061444A2 (en) * 1998-05-26 1999-12-02 Warner-Lambert Company Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation

Cited By (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US7629462B2 (en) 2000-03-02 2009-12-08 Smithkline Beecham Corporation Tetrasubstituted pyrimidine compounds as chemical intermediates
US7700768B2 (en) 2000-03-02 2010-04-20 Glaxosmithkline Llc Compounds
US7759486B2 (en) 2000-10-23 2010-07-20 Glaxosmithkline Llc 2,4,5-Trisubstituted pyrimidine compounds
US7323472B2 (en) 2000-10-23 2008-01-29 Smithkline Beecham Corporation 2,4,8-trisubstituted-8H-pyrido[2,3-d]pyrimidin-7-one compounds
US6696566B2 (en) * 2001-02-12 2004-02-24 Syntex (U.S.A.) Llc 6-substituted pyrido-pyrimidines
EP1364950A1 (en) * 2001-02-26 2003-11-26 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
EP1364950A4 (en) * 2001-02-26 2005-03-09 Tanabe Seiyaku Co Pyridopyrimidine or naphthyridine derivative
US7078522B2 (en) 2001-02-26 2006-07-18 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
WO2003000011A2 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidines and uses thereof
WO2003000011A3 (en) * 2001-06-21 2003-03-20 Ariad Pharma Inc Novel pyridopyrimidines and uses thereof
WO2003000270A1 (en) * 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyridopyrimidones and uses thereof
USRE47739E1 (en) 2002-01-22 2019-11-26 Warner-Lambert Company Llc 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
HRP20040660B1 (en) * 2002-01-22 2012-10-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3-d]PYRIMIDIN-7-ONES
US7456168B2 (en) 2002-01-22 2008-11-25 Warner-Lambert Company 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones
WO2003062236A1 (en) * 2002-01-22 2003-07-31 Warner-Lambert Company Llc 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES
US6936612B2 (en) 2002-01-22 2005-08-30 Warner-Lambert Company 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
US7208489B2 (en) 2002-01-22 2007-04-24 Warner-Lambert Company 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
AP1767A (en) * 2002-01-22 2007-08-13 Warner Lambert Co 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones.
EA007395B1 (en) * 2002-01-22 2006-10-27 Уорнер-Ламберт Компани Ллс 2-(PYRIDINE-2-YLAMINO)PYRIDO[2,3d]PYRIMIDIN-7-ONES
EA007395B3 (en) * 2002-01-22 2018-02-28 Уорнер-Ламберт Компани Ллс 2-(PYRIDINE-2-YLAMINO)PYRIDO[2,3-d]PYRIMIDIN-7-ONES
CN101001857B (en) * 2002-01-22 2011-06-22 沃尼尔·朗伯有限责任公司 2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
US7629350B2 (en) 2002-04-19 2009-12-08 Smithkline Beecham Corporation Compounds
US8252800B2 (en) 2002-07-31 2012-08-28 Critical Outcome Technologies Protein tyrosine kinase inhibitors
US7585866B2 (en) 2002-07-31 2009-09-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
WO2004065378A1 (en) * 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
US7750152B2 (en) 2003-02-26 2010-07-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Intermediate compounds for making dihydropteridinones useful as pharmaceutical compositions and processes of making the same
US8003786B2 (en) 2003-02-26 2011-08-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinone compounds
US7786299B2 (en) 2003-02-26 2010-08-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methods for treating diseases or conditions using dihydropteridinone compounds
US7816530B2 (en) 2003-02-26 2010-10-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Piperazinyl compounds
US8362017B2 (en) 2003-08-29 2013-01-29 Exelixis, Inc. C-kit modulators and methods of use
JP2007504160A (en) * 2003-08-29 2007-03-01 エグゼリクシス， インコーポレイテッド c-Kit Regulator and Method of Use
US7750016B2 (en) 2003-11-13 2010-07-06 Roche Palo Alto Llc Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
US7348331B2 (en) 2003-11-13 2008-03-25 Roche Palo Alto Llc Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones
US7759347B2 (en) 2004-06-21 2010-07-20 Boehringer Ingelheim International Gmbh 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments
US8193188B2 (en) 2004-07-09 2012-06-05 Boehringer Ingelheim International Gmbh Methods of using pyridodihydropyrazinones
US7544682B2 (en) 2004-07-15 2009-06-09 Sanofi-Aventis Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof
US7893259B2 (en) 2004-07-15 2011-02-22 Sanofi-Aventis Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof
US8143247B2 (en) 2004-08-14 2012-03-27 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US8058270B2 (en) 2004-08-14 2011-11-15 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US8591895B2 (en) 2004-08-14 2013-11-26 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
US8445675B2 (en) 2004-08-14 2013-05-21 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US8034816B2 (en) 2004-08-14 2011-10-11 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US8202867B2 (en) 2004-08-14 2012-06-19 Boehringer Ingelheim International Gmbh Methods of using hydrates and polymorphs of 4-[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US8138341B2 (en) 2004-08-14 2012-03-20 Boehringer Ingelheim International Gmbh Intermediate compounds useful for the manufacture of dihydropteridinones
US8138373B2 (en) 2004-08-14 2012-03-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US7723517B2 (en) 2004-08-25 2010-05-25 Boehringer Ingelheim International Gmbh Dihydropteridione derivatives, process for their manufacture and their use as medicament
US7700769B2 (en) 2004-08-25 2010-04-20 Boehringer Ingelheim International Gmbh Dihydropteridione derivatives, process for their manufacture and their use as medicament
US7807831B2 (en) 2004-08-25 2010-10-05 Boehringer Ingelheim International Gmbh Dihydropteridione derivatives, process for their manufacture and their use as medicament
US7629460B2 (en) 2004-08-25 2009-12-08 Boehringer Ingelheim International Gmbh Dihydropteridione derivatives, process for their manufacture and their use as medicament
WO2006021547A1 (en) * 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
USRE43115E1 (en) 2004-12-02 2012-01-17 Boehringer Ingelheim International Gmbh Process for the manufacture of fused piperazin-2-one derivatives
US7652041B2 (en) 2005-01-14 2010-01-26 Millennium Pharmaceuticals, Inc. Cinnamide and hydrocinnamide derivatives with kinase inhibitory activity
US7678801B2 (en) 2005-03-25 2010-03-16 Glaxo Group Limited Compounds
US7479558B2 (en) 2005-03-25 2009-01-20 Glaxo Group Limited Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one derivatives
US7674789B2 (en) 2005-03-25 2010-03-09 Glaxo Group Limited Compounds
US7423042B2 (en) 2005-03-25 2008-09-09 Glaxo Group Limited Compounds
US8008310B2 (en) 2005-07-01 2011-08-30 Sanofi-Aventis Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same
EP2020410A1 (en) * 2005-07-01 2009-02-04 sanofi-aventis Pyrido[2,3d]pyrimidine derivatives, process for their preparation and their therapeutical use
FR2887882A1 (en) * 2005-07-01 2007-01-05 Sanofi Aventis Sa PYRIDO [2,3-D] PYRIMIDINE DERIVATIVES, THEIR PREPARATION, THEIR THERAPEUTIC APPLICATION
EA014312B1 (en) * 2005-07-01 2010-10-29 Санофи-Авентис Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same
KR101298344B1 (en) 2005-07-01 2013-08-20 사노피 Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same
US7504406B2 (en) 2005-07-01 2009-03-17 Sanofi-Aventis Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same
WO2007003765A1 (en) 2005-07-01 2007-01-11 Sanofi Aventis Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same
CN101213196B (en) * 2005-07-01 2011-09-07 赛诺菲-安万特 Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same
US7728003B2 (en) 2005-09-14 2010-06-01 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of c-fms kinase
US7642270B2 (en) 2005-09-14 2010-01-05 Janssen Pharmaceutica N.V. 5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
WO2007044698A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
JP2013079255A (en) * 2005-10-07 2013-05-02 Exelixis Inc PYRIDOPYRIMIDINONE INHIBITOR OF PI3Kα
EA016945B1 (en) * 2005-10-07 2012-08-30 Экселиксис, Инк. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
JP2009511498A (en) * 2005-10-07 2009-03-19 エクセリクシス， インク． PI3Kα pyridopyrimidinone type inhibitor
WO2007044813A1 (en) * 2005-10-07 2007-04-19 Exelixis, Inc. PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
JP2009511504A (en) * 2005-10-07 2009-03-19 エクセリクシス， インク． PI3Kα pyridopyrimidinone type inhibitor
US8247408B2 (en) 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
US8044062B2 (en) 2005-10-07 2011-10-25 Exelixis, Inc. Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha
EP2322523A1 (en) * 2005-10-07 2011-05-18 Exelixis, Inc. Pyridopyrimidinone Inhibitors of PI3Kalpha
AU2006302148B2 (en) * 2005-10-07 2012-12-06 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
AU2006302078B2 (en) * 2005-10-07 2012-11-22 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kalpha
US7842806B2 (en) 2006-01-13 2010-11-30 Sanofi-Aventis Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof
US8188086B2 (en) 2006-02-08 2012-05-29 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US8664222B2 (en) 2006-02-08 2014-03-04 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US8273755B2 (en) 2006-09-15 2012-09-25 Pfizer Inc 4-methylpyridopyrimidinone compounds
US8633204B2 (en) 2006-09-15 2014-01-21 Pfizer Inc. 4-methylpyridopyrimidinone compounds
WO2008047307A1 (en) * 2006-10-16 2008-04-24 Gpc Biotech Inc. Pyrido [2, 3-d] pyrimidines and their use as kinase inhibitors
US8518958B2 (en) 2006-10-16 2013-08-27 Forma Therapeutics, Inc. Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors
EP1914234A1 (en) * 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
WO2008055013A2 (en) * 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
WO2008055013A3 (en) * 2006-10-31 2009-01-22 Janssen Pharmaceutica Nv 5-oxo-5,8 - dihydro - pyrido - pyrimidines as inhibitors of c-fms kinase
US8236811B2 (en) 2006-12-28 2012-08-07 Sanofi Therapeutic use for treating of leukemia
US9284275B2 (en) 2007-01-11 2016-03-15 Critical Outcome Technologies Inc. Inhibitor compounds and cancer treatment methods
WO2008153207A1 (en) * 2007-06-15 2008-12-18 Banyu Pharmaceutical Co., Ltd Bicycloaniline derivative
US8436004B2 (en) 2007-06-15 2013-05-07 Msd K.K. Bicycloaniline derivative
US8329695B2 (en) 2007-08-03 2012-12-11 Boehringer Ingelheim International Gmbh Crystalline form of the free base N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide
US8980903B2 (en) 2007-12-19 2015-03-17 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8841312B2 (en) 2007-12-19 2014-09-23 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8895556B2 (en) 2007-12-26 2014-11-25 Critical Outcome Technologies Inc. Compounds and method for treatment of cancer
EP2100894A1 (en) * 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
WO2009112524A1 (en) * 2008-03-12 2009-09-17 4Sc Ag Pyridopyrimidines as plk1 ( polo-like kinase) inhibitors
US8389533B2 (en) 2008-04-07 2013-03-05 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2112150A1 (en) 2008-04-22 2009-10-28 GPC Biotech AG Improved raf inhibitors
US8101622B2 (en) 2008-09-30 2012-01-24 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα and mTOR
US9096624B2 (en) 2009-06-01 2015-08-04 OSI Pharmaceuticals, LLC Amino pyrimidine anticancer compounds
WO2010141406A2 (en) 2009-06-01 2010-12-09 Osi Pharmaceuticals, Inc. Amino pyrimidine anticancer compounds
US8399433B2 (en) 2009-06-01 2013-03-19 OSI Pharmaceuticals, LLC Amino pyrimidine anticancer compounds
EP2512250A4 (en) * 2009-12-18 2013-06-05 Univ Temple Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
US8889696B2 (en) 2009-12-18 2014-11-18 Temple University—Of the Commonwealth System of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8H)-ones and therapeutic uses thereof
WO2011075616A1 (en) 2009-12-18 2011-06-23 Temple University - Of The Commonwealth System Of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
KR101754664B1 (en) 2009-12-18 2017-07-06 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
EP2512250A1 (en) * 2009-12-18 2012-10-24 Temple University - Of The Commonwealth System of Higher Education Substituted pyrido[2,3-d]pyrimidin-7(8h)-ones and therapeutic uses thereof
US8901137B2 (en) 2010-02-09 2014-12-02 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of PI3K and mTOR in combination with autophagy inhibitors
US8987272B2 (en) 2010-04-01 2015-03-24 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9624220B2 (en) 2010-04-01 2017-04-18 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US9422282B2 (en) 2010-04-01 2016-08-23 Critical Outcome Technologies Inc. Compounds and method for treatment of HIV
US8987267B2 (en) 2010-08-05 2015-03-24 Temple University—Of the Commonwealth System of Higher Education 2-substituted-8-alkyl-7-OXO-7,8-dihydropyrido[2,3-D]pyrimidine-6-carbonitriles and uses thereof in treating proliferative disorders
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9133224B2 (en) 2010-11-29 2015-09-15 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
WO2012074951A1 (en) 2010-11-29 2012-06-07 OSI Pharmaceuticals, LLC Macrocyclic kinase inhibitors
US8623885B2 (en) 2011-03-23 2014-01-07 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
US9359355B2 (en) 2011-03-23 2016-06-07 Amgen Inc. Fused tricyclic dual inhibitors of CDK 4/6 and FLT3
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US9718821B2 (en) 2012-02-23 2017-08-01 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
WO2013126656A1 (en) * 2012-02-23 2013-08-29 Abbvie Inc. Pyridopyrimidinone inhibitors of kinases
RU2619944C2 (en) * 2013-02-21 2017-05-22 Пфайзер Инк. Solid forms of selective cdk4/6 inhibitor
US9956225B2 (en) 2013-07-26 2018-05-01 Boehringer Ingelheim International Gmbh Treatment of myelodysplastic syndrome
US9828373B2 (en) 2014-07-26 2017-11-28 Sunshine Lake Pharma Co., Ltd. 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof
US9867831B2 (en) 2014-10-01 2018-01-16 Boehringer Ingelheim International Gmbh Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
US11464779B2 (en) 2016-03-29 2022-10-11 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
US10233188B2 (en) 2016-08-15 2019-03-19 Pfizer Inc. CDK2/4/6 inhibitors
US10800783B2 (en) 2016-08-15 2020-10-13 Pfizer Inc. CDK2/4/6 inhibitors
US11396512B2 (en) 2016-08-15 2022-07-26 Pfizer Inc. CDK2/4/6 inhibitors
US11174252B2 (en) 2018-02-15 2021-11-16 Nuvation Bio Inc. Heterocyclic compounds as kinase inhibitors
US11697648B2 (en) 2019-11-26 2023-07-11 Theravance Biopharma R&D Ip, Llc Fused pyrimidine pyridinone compounds as JAK inhibitors
WO2024107730A1 (en) * 2022-11-14 2024-05-23 Onconova Therapeutics, Inc. Methods and compositions for treating cancer

Also Published As

Publication number Publication date
TNSN01036A1 (en) 2005-11-10
SV2001000338A (en) 2001-11-30
MXPA02008535A (en) 2002-12-13
CO5280200A1 (en) 2003-05-30
IS6524A (en) 2002-08-23
AU2001233028A1 (en) 2001-10-03
AR034119A1 (en) 2004-02-04
NO20024235D0 (en) 2002-09-05
PL358271A1 (en) 2004-08-09
HN2001000040A (en) 2001-09-06
HUP0300136A2 (en) 2003-05-28
YU66502A (en) 2005-09-19
MA26881A1 (en) 2004-12-20
OA12227A (en) 2004-03-18
NO20024235L (en) 2002-11-05
DZ3308A1 (en) 2001-09-27
CA2401368A1 (en) 2001-09-27
SK12472002A3 (en) 2003-04-01
ZA200207110B (en) 2003-12-04
BG107161A (en) 2003-06-30
KR20020075805A (en) 2002-10-05
EE200200506A (en) 2004-02-16
EA200200802A1 (en) 2003-02-27
EP1268476A1 (en) 2003-01-02
AP2002002643A0 (en) 2002-12-31
HRP20020798A2 (en) 2004-02-29
PA8513201A1 (en) 2003-06-30
IL151480A0 (en) 2003-04-10
BR0109056A (en) 2003-06-03
JP2003528101A (en) 2003-09-24
CZ20022929A3 (en) 2003-02-12
GT200100037A (en) 2002-03-04
CR6736A (en) 2004-03-10
NZ520962A (en) 2003-09-26
PE20011177A1 (en) 2001-11-23
CN1422268A (en) 2003-06-04

Similar Documents

Publication Publication Date Title
WO2001070741A1 (en) 5-alkylpyrido[2,3-d]pyrimidines tyrosine kinase inhibitors
USRE47739E1 (en) 2-(pyridin-2-ylamino)-pyrido[2,3-D]pyrimidin-7-ones
JP5513558B2 (en) Compounds and compositions as protein kinase inhibitors
TWI413641B (en) Compounds and compositions as protein kinase inhibitors
AU2003237009A1 (en) 2-(pyridin-2-ylamino)-pyrido[2,3d]pyrimidin-7-ones
US7053070B2 (en) Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
WO2001019825A1 (en) Pteridinones as kinase inhibitors
EP1254137A1 (en) PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS
TWI464170B (en) 5-oxo-5,8-dihydropyrido[2,3-d]pyrimidine derivatives, preparation thereof and therapeutic use thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-665/02

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001233028

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 520962

Country of ref document: NZ

Ref document number: IN/PCT/2002/01150/MU

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 151480

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2001905114

Country of ref document: EP

Ref document number: 2401368

Country of ref document: CA

Ref document number: 200200802

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: PV2002-2929

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/008535

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12472002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 2002/07110

Country of ref document: ZA

Ref document number: 200207110

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2001 568942

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020027011627

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 018075908

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2001 107161

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: AP/P/2002/002643

Country of ref document: AP

ENP Entry into the national phase

Ref document number: 20020678

Country of ref document: UZ

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: P20020798A

Country of ref document: HR

Ref document number: 1200200916

Country of ref document: VN

WWP Wipo information: published in national office

Ref document number: 1020027011627

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001905114

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-2929

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 520962

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 520962

Country of ref document: NZ